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iii Abstract 
Hepatic lipogenesis and the secretion of very low-density lipoproteins are 
severely perturbed in orotic-acid fed rats.  Proteomic analysis of this rodent fatty liver 
identified a protein enriched in the microsomal fraction. The protein contains a 
domain of unknown function 108 (DUF 108) and is found to compose a complete 
protein in archaebacteria and mammalian species, but a single domain in 
Caenorhabditis elegans protein Q19527.  The cDNA for human protein A6ND91 was 
cloned and stable rat hepatoma cell lines, expressing recombinant A6ND91-FLAG 
tagged protein were produced. Significant increases in de-novo lipogenesis and 
secretion of triglyceride-enriched lipoproteins were observed. 
This thesis considers A6ND91 protein in terms of structure and proposed 
function.  Previous work has indicated that the homologous protein Thermatoga 
maritime 1643 (TM1643) possesses NAD+ or NADP+-dependent dehydrogenase 
activity towards L-Aspartate, producing NADH or NADPH plus iminoaspartate, a 
substrate that rapidly degrades into oxaloacetate (OAA) and ammonia. In this thesis, 
analyses of primary and predicted secondary structure of A6ND91 and TM1643 
revealed that residues binding NAD+/NADP+ and the proposed active catalytic 
residue, Histidine198, are conserved.   
Northern-blot analysis identified A6ND91 is highly expressed in human liver, 
moderately in kidney, and at low levels in the brain. Western-blot analysis identified 
that A6ND91 is predominately localised to the cytosol, with minimal amounts in the 
microsomal fraction.  Proteomic analysis revealed that A6ND91 contains a 
phosphorylated residue, Serine168.  The kinase potentially responsible for 
phosphorylation of the residue is Glycogen Synthase Kinase 3 (GSK3), a well-
characterised enzyme involved in regulation of glycogen metabolism and acetyl-CoA 
production.   
Microarray analyses indicate that over-expression of A6ND91 perturbs activity 
of several metabolic pathways involved in carboxylic acid metabolism, cholesterol 
synthesis and complement activation. Closer inspection of the perturbed metabolic 
pathways revealed an overlap through the substrates OAA/pyruvate/acetyl-CoA.   
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Assays were performed to establish the NAD+/NADH and NADP+/NADPH 
redox state in cell lines expressing A6ND91. Results established that NAD+/NADH 
ratio was significantly reduced, suggesting that A6ND91 may operate as a 
dehydrogenase. 
Collectively, results suggest that L-Aspartate dehydrogenase activity of 
TM1643 is conserved in human A6ND91, playing a key role in hepatic lipid and 
energy metabolism through the production of OAA and its subsequent conversion to 
pyruvate/acetyl-CoA and cholesterol. 
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Chapter 1 Introduction 
1.1 General Introduction 
Lipids synthesised by the liver are secreted as very-low density lipoproteins 
(VLDL). VLDL comprise a hydrophobic core of cholesterol ester and triglyceride, and 
an amphiphilic coat consisting of phospholipids, free cholesterol, and apolipoproteins 
(Apo) especially ApoB. As the core lipid is catabolised, VLDL converts to 
intermediate density lipoproteins (IDL) and then low-density lipoproteins (LDL), which 
are subsequently cleared by the liver via the LDL receptor.  
Disorders in lipid metabolism are varied. One such disorder is the metabolic 
syndrome which describes the clustering of factors including dyslipidaemia, glucose 
intolerance and hypertension with increased central adiposity. The syndrome is 
increasing in prevalence on a worldwide level, impacting on the prevalence of 
cardiovascular disease and type-2 diabetes. The prevalence of the metabolic 
syndrome in Europeans is between 12% and 25% (Sattar et al 2003, Rennie et al 
2003, Laaksonen et al 2002, Villegas et al 2003), which is comparable to studies in 
North America (Ford ES et al 2002, Ridker PM et al 2003). The clustering of 
impaired glucose tolerance, hypertension, hypertriglyceridaemia and 
hypercholesterolemia was first described by Reaven in 1988 (Reaven et al 1988). 
The original description placed insulin resistance causal to glucose intolerance, 
hyperinsulinaemia, increased serum VLDL levels, decreased high-density 
lipoproteins HDL and hypertension however obesity was not included in the cluster 
(Ferrannini et al 1997).  
 
1.2 Metabolism of Amino Acids and Impact on Lipogenesis 
It is known that carbohydrate and amino acid metabolism also contribute to 
plasma lipid levels (Nagata et al 1982, Sugiyama et al 1986). Carbohydrates are 
mainly metabolised in the form of monosaccharide glucose. This enters the blood via 
two routes; either through diet or is synthesised de novo through gluconeogenesis by 
the liver and kidney. Glucose is degraded through glycolysis, into pyruvate and 
acetyl-CoA, which is the precursor for fatty acid synthesis (Frayn et al 2003). 
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Increased glycolysis produces more pyruvate stimulating the production of acetyl-
CoA. In turn, acetyl-CoA is converted into malonyl-CoA, thus entering fatty acid 
synthesis (i.e. de novo lipogenesis). Malonyl-CoA inhibits carnitine palmitoyl 
transferase 1 (CPT1), which catalyzes the binding of carnitine to long-chain fatty 
acids, a necessary step for their entry into mitochondria and subsequent -oxidation 
(López-Viñas et al 2007). In general, fatty acids cannot be turned back into glucose 
by mammals because the enzyme system for this conversion is lacking, the 
exception being odd-chain fatty acids which yield propionyl-CoA a precursor for 
succinyl-CoA.  
Glucose is produced through gluconeogenesis from various substrates, 
including amino acids, lactate and pyruvate. The gluconeogenesis pathway operates 
in most liver cells and in certain kidney cells, such as those in the proximal tubule 
(Stumvoll et al 1998, Cojocel et al 2003). When amino acids are in excess of the 
body's biological requirements, they are catabolised to glycogen, triglyceride or 
subsequently enter the Tricarboxylic Acid (TCA) cycle for the production of ATP 
(Figure 1.0 and 1.1). The final products of amino acid catabolism include carbon 
dioxide, water, ATP, urea, and ammonia.  
Excess amino acids are degraded by removing their amino group and the 
resulting carbon skeleton is converted into TCA intermediates including acetyl-CoA, 
pyruvate and oxaloacetate (OAA). When energy sources are high, amino acids are 
mainly converted to fatty acids through the intermediate acetyl-CoA or to glucose 
through pyruvate (Korman et al 2006, Dioguardi et al 2004). In this respect, amino 
acids fall into three categories: glucogenic, ketogenic, or glucogenic and ketogenic. 
Glucogenic amino acids are those that give rise to pyruvate or TCA cycle 
intermediates, such as 2-oxoglutarate or oxaloacetate, all of which are precursors to 
glucose via gluconeogenesis (Figure 1.0). All amino acids except lysine and leucine 
are partly glucogenic (Brosnan et al 2003). Lysine and leucine are the only amino 
acids that are solely ketogenic, giving rise only to acetyl-CoA. A small group of 
amino acids comprising isoleucine, phenylalanine, threonine, tryptophan, and 
tyrosine give rise to both glucose and fatty acid precursors (Dioguardi et al 2004), 
and are thus characterized as being glucogenic and ketogenic . In most mammals, 
amino acid catabolism occurs in the liver, however, branched-chain amino acids are  
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Figure 1.0 Glucogenic and Ketogenic Amino Acids and Energy Metabolism. A 
significant amount of metabolic energy can come from amino acid metabolism. The 
metabolism of amino acids occurs through common metabolic intermediates, many 
of which are part of, or are linked to the TCA cycle (Figure 1.1). Metabolic 
intermediates such as pyruvate and oxaloacetate contribute to the synthesis of 
glucose via gluconeogenesis. Amino acids that are degraded into these 
intermediates are called glucogenic amino acids. Another common metabolic 
intermediate in amino acid metabolism is acetyl-CoA. Animals are unable to convert 
this intermediate into glucose, instead acetyl-CoA is converted into fatty acids or 
ketone bodies. Amino acids that are metabolized to produce only acetyl-CoA and 
acetoacetate are called ketogenic amino acids. Several of the amino acids do not fall 
cleanly into one group or another and are both ketogenic and glucogenic. 
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Figure 1.1 Amino Acids and TCA Cycle. The carbon skeletons of amino acids can 
be used for energy production (i.e. by-products NADH and FADH2 used for ATP 
synthesis) via oxidation in the TCA cycle. 1. Amino acids which are converted to 
acteoacetate include L-Leucine (Leu), L-Lysine (Lys), L-Phenylalanine (Phe), L-
Tryptophan (Trp) and L-Tyrosine (Tyr). 2. Amino acids which are converted to acetyl-
CoA include isoleucine (Iso), Leu and Try. 3. Amino acids which are converted to 
pyruvate include L-Alanine (Ala), L-Serine (Ser), Glycine (Gly), L-Threonine (Thr), L-
Cysteine (Cys), Trp. 4.  Amino acids converted to oxaloacetate include L-Aspartate 
(Asp), L-Asparagine (Asn). 5.  Amino acids converted to 2-oxoglutarate include L-
Glutamate (Glu), L-Glutamine (Gln), L-Proline (Pro), L-Histidine (His), L-Arginine 
(Arg). 6. Amino acids converted to succinyl-CoA include L-Methionine (Met), Iso, L-
Valine (Val), Thr. 7. Amino acids converted to fumarate include Asp, Phe and Tyr.  
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catabolised mainly in muscle, adipose tissue, kidney and brain (Harper et al 1984). 
Hepatic catabolism of amino acids involves two major reactions: transamination and 
oxidative deamination. Transamination is catalyzed by aminotransferases. These 
enzymes are found with very high activity in the liver, but are also present in other 
tissues (Panteghini et al 1990, Yang et al 2002). Glutamate-oxaloacetate 
transaminase (GOT) and Glutamate pyruvate transaminase (GPT) have been 
studied extensively, and increased serum levels are found secondary to various 
types of liver injury (Ozer et al 2008). 
Patients with Non-Alcoholic Fatty Liver Disease (NAFLD) often have 
perturbed levels of GOT and/or GPT, also known as Alanine aminotransferase (ALT) 
and Aspartate aminotransferase (AST), respectively (Clark et al 2006).  In NAFLD, 
patients present with serum ALT > serum AST (Clark et al 2006). However, patients 
with serum AST > serum ALT may have cirrhosis or alcoholic hepatitis.  In NAFLD, 
lipid accumulation is commonly linked with perturbed VLDL secretion and is 
frequently associated with several components of the Metabolic Syndrome: obesity, 
dyslipidemia and type II diabetes mellitus (NIDDM) (Postic et al 2008), but the 
condition can also occur in lean, normolipidaemic individuals (Marchesini et al 2003, 
Grant et al 2004). Evidence indicates that NAFLD patients have enhanced hepatic 
lipogenesis, potentially fuelled through increased hepatic de-novo fatty acid 
synthesis (Diraison et al 2003). The causal factor(s) are still unknown, however, 
disruption of transcription factors in-vivo, such as peroxisome proliferator-activated 
receptors (PPARs), liver X receptor (LXR) or sterol response element binding protein 
(SREBP), result in fatty liver and dyslipidaemia, which is reversed by the correction 
of the defect (Grefhorst et al 2002, Sekiya et al 2003, Yeon et al 2004). 
Sulfur-containing amino acids (SAA) are some of the most potent modulators 
of lipid metabolism (Oda et al 2006). Rats subcutaneously implanted with an ascites 
hepatoma line (i.e. AH109A) displayed hypertriglyceridemia (Yagasaki et al 1986) 
with a notable decrease in high-density lipoprotein (HDL) and increases in VLDL plus 
LDL (Irikura et al 1985). When rats‟ diets were supplemented with cysteine and 
methionine, decreases in serum triglyceride, serum cholesterol and suppression of 
hepatic fatty acid synthesis resulting in hypocholesterolemia was observed 
(Kawasaki et al 1998).  Likewise, analysis of the mechanism underlying 
hypocholesterolemia observed in rats fed  soybean protein with a cholesterol-free 
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diet, have revealed that 40% of the hypocholesterolemic effect is due to the low 
methionine content of soybean. Additionally this effect can be reversed by 
methionine supplementation (Sugiyama et al 1997).   
Taurine, an end product of SAAs metabolism (Figure 1.2), strongly induces 
cytochrome P450, family 7A1 (Cyp7a1) gene expression and enzyme activity, thus 
reducing VLDL-cholesterol in rats fed a high-cholesterol diet. The 
hypocholesterolemic effect of taurine in these rats is mainly due to the enhancement 
of cholesterol degradation through the excretion of bile acid. (Yokogoshi et al 2000). 
In rats, taurine supplementation also enhances serum HDL-cholesterol concentration 
in a dose-dependent manner (Mochizuki et al 1998). Moreover, dietary taurine 
significantly reduces atherosclerotic lesions in ApoE-deficient mice (Kondo et al 
2000). However, this is independent of total plasma cholesterol levels (i.e. total 
cholesterol was significantly elevated after taurine treatment) with results suggesting 
that the anti-oxidative effect of taurine is related to its anti-atherosclerotic actions. 
These data indicate SAAs may be beneficial for the prevention or treatment of 
atherosclerosis by elevating HDL-cholesterol, decreasing VLDL-cholesterol and 
increasing anti-oxidative protection. 
SAAs (excluding taurine) alter the cellular redox state through the substrate 
glutathione (Wang et al 1997). Cysteine and methionine (which can be converted to 
cysteine), are essential components for reduced glutathione (GSH) synthesis 
through the action of glutamylcysteine synthetase. Therefore, an adequate supply of 
these SAAs is crucial for maintaining a normal hepatic GSH level (Wang et al).  The 
concentration and ratio of GSH to the oxidized form (GSSG) of glutathione increases 
the activity of HMG-CoA (3-hydroxy-3-methylglutaryl coenzyme A) reductase 
(HMGCR) and CYP7A1. HMGCR and CYP7A1 are rate-limiting enzymes in 
cholesterol synthesis and degradation, respectively (Cappel et al 1986 Waxman et al 
1986). Additionally, the supplementation of SAAs to diets can lead to an increase in 
plasma homocysteine levels through the metabolism of methionine (Shoveller et al 
2004), a potent risk factor for atherosclerosis (Duell et al 1997). In humans, plasma 
homocysteine levels are inversely related to plasma levels of folate (Verhoef et al 
1998). Folate is a co-factor of methionine synthase, an enzyme that converts 
homocysteine to methionine (Banerjee et al 1987).  
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Figure 1.2 Metabolism of Taurine. The major pathway for mammalian taurine 
synthesis occurs in the liver via the cysteine sulfinic acid pathway. In this pathway, 
the sulfhydryl group of cysteine is first oxidized to 3-sulfino-alanine by the enzyme 
cysteine dioxygenase (CDO1). 3-sulfino-alanine, in turn, is decarboxylated by 
sulfinoalanine decarboxylase (CSAD) to form hypotaurine. It is unclear whether 
hypotaurine is then spontaneously or enzymatically oxidized to yield taurine. 
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Betaine homocysteine methyltransferase (BHMT) catalyzes a methyl group transfer 
from betaine to homocysteine, forming dimethylglycine and methionine. 
The release of amino groups in the form of free ammonia is catalysed mainly 
by the following deaminating enzymes: glutamate dehydrogenase, glycine-cleavage 
system, serine-dehydratase and the enzymes of the purine nucleotide cycle. Amino 
groups are toxic and must be removed by the liver through the transfer of the amino 
group to glutamate and eliminated via the urea cycle (Figure 1.3). Glutamate 
dehydrogenase (GLUD) is a key regulatory step in amino group degradation (Stanley 
et al 2004). High energy conditions (i.e. high cellular ATP and GTP) inhibit this 
catabolic, energy producing process, whereas low energy conditions (i.e. low cellular 
GDP and ADP) activate GLUD (Frieden et al 1985). When excessive amounts of 
ammonia are present, a shift in equilibrium lowers levels of the TCA intermediate 2-
oxo-glutarate, depleting energy in the cell (Bonarius et al 1998). Mutations in 
mitochondrial GLUD (GLUD1) have been identified in two infants with 
hyperinsulinemic-hypoglycemia and hyperammonemia (Stanley et al 1998). 
Hyperinsulinism-hyperammonemia is predominantly due to excessive oxidation of 
glutamate by GLUD1. Mutations of GLUD1 cause hyperinsulinism/hyperammonemia 
syndrome by desensitizing GLUD1 to allosteric inhibition by GTP (Fang et al 2002). 
Table 1.0 shows several other rare genetic disorders of amino acid 
metabolism include phenylketonuria, albinism, alkaptonuria, type 1 tyrosinaemia, 
non-ketotic hyperglycinaemia, histidinaemia, homocystinuria, and maple syrup urine 
disease. Several of these conditions present with mental retardation possibly due to 
high levels of ammonia (i.e. hyperammonemia) (Zellweger et al 1961 (A), Zellweger 
et al 1961(B), Camargo et al 2008, Cagnon et al 2007).  The brain is susceptible to 
hyperammonemia resulting in irreversible damage to the developing central nervous 
system. Hyperammonia induces cortical atrophy, ventricular enlargement and 
demyelination, resulting in cognitive impairment, seizures and cerebral palsy 
(Cagnon et al 2007). Experimental models have identified that ammonia exposure 
alters several amino acid pathways and neurotransmitter systems, as well as 
cerebral energy metabolism, nitric oxide synthesis, oxidative stress, mitochondrial 
permeability transition and signal transduction pathways (Cagnon et al 2007).  
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1.3 Metabolism of Glutamate. Glutamate dehydrogenase (GLUD) is the first 
committed step in mammalian nitrogen excretion, leading eventually to the 
production of urea. GLUD is almost entirely confined to the liver mitochondrial matrix 
space, catalysing a net loss of nitrogen from the amino acid pool. The process is 
termed "oxidative deamination". NAD+ (or NADP+) is a cofactor for GLUD, producing 
2-oxoglutarate and ammonium (NH4
+) as a by-product. 
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Amino Acid Medical Disorder Symptoms 
Glycine Non-ketotic 
hyperglycinemia  
Lethargy, hypotonia, myoclonic jerks, seizures, mental 
retardation, apnea and often leading to death.  
Homocysteine Hyperhomocysteinemia  Risk factor for coronary artery disease. 
Leucine, 
Isoleucine, 
Valine 
Maple syrup urine disease 
 
Poor feeding, vomiting, dehydration, lethargy, 
hypotonia, seizures, ketoacidosis, opisthotonus, 
pancreatitis and neurological decline. Brain damage 
and death 
Lysine Hyperlysinemias  Mental retardation, recurrent emesis, hypotonia, 
lethargy, diarrhoea, and developmental delay. 
Methionine  Homocystinuria Disorder of the connective tissue, muscles, CNS, and 
cardiovascular system. 
Phenylalanine  Phenylketonuria  Mental retardation and seizures 
 Hyperphenylalaninemia  Mental retardation, seizures and behavioural problems 
Proline Hyperprolinemia Type I – Generally asymptomatic, some seizures, 
mental retardation or other neurological problems 
Type II - Seizures, convulsions and mental retardation 
Tryptophan  Hartnup disease Failure to thrive, photosensitivity, intermittent ataxia, 
nystagmus and tremor 
Tyrosine  Oculocutaneous albinism  Disruption of melanin synthesis in eyes and skin. 
 Tyrosinemia  Liver and kidney disturbances and mental retardation 
 Alkaptonuria  Excessive homogentisic acid (tyrosine by-product) 
damages cartilage (ochronosis, leading to 
osteoarthritis) and heart valves as well as precipitating 
as kidney stones. 
Urea cycle Ornithine 
carbamyltransferase 
deficiency  
Hyperammonemia, orotic-acidaemia, seizures, coma, 
mental retardation, progressive liver damage, skin 
lesions, irrational behaviour (caused by encephalitis). 
 Carbamyl-phosphate 
synthase I deficiency 
disease  
Type I - Lethargy, lack of appetite, poorly controlled 
breathing rate and body temperature.  
Type II - Seizures, mental retardation and coma.  
 Citrullinemia  Lethargy, poor feeding, vomiting, seizures, loss of 
consciousness. Confusion, abnormal behaviours, 
seizures, coma. Neonatal intrahepatic cholestasis. 
 Hyperargininemia  Spasticity, slow growth, mental retardation, seizures, 
tremor, and ataxia.  
 
Table 1.0 Disorders of Amino Acid Metabolism. The most common disorders of 
amino acids metabolism in humans are summarized with their clinical and 
pathological findings. 
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These perturbed pathways may explain neuronal loss and impairment of axonal and 
dendritic growth observed in the different models of congenital hyperammonemia 
(Cagnon et al 2007). 
Amino acids are not only used in protein synthesis and as an energy source, 
they can also serve as neurotransmitters. Inhibitory amino acids (IAA) (i.e. glycine, β-
alanine, and taurine or) excitatory amino acids (EAA) (i.e. L-Glutamate, L-Aspartate, 
L-Cysteine, and L-Homocysteine) active post-synaptic cells. Amino acids are also 
precursors of hormones (i.e. tyrosine is used to synthesise catecholamines and 
thyroid hormones, whereas tryptophan is the precursor to serotonin and melatonin 
(Wu et al 2009). The synthesis of nucleotides such as purines and pyrimidines is 
also dependent on amino acids (D'Mello et al 1982). Figure 1.4 shows de novo 
synthesis of purines (i.e. adenosine monophosphate (AMP) and guanosine 
monophosphate (GMP)). Purine synthesis begins with the amino acids glycine, L-
Aspartate plus L-Glutamine and the generation of inosine monophosphate (IMP), 
which is turn converted to either AMP or GMP. Pyrimidines such as Uridine-5'-
triphosphate (UTP), Thymidine triphosphate (TTP), Cytidine triphosphate (CTP) and 
Orotic Acid (OA) require Aspartate and Glutamine (Figure 1.5). Pyrimidine synthesis 
begins with the synthesis of carbamyl phosphate from the amino acid L-Glutamine. 
L-Glutamine condenses L-Aspartate in the presence of aspartate transcarbamylase 
(CAD) yielding carbamyl-L-Aspartate. This is converted to dihydro-orotate by CAD 
producing the free-base pyrimidine, OA. Deficiencies of ornithine transcarbamylase, 
UMP synthase (UMPS) and L-Arginine (Table 1.0) result in excess OA formation and 
increased amounts of blood and urinary OA (i.e. Orotic aciduria) (Brosnan et al 2007, 
Smith et al 1961).  
 
1.3 Orotic Acid and Fatty Liver 
In 1955, dietary OA was shown to cause fatty livers in rats (Standerfer et al 
1955).  Severe fatty liver develops with 1% dietary OA; however more than 0.1% is 
necessary to induce this effect (Durschlag et al 1980). Cartwright et al observed that 
rats with OA-induced fatty liver had elevated levels of total hepatic triglyceride, 
cholesterol and phospholipids associated with decreases in serum VLDL (Cartwright 
et al 1993).  
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Figure 1.4 De novo synthesis of Purines. Inosine 5'-monophosphate (IMP) is 
formed in 10 enzymatic reactions by stepwise additions of functional groups on 
Phosphoribosyl pyrophosphate (PRPP). L-Glutamine donates an amino group by 
Phosphoribosyl pyrophosphate amidotransferase (PPAT) and 5‘-Phosphoribosyl -
formylglycinamide-L-glutamine amido-ligase (PFAS). Glycine is added by Phospho-
ribosylglycinamide synthetase domain of 5-Phospho-D-ribosylamine: glycine ligase 
(GART). L-Aspartate is then ligated by Phosphoribosyl aminoimidazolesuccino- 
carboxamide synthase (PAICS). AMP and GMP are synthesized from IMP by 
modification to the hypoxanthine ring. Phosphorylation of GMP and AMP yields GDP 
and GTP plus ADP and ATP, respectively. ADSL, Adenylosuccinate lyase;  ATIC, 5-
aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolas; 
PFAS, phosphoribosylformylglycinamidine synthase. 
 
 
34 
 
Furthermore, rats are unique in their susceptibility to fatty livers induced by orotic 
acid. Mice, guinea pigs, hamsters, chicks, dogs, pigs, and monkeys do not respond 
similarly to diets with 1% orotic acid (Durschlag et al 1980 Bloomfield et al 1969, 
Koteish et al 2002).The lack of susceptibility in mice is in part due to increased 
urinary excretion of dietary OA (Durschlag et al 1980). The basis for the absence of 
response in other species is unknown. 
OA elevates hepatic lipids by increasing triglycerides synthesis and 
decreasing the secretion of lipoproteins that accumulate in the GOLGI apparatus 
(Sabesin et al 1977) resulting in reduced serum lipid levels (Windmueller et al 1964). 
Hepatic lipid deposition was unaffected on day 3 but was increased on 7 days and 
still further by day 10. Accumulated hepatic lipid contained high levels of de novo 
synthesized triglycerides, cholesterol and phospholipids (Creasey et al 1961, 
Windmueller et al 1964). Klain and Whitten additionally reported altered lipogenesis 
in white adipose tissue from rats fed an orotic acid diet for 10 days OA. Increased 
incorporation of glucose-U-I4C into fatty acids indicates that OA may alter 
lipogenesis from an impact in glucose metabolism (Klain et al 1967). In support of 
this, altered hepatic glucose levels were identified by Griffin et al in the livers and 
plasma of two strains of rats fed OA (Griffin et al 2004). Decreases in liver glucose 
and glycogen in both Wistar and Kyoto rats over 3 to 14 days OA feeding were 
coupled with increased levels of plasma -hydroxybutyrate, lactate, acetate and 
glucose. These metabolites are linked through the substrates pyruvate plus acetyl-
CoA, overlapping with gluconeogenesis/glycolysis pathways.  
Bogin et al observed altered levels of several enzymes involved in glucose, 
pyruvate and amino acid metabolism in the plasma and livers of rats fed OA for two 
to three weeks. Increased plasma levels were detected for Alanine aminotransferase 
(Alt), Malate dehydrogenase (Mdh) and decreased levels of gamma-glutamyl 
transpeptidase (Ggt)) (Bogin et al 1986). Additionally increased levels of Glucose 6-
phosphate dehydrogenase (G6pd), Malic enzyme (Me), Ggt, 6-phosphogluconate 
dehydrogenase (Pgd), Aspartate aminotransferase (Ast), Mdh, Lactate 
dehydrogenase (Ldh) and decreased levels of Alt were observed in the livers of rats 
fed OA. Combined these results suggest that OA may increase hepatic lipogenesis 
via perturbed gluconeogenesis/glycolysis through altered pyruvate and related 
substrates (i.e. oxaloacetate and acetyl-CoA). 
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Figure 1.5 De novo Synthesis of Pyrimidines. The synthesis of pyrimidines (UTP, 
CTP and TTP) begins with the cytoplasmic formation of carbamyl phosphate from 
glutamine, bicarbonate (HCO3) and ATP. This is followed by the addition of L-
Aspartate to produce carbamyl L-Aspartate, which then undergoes cyclization to give 
rise to dihydro-orotate. These first 3 reactions are carried out by the multifunctional 
protein CAD that initiates and regulates de novo pyrimidine biosynthesis. CAD 
contains active sites for 1. Carbamyl phosphate synthetase II (CPS II)  2. Aspartate 
carbamyltransferase, and 3. Dihydro-orotase. 4. The fourth enzyme, Dihydro-orotate 
dehydrogenase (DHODH), catalyzes the oxidation of dihydro-orotate to orotic acid.  
Orotic acid is then converted to UMP by the multifunctional enzyme UMP synthase 
(UMPS); 5. Orotate phosphoribosyltransferase, and 6. Orotidylate decarboxylase 
activity. (PRPP = 5-Phospho-alpha-D-ribose 1-diphosphate). 
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OA consumption is also associated with changes in liver acid-soluble 
nucleotides (Von Euler et al 1963). The ratio of purine/pyrimidine was depressed 
significantly within 3 days after OA was introduced into the diet, and this persisted 
through to day 10. At all three time points (i.e. days 1, 5 and 10) the altered ratio was 
due a decrease in purines and increase in pyrimidines. The most prominent 
alterations in nucleotides were a 400% increase of uridine nucleotides and a 50% 
decrease in adenine nucleotides. Purines are likely to be decreased due to 
competition for Phosphoribosyl pyrophosphate (PRPP) which is used for both purine 
(Figure 1.4) and pyrimidine nucleotide synthesis (Figure 1.5). Total cellular 
pyrimidine levels are increased due to high levels of dietary OA, a precursor 
substrate for pyrimidine nucleotide synthesis. Windmueller et al identified within 16 
hours of OA feeding, rat plasma concentrations of triglycerides, cholesterol, and 
phospholipid fell to between 10 to 15% of normal values. By day 4, hepatic lipid 
accumulation began. Addition of adenine to the diet of these rats, returned the 
circulating lipid to normal, followed by a reduction in hepatic lipid levels (Windmueller 
et al 1964).  
 
1.4  Identification of Mammalian DUF 108 Protein  
Using a combined two-dimensional gel and proteomic analysis, our group 
identified a novel ~36KDa protein, EDM07494, from liver microsomes prepared from 
Kyoto rats fed standard chow containing 1% OA. Mass spectrometry analysis of 
peptide fragments identified 20% coverage of rat protein EDM07494 (Table 1.1). At 
the one-day time point, EDM07494 was increased approximately two-fold compared 
to approximately fifteen-fold at the 14-day time point, as assessed by silver stained 
2D gels (Figure 1.6).  Figure 1.7 shows an integrated genomic analysis using 1H 
NMR spectroscopy and microarray analysis on liver samples from those rats fed OA 
over a 14 day time-course.  Several changes were revealed in levels of key 
methylation metabolites (i.e. choline, betaine and trimethylamine-N-oxide) as well as 
transcripts encoding enzymes participating in the synthesis of glycerolipid (e.g. 
glycerol-3-phosphate acyltransferase) and de novo fatty acid synthesis (e.g. fatty 
acid synthase, stearyl CoA desaturase 1, ATP citrate lyase) (Griffin et al 2004). 
Increased triglyceride accumulation was coupled with an additional block in the 
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secretion of VLDL-TG. This „block‟ may be partly attributable to decreases in cellular 
choline.  Dietary deficiency of choline results in fatty liver (Lombardi et al 1968). 
EDM07494 shares extensive sequence identity with an ancient family of 
proteins containing a Domain of Unknown Function (DUF 108). Highly conserved 
residues are predicted to form a Rossmann fold that binds dinucleotides. 
Subsequently the co-ordination of dinucleotides NAD+/NADP+ was observed in a 
crystal structure of a homologous protein from eubacterium Thermatoga maritime 
(TM1643) (Figure 1.8) (Yang et al 2003). The group also identified that TM1643 
possesses dehydrogenase activity toward L-Aspartate producing iminoaspartate, 
which rapidly degrades to OAA plus ammonia. Additionally AF1838 from 
Archaeoglobus fulgidus whose predicted amino acid sequence exhibits 38% identity 
with that of TM1643 is also reported to act as a highly thermostable L-Aspartate 
dehydrogenase (Yoneda et al 2007). In an electron-density map of AF1838 Yoneda 
et al found that a citrate molecule could also be modelled into the protein. These 
data suggest that the mammalian form of this protein may influence metabolic 
processes involving NAD, L-Aspartate, OAA, pyruvate and/or citrate. 
In-silico cloning of homologous human A6ND91 cDNA, encoding 283 amino 
acids, predicts a protein of an estimated mass of ~30kDa, 6kDa smaller than the 
apparent mass of rat EDM07494. Stable transfected rat hepatoma cells (McA-
RH7777) expressing human A6ND91-FLAG showed increased synthesis of 
cholesterol, fatty acid, TG (Figure 1.9), increased total cellular TG level and 
increased secretion of TG-rich, ApoB-containing lipoproteins (Figure 1.10). 
 
 
 
 
 
 
 
 
 
38 
 
Amino Acid Calculated Mr Observed  Mr Sequence 
68-75 806.45 806.43  (K)VGVVGYGR(H) 
298-305 954.49  954.49 (R)SFAVHTHR(E) 
232-240 1033.57 1033.54 (R)TVLYEGPVR(G) 
196-206 1100.61  1100.58 (R)LDAAGGLQSLR(V) 
185-195 1263.58 1263.56 (R)GALWGCEDIS(L) 
138-148 1264.74 1264.77 (K)IIHESGVQILR(H) 
64-75 1267.73 1267.67 (R)VPHKVGVVGYGR(H) 
126-137 1340.73 1340.66 (R)HPDLVVEVAHPK(I) 
218-231 1362.72 1362.66 (R)LEGPLAAAHSSGPR(T) 
149-167 1980.02  1979.95 (R)HANLLVGSPALADQTTER(Q) 
 
Table 1.2 Measured Peptide Masses of EDM07494 from Rat Microsomes. 
Electrospray tandem mass spectrometry was performed on ~36KDa spot separated 
from the microsomal fraction of rats fed 1% orotic acid in standard chow. 
 
                                 
Figure 1.6 Microsomal Proteins Separated on 2D gels. Microsomal fraction from 
rats fed standard chow (No orotic acid) and 1% orotic acid plus standard chow for 3 
days. Proteins were separated on 2D gels then silver stained. At the one-day time 
point, EDM07494 was estimated to be increased ~two-fold (data not shown). At the 
two-day time point EDM07494 was increased ~three-fold (data not shown); three-
day time point EDM07494 was increased ~nine-fold and increased ~fifteen-fold at 
the 14-day time point as judged by image analysis software Melanie (v2). Performed 
by Dr. C. Mann. 
pI 
Mr 
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Figure 1.7 Perturbed Metabolic Pathways Identified by Microarray and NMR in 
14 Day Orotic Acid Fed Rats. Pathways were constructed using the Kyoto 
Encyclopaedia of Genes and Genomes (KEGG), with those associated with 
triglyceride/phospholipid synthesis, choline metabolism, and methyl donor 
metabolism. Red = increased expression; Green = decreased expression; Italics = 
enzymes with perturbed transcription (Griffin et al 2004). 
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Figure 1.8 Crystal Structure of TM1643. Recombinant protein was expressed in E. 
coli BL21 (DE3) cells and crystallized using the hanging-drop vapour diffusion 
method (Yang et al 2003).  The crystal structure was analysed by X-ray 
crystallography to a 2.6 Å Resolution. The crystal structure is complexed with NAD+ 
(shown in grey) and consists of two domains; N-terminal domain (residues 1-105) 
co-ordinates the binding of NAD+, whereas; C-terminal domain (residues 113-241) 
has  and  domains forming an open-faced sandwich structure.  The nicotinamide 
ring of NAD+ is located at the interface between the two domains, indicating that this 
location may contain the enzymes active site. A nearby histidine amino acid (shown 
in red) is proposed to function as the catalytic residue. In support of this observation, 
the His-193 residue is structurally equivalent to the catalytic His residue in ASA-DH 
(Hadfield et al 2001). In addition this residue is strictly conserved among all DUF 108 
family members.
 
 
41 
 
 
 
Figure 1.9 and 1.10 Expression of A6ND91-FLAG in McA-RH7777 cells. De novo fatty acid synthesis (FA), cholesterol ester 
(CE), phospholipid (PL) and triglyceride (TG) synthesis were measured using 14C acetate (Figure 1.9). Total cellular TG and VLDL-
TG were measured with 14C oleate (Figure 1.10). A6ND91-Flag expression increases de novo fatty acid, cholesterol ester (CE), 
phospholipid (PL) plus triglyceride (TG) synthesis and the total cellular triglyceride content and VLDL secretion compared to control 
cells. Methods are described by Hebbachi et al 1997. Experiments performed by Dr. A. Hebbachi. Data is the mean of 3 
experiments.
4
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1.5 Aims 
The aim of this thesis was to characterise human protein A6ND91, a 
proposed L-Aspartate dehydrogenase and to understand the perturbed metabolic 
pathways in cell lines expressing recombinant A6ND91-FLAG tagged protein.  
Specific aims were: 
• To characterise the structures and biochemical trait of human A6ND91 and rat 
EDM07494 
• To produce and analyse a microarray data-set of cells expressing A6ND91 
and appropriate controls. 
• To translate the microarray data-set in terms of Gene Ontology and perturbed 
KEGG metabolic pathways. 
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Chapter 2 Materials and Methods 
2.1 Molecular and Protein Materials and Methods 
All reagent recipes are available in Appendix I. 
 
2.1.1 Human and Rat Tissue 
Pooled human total liver protein and human microsomal and cytosolic 
fractions were purchased from BD Bioscience (20mg/ml). Control and OA fed Wistar 
and Kyoto rat total liver homogenate and microsomal, mitochondrial and cytosolic 
fractions were prepared by Dr. Abdul Hebbachi (Oxford). Essentially, 1 gram of wet 
liver tissue was placed in ice-cold 5 mM Tris-HC1, 1 mM MgCl pH 7.4, 2.5 ml of 0.5 
M sucrose plus protease inhibitors, and homogenised by hand with a glass 
homogenizer. Tissue homogenate was centrifuged at 800g for 30 mins to pellet 
nuclei and fibrous tissue. Supernatant was carefully removed and centrifuged at 
6,000g for 1 hour to pellet mitochondria. Supernatant was re-centrifuged at 100,000g 
for 1 hour to pellet microsomal fraction and separate the cytosol fraction. This 
fraction was immediately frozen at -80°C. Mitochondrial and microsomal fractions 
were partially solubilised  in solubilisation buffer (20 mM Tris-HCl (pH 7.8), 0.4 M 
NaCl, 15% glycerol, 1 mM DTT, 1 mM Phenyl-MethylSulphonyl Fluoride (PMSF) and 
1.5% Triton-X-100), and further solubilised by sonication on ice at a high frequency 
in four 5–10-sec bursts with 30-sec pauses, to prevent the sample over heating. 
Samples were stored at -80°C. The purity of fractions were determined by the activity 
of marker enzymes glucose-6-phosphatase (microsomal), Succinate dehydrogenase 
(mitochondrial) and lactate dehydrogenase (cytosol), and found to pass standard 
criteria (Cartwright et al 1994). I thank Dr. A. Hebbachi for the preparation of total rat 
liver homogenate, microsomal, mitochondrial and cytosolic fractions. 
 
2.1.2 Generation of Rabbit Polyclonal Human A6ND91-FLAG Antibody 
Generation of polyclonal A6ND91-FLAG antibody were performed by Dr. P. 
Ritchie and Mr. Richard Ewan. Essentially, BL21 cells transformed with a pET-29 
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vector-c containing A6ND91 cDNA and a genetically engineered carboxyl terminal 
FLAG epitope tag (DYKDDDDK) juxtaposed to a terminator codon were incubated 
with 1mM isopropyl -thiogalactopyranoside for 2hours at 37°C. Cells were pelleted 
by centrifugation and re-suspended in ice-cold 50mM Tris-HCL pH7.4 containing 
150mM NaCl (TBS) plus protease inhibitors.  A6ND91-FLAG was applied to an anti-
FLAG M2 affinity gel column (Sigma) and eluted, to the manufacturer‟s instructions.  
A6ND91-FLAG was concentrated in a Centricon 30 cartridge, with two 1ml TBS 
washes, and mixed with glycerol at a final concentration of 20%.  New Zealand white 
rabbits (n=2) were inoculated with 100g of recombinant A6ND91-FLAG, emulsified 
in complete Freund‟s adjuvant (Harlan Sera Laboratories Limited).  Repeat 
inoculations (n=5) were performed at 2-weekly intervals.  For detection of A6ND91-
FLAG, immuno-blotting of McRH7777 cells expressing human A6ND91-FLAG was 
performed (Section 2.1.10). Pre-hybridisations were performed overnight in a 5% 
non-fat milk powder solution containing 10mM Tris pH 7.4, 1M NaCl, 0.5% Tween at 
room temperature.  Hybridizations were for 1 hour at room temperature with the 
primary polyclonal A6ND91-FLAG antibody diluted 1:500 in the prehybridization 
buffer.  Immunoreactive products were visualised with anti-rabbit IgG horseradish 
peroxidase conjugate secondary antibody (BioRad) diluted 1:3000 in the 
prehybridization buffer, followed by enhanced chemiluminescence (Pierce). 
      
2.1.3 Cellular Homogenisation 
Cells were washed three times with 10mls Phosphate Buffered Saline (PBS) 
at room temperature and removed by scraping in 1ml ice-cold PBS/2mM EDTA 
containing 1l/ml protease inhibitor cocktail (Biorad) and 1l/ml phosphatase 
inhibitors (Sigma). Cells were pelleted for 15 secs at 6,000rpm in an Eppendorf 
bench top centrifuge and washed three times with 1ml ice-cold PBS/2mM EDTA 
containing protease inhibitor cocktail. Cells were re-suspended in 1ml 250mM 
sucrose/20mM imidazole (pH 7.4) containing protease and phosphatase inhibitors 
and lysed with 100 plus strokes in a glass homogeniser. Homogenates were 
checked under a light microscope to ascertain complete cellular lysis; 50l was 
removed for total protein estimation. For 1g liver tissue, homogenisation protocol 
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was performed in 1ml ice-cold 5mM Tris-HCL/1mM MgCl2/pH7.2 with protease and 
phosphatase inhibitors. 
 
2.1.4 Protein Solubilisation and Quantification  
Proteins were solubilised with 250-1000l PBS/ 2mM EDTA/1% Triton x100 
on ice with brief vortexing for 30mins. Samples were clarified at 10,000rpm at 4°C for 
10 min in a 5402 Eppendorf centrifuge (Anderman). Total protein concentrations 
were estimated using the Lowry assay (Lowry et al 1951). A standard curve was 
produced using Bio-Rad DC protein assay reagents with 0-1mg/ml BSA standards. 
Total protein samples were diluted 1/20
th to a final volume of 200l in duplicate and 
mixed with 100l of Reagent A, followed by 800l of Reagent B. Samples were 
incubated for 20 mins at room temperature, then aliquoted into polystyrene cuvettes  
(Plastibrand). Absorbances were measured at 750nm on an Ultraspec 3000 
spectrophotometer (Pharmacia Biotech) and protein concentrations determined from 
the standard curve. 
 
 2.1.5 Shrimp Alkaline Phosphatase (SAP) Assay 
Into individual tubes containing 1x SAP Reaction Buffer (50mM Tris-HCl (pH 
8.0)), 10g human A6ND91-FLAG or 200g of rat EDM07494-FLAG solubilised 
cellular lysate prepared without phosphatase inhibitors were incubated with 500 units 
SAP (Promega) at 37°C for 30 mins. Reactions were terminated by heating at 65°C 
for 15 mins. Control assays were performed using 500 units of heat inactivated SAP. 
Results were analyzed by 2-dimensional SDS-PAGE (Section 2.1.7) and immuno-
blotting with anti-FLAG (Section 2.1.10).   
 
2.1.6 SDS-PAGE 
Individual protein samples (1-200g) were made up to 80l with water and 
were incubated at 94°C for 5-10mins with 20l 6x Sodium Dodecyl Sulphate (SDS) 
loading buffer. Samples were size-fractionated, through a 12% denaturing gel with 
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1% acrylamide (Biorad) stacks and run at 4°C using the Hoeffer SE600 apparatus 
with a constant current of 80mA in 1x SDS-PAGE running buffer, until the 
bromophenol blue dye front had migrated from the gel. 
 
2.1.7 Two-Dimensional (2D) Iso-Electric Focusing (IEF) 
All consumables were from Amersham Biosciences, unless stated. 
Solubilised samples (500-1000g) were mixed with De-streak Re-hydration 
solution, 7l De-streak Reagent plus 3.5l pH 3-10 IPG buffer, to a final volume of 
500l and loaded into porcelain 13 cm coffins. Immobiline dry strip pH 6.2-7.4 or pH 
3-10 were placed, gel-side down on to the sample and re-hydrated for 10 hours at 
20°C. Samples were iso-electric focused on an Ettan IPGphor II unit according to 
manufacturer recommendations for the given dry strip. On completion, IEF strips 
were removed and incubated in IEF equilibration buffer for 30 mins on a shaking 
platform. IEF strips were loaded on to a single well 12% acrylamide denaturing gel 
with 20l of Pre-stained SDS-PAGE Standards (BioRad) and run at 4°C using the 
Hoeffer SE600 apparatus with a constant current of 80mA in 1x SDS-PAGE running 
buffer, until the bromophenol blue dye front had migrated from the gel.  Proteins 
were either visualised using silver-staining kit (Amersham Pharmacia Biotech) 
performed by Dr. C. J. Mann, colloidal coomassie staining, or by immunoblotting 
(Section 2.1.10).   
 
2.1.8 Matrix-assisted laser-desorption ionization (MALDI) MS 
Protein digestion and MALDI-MS analysis was performed by Dr. R. Waite 
(Imperial College London, Mass Spectrometry and Proteomics Unit). Essentially, 
tryptic fragments were prepared by standard methodologies (Shevchenko et al 
1996). Mass spectra were recorded on a TofSpec 2E spectrometer (Micromass, 
Manchester, UK) equipped with a 337nm nitrogen laser. The instrument was 
operated in the positive-ion reflection mode at 20kV accelerating voltage. The matrix 
was a mixture of a-cyano-4-hydroxycinnamic acid and nitrocellulose, applied to the 
target as a microcrystalline thin film. Spectra were internally calibrated using trypsin 
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autolysis products, and the resulting mass fingerprints searched against the National 
Centre for Biotechnology Information (NCBI) non-redundant database 
(http:www.ncbi.nlm.nih.gov) using the Protein Probe search engine (Micromass, 
Manchester, UK). One missed cleavage per peptide was allowed, and an initial mass 
tolerance of 50 p.p.m was used in all searches. Cysteine residues were assumed to 
be carbamidomethylated. Other potential modifications were not considered in the 
first-pass search.   
 
2.1.9 HPLC Electrospray Tandem MS 
Protein digestion and Quadrupole/ Time-of-Flight (Q-Tof) analysis were 
performed by Miss Dinah Raman of Imperial College Proteomics Department for 
A6ND91-FLAG and Dr. R. Wait for EDM07494. Tandem electro-spray mass spectra 
were obtained with a Q-ToF hybrid Quadrupole/orthogonal acceleration Time-of-
Flight spectrometer (Micromass) interfaced to a Micromass CapLC capillary 
chromatograph. Amino acid sequences deduced with the aid of the Micromass‟s 
peptide sequencing program PepSeq, were used as query sequences in a Blast 
Search against the NCBI‟s non-redundant and EST databases.   
 
2.1.10 Western Blotting 
Resolved proteins were transferred to Polyscreen PVDF Transfer Membrane 
(Applied Biosciences) according to manufacturer‟s protocol in 1x [cyclohexlamino]-1-
propanesulphonic acid (CAPS) using a BioRad Trans-BlotTM apparatus with a 
constant current of 100mA for 2 hours at 4°C. PVDF membranes were dried to 
manufacturer‟s recommendations and non-specific binding sites blocked by 
overnight 4°C incubation in 5% non-fat milk powder/High Salt Tween (HST). All 
subsequent incubations and washes were carried out on a shaking platform at room 
temperature for 1hour, unless stated. Blots were exposed to primary antibody, either, 
1/500 dilution of polyclonal rabbit human A6ND91-FLAG, or 1/3000 dilution 
monoclonal FLAG (M2) antibody in 50mls of 5% milk powder/HST, and then washed 
several times in HST. Secondary antibody (anti-rabbit or anti-mouse conjugated to 
Horseradish Peroxidase (HRP)) was diluted to 1/3000 in 50mls 5% milk powder/HST 
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and incubated with blots for 1 hour at room temperature, followed by several washes 
in HST. Immunoreactive proteins were visualised using Femto-Enhanced 
Chemiluminescence‟s (Pierce) reagents as described by manufacturer‟s protocol. 
 
2.2 Characterisation of Human A6ND91-FLAG 
2.2.1 Generation of Human A6ND91-FLAG Probe   
A6ND91 constructs were designed and made by Dr. C. J. Mann. I.M.A.G.E 
clone W88721 containing an 870 base pair fragment of A6ND91 (Figure 2.0) within 
pT7T3D vector was grown in 5mls Luria-Bertani (LB) medium plus 100g/ml 
ampicillin and incubated for three hours at 37°C in shaking incubator at 225 rpm.  
The culture was inoculated into 150mls LB plus100g/ml ampicillin and incubated for 
16 hours at 37°C in a shaking incubator overnight at 37°C. Plasmids were purified 
using QIAGEN Plasmid-Plus Maxi Kit to manufacturer‟s instructions.  In brief, 
pelleted bacteria were re-suspended in 5 ml P1 buffer and gently mixed with 5 ml of 
Buffer P2 for 3 mins at room temperature. The mix was incubated with 5 ml of Buffer 
S3 at room temperature for 5 mins, and lysate transferred to QIAfilter cartridge and 
incubated at room temperature for 10 mins. Plunger was gently inserted into QIAfilter 
cartridge and cell lysate filtered into new tube. Filtered lysate was mixed, by inverting 
4-6 times, with 5 ml Buffer BB and transferred to QIAGEN Plasmid-Plus Maxi spin 
column contained in 2 ml collection tube. Column was washed twice with 0.7 ml 
Buffer ETR and centrifuged for 1 min at 10,000 rpm. Residual wash buffer was 
removed by centrifugation at 10,000 rpm for 1 min. DNA was eluted by adding 400 μl 
of Buffer EB (10 mM Tris·Cl, pH 8.5) to centre of QIAGEN Plasmid Plus Maxi spin 
column for at least 1 min, and centrifuged for 1 min at 10,000rpm. Plasmid DNA 
concentration was quantified using 260nm absorption and DNA purity was quantified 
using 260 nm/280 nm ratio where average extinction coefficient for double-stranded 
DNA at A260 = 50 µg/ml. Plasmid was sequenced using Prbm12 oligonuceotides 
(Appendix II) before use by Clinical Sciences Centre (CSC) sequencing facility.  
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Figure 2.0 W88721 Cloned into Expression Vector pT7T3D. Construct was made 
by Dr. C. J. Mann (Section 2.1.1). Restriction sites EcoR1 and BamH1 within Multiple 
Cloning Site (MCS) were used to ligate 870 bp A6ND91 cDNA (W88721). Arrows 
indicate direction of transcription. W88721 cDNA is represented with large light blue 
arrow. Numbers within pT7T3D represent nucelotide length. AmpR = amplicillin 
resistance cDNA. T3 promotor = T3 RNA polymerase binding site. T7 promotor = T7 
RNA polymerase binding site. See Appendix X for W88721 sequence. 
 
 
 
50 
 
2.2.2 Probe Labelling and Northern Blot 
The 830bp stretch of human A6ND91 cDNA (covering from nucleotide 101 to 
the 3' polyadenylation site) in plasmid W88721 was excised using restriction 
enzymes EcoR1 and BamH1. Briefly, 15g of W88721 was incubated with 2.5l of 
both EcoR1 (10U/l) and BamH1 (10U/l) (New England Biolab), 5l of React 3 
buffer and 35ml of DNase-free water. Incubations were carried out for two hours at 
37°C then terminated at 85°C for 20 minutes. Products were resolved in 1.5% low-
melting agarose (Sigma) Tris-Acetate EDTA buffer (TAE) gel, excised then purified 
using Wizard DNA Purification kit (Promega) to manufacturer‟s instructions.  
A6ND91 and GAPDH (Clontech) probes (25ng each) were labelled using 
Redivue 32P dCTP (Amersham Bioscience) with a specific activity of 3000 Ci/mmol 
and RediPrime II (Amersham Bioscience). Samples were incubated at 37°C for 10 
mins and stopped with 5l 0.2M EDTA. Unincorporated 32P labelled nucleotides 
were removed using NICK Spin columns (Pharmacia) according to manufacturer‟s 
instructions. Specific activities of A6ND91-FLAG and GAPDH probe were calculated 
using a LS60000SC scintillation counter (Beckman) with 4mls Eco-scint scintillation 
fluid (National Diagnostics). Probes were incubated with 10mg/ml denatured sheared 
salmon testes DNA (Sigma) for 5 mins at 95°C. Using calculation below 17.2l of 
A6ND91-FLAG and 9l of GAPDH generated 1x106cpm/ml, respectively. 
Volume of Hybridisation Buffer x (1x106cpm/ml) 
Specific activity of probe (cpm/ml)  
 
 
Human Multiple Tissue Northern Blot (Clontech) was pre-hybridized in 15ml 
ExpressHyb (Clontech) for 30 mins, with continuous rotation for 30 mins at 37°C in a 
Hybridisation oven (Amersham).  Express-Hyb solution was removed and replaced 
immediately with 15ml of fresh Express-Hyb solution containing labelled probes and 
incubated for 1 hr at 37°C. Incubation solution was removed and blot was washed in 
50mls of 2X Saline Sodium Citrate buffer (SSC) containing 0.05% SDS several times 
at room temperature then washed for 1 hour with continuous agitation at 37°C. Wash 
was removed and replaced with 50mls 0.1X SSC, 0.1% SDS wash solution and 
under continuous rotation blot was washed for 1 hour at 37°C. Blot was removed 
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with forceps and immediately covered with plastic wrap, to ensure the membrane did 
not dry. The wrapped blot was securely placed in an X-ray film cassette and exposed 
for 24 hours to X-ray film (Sigma) at –70°C with two intensifying screens. 
Prior to membrane incubation with the GAPDH probe, membrane bound 
A6ND91 probes were removed from membrane by placing blot immediately in sterile 
H2O containing 0.5% SDS at 90–100°C. Blot was incubated for 10 min, shaking 
frequently and removed, checked with a Geiger counter, air-dried, and then re-used.  
 
2.2.3 In-vitro Expression of Human A6ND91-FLAG  
A6ND91-FLAG construct was designed and cloned using Marathon-ready 
human liver cDNA (BD Clontech) by Dr. C. J. Mann. The sequence of the forward 
oligonucleotide (human OAP37A, see Appendix II) contained an EcoR1 restriction 
site for cloning purposes. The reverse oligonucleotide (human OAP37B2, see 
Appendix II) contained the FLAG epitope tag (DYKDDDDK), which was fused in-
frame to the carboxyl terminus of human A6ND91 cDNA, followed by a terminator 
codon and a BamH1 restriction site. The cDNA was inserted into pCDNA4/TO 
(Invitrogen) (Section 2.3.3-2.3.6).  
Using the T-Rex mammalian expression system (Invitrogen), the tetracycline-
repressor expression vector (pcDNA6/TR) was stably transformed into a rat 
hepatoma McRH7777 cell line, kindly donated by the Jan Boren laboratory 
(Wallenberg Laboratory, Goteborg University, S-41345 Goteborg, Sweden). 
Transfections with pCDNA4/TO vectors were performed with the Calcium Phosphate 
Transfection kit (Invitrogen), and individual clones were isolated as described in 
Chapter 2.3.10.  This work was performed by Dr. C. J. Mann.  
Cell lines were maintained in D-MEM Complete, made up of D-MEM (1X) L-
Glutamine, 4500 mg/L D-Glucose, without Sodium Pyruvate (Invitrogen), 
supplemented with 10% Fetal Calf Serum (Labtech International), 200 U/ml 
Penicillin-Streptomycin (Invitrogen), 2mM L-Glutamine (Invitrogen). Cells containing 
pcDNA6/TR and pcDNA4/TO vectors were selected with Zeocin (250ug/ml) 
(Invitrogen) and Blasticidin (3g/ml) (Sigma). Transcription was induced by overnight 
incubation with tetracycline (100ng/ml) (Sigma). Cells were incubated at 37°C in 
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5.0% CO2 until 70% confluent. Cells were washed with PBS and removed from 
flasks with 15mls of 0.05 % Trypsin, 0.53 mM EDTA (Invitrogen) for 3 mins. Trypsin 
was inactivated with 30ml of D-MEM Complete. Cells were pelleted at 1,000rpm for 3 
mins (Meistral 3000C Centrifuge) and re-suspended in 1ml of D-MEM Complete. An 
equal aliquot of cells and 0.4% Trypan blue (Sigma) were mixed and using a 
haemocytometer viable (clear) cells were counted. Viable cells were seeded to 2x106 
in a 6cm dish. A6ND91-FLAG and control cells were incubated overnight with 
1mg/ml tetracycline to induce human A6ND91-FLAG transcription. 
 
2.2.4 NAD: NADH and NADP: NADPH Assays 
NAD: NADH and NADP: NADPH Assays (BioVision) were reconstituted to 
manufacturer‟s instructions.  Briefly: NAD Cycling Enzyme Mix was reconstituted 
with 220µl NAD Cycling Buffer and 2µl/assay aliquoted.  NADH and NADPH 
developer was solubilised with 1.2 ml of ddH2O (Biovision). NADH and NADPH 
standards were prepared with 200µl DMSO (Sigma) to generate 1 nmol/µl NADH 
and NADPH standard solutions.  
A6ND91-FLAG cells and control cells were seeded at 2 x 105 in 10mls of 
Complete D-MEM and incubated at 37oC in the presence of tetracycline for 16 hours. 
Cells were washed with ice-cold PBS to remove residual media. Cells were removed 
by scraping and pelleted at 3,000 rpm for 5min. Excess PBS was removed from 
pellet and cells were extracted with 400µl of NADH/NAD or NADPH/NADP Extraction 
Buffer by two cycles of freeze/thaw (20min on dry-ice, then 10min at room 
temperature). Samples were vortexed for 10sec and centrifuged at 14,000 rpm for 
5min. Extracted NADH/NAD and NADPH/NADP supernatant was transferred into a 
new tube and kept on ice. 
Standard Curves for NADH and NADPH were set up to manufacturer‟s 
instructions in duplicate to generate 0, 20, 40, 60, 80, 100 pmol/well standards, to 
final volumes of 50µl with NADH/NAD or NADPH/NADP extraction buffer, 
respectively.   
A total of 50µl of A6ND91-FLAG and control sample extracts were transferred 
into a 96-well plate in duplicate and kept on ice.  Another 200µl of extracted 
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A6ND91-FLAG and control samples were heated to 60°C for 30mins to degrade 
NAD and NADP. Samples were cooled on ice and precipitates were removed by 
centrifugation for 30sec at 14,000rpm. 50µl of NAD or NADP decomposed A6ND91-
FLAG and control samples were aliquoted into 96-well plate in duplicate. NAD or 
NADP Cycling Mix was made up to manufacturer‟s instructions and 100µl was added 
to ALL samples in a 96 well-plate. Samples were mixed and incubated at room 
temperature for 5mins to convert NAD to NADH or NADP to NADPH. After 
incubation period, 10µl NADH or NADPH developer was aliquoted into each sample 
and left at room temperature for 4 hours. Reactions were stopped by adding 10µl of 
Stop Solution. Samples were analysed at OD450 nm on LP400 micro-plate reader 
(Bio-Rad Laboratories). A6ND91-FLAG and control sample OD readings were 
applied to NADH or NADPH standard curve. Amounts of total NAD(t), NADH, NADPt 
and NADPH were calculated and divided by the samples‟ protein concentration. 
Concentration of NADt or NADH was expressed in ng/mg protein.  
NAD: NADH Ratio is calculated as: [NADt – NADH]/NADH 
NADP: NADPH Ratio is calculated as: [NADPt – NADPH]/NADPH 
 
2.2.5 ATP: ADP Assays 
A6ND91-FLAG cells were plated at a cell density of 2 x106 into 9cm diameter 
NUNC cell culture plates. Cells were incubated with 10l tetracycline (100ng/ml) for 
16 hours under standard cell conditions.  After incubation, all media were removed 
and cells were washed in ice-cold PBS solution to remove any traces of media. Cells 
were harvested with cell scrapers into 600l of ice-cold perchloric acid (5% PCA w/v) 
(Sigma). Cellular homogenate was vortexed for 30 secs and PCA-insoluble material 
was removed by centrifugation at 10,000rpm for 2 min. Supernatant was transferred 
to a new Eppendorf tube. To supernatant, 1.1 volume of tri-n-octylamine and 1, 1, 2-
trichlorotrifluorethane (1:1) (Sigma) was pipetted, vortexed briefly, then centrifuged at 
10,000 rpm for 30 secs. The top layer was transferred to an Eppendorf, and re-
extracted twice more with 1.1 volume of solvent. Samples were stored at -80°C.  
Nucleotides were separated by ion-exchange chromatography on a Mono-Q 
PC1.6/5 column run on a SMART System (Amersham Biosciences). Adenine 
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nucleotides were resolved using a linear (0-175mM) KCl gradient in 10mM K2HPO4 
pH8.0 and 50mM K2HPO4 pH8.0, 250mM KCl and detected by absorbance of 
254nm, at a flow rate of 0.2 ml/min. Peaks were analysed using SMART System 
software and compared to nucleotide standards (AMP, ADP and ATP) (Sigma) made 
up to 1mM in HPLC grade H2O (Sigma). Areas under ADP and ATP peaks were 
quantified by SMART System software and used to calculate ADP: ATP ratios. 
 
2.3 Cloning and Expression of EDM07494-FLAG  
2.3.1 Construction of EDM07494-FLAG cDNA 
RNA from Kyoto rats was converted into double-stranded cDNA by reverse 
transcription using SuperScript™ III First-Strand Synthesis System (Invitrogen).  
Briefly, 5μg of total RNA was mixed with 1μl of 50μM oligo (dT)20  oligonucleotide, 
1μl of 10 mM dNTP mix and made up to 10μl with DEPC-treated water. Samples 
were incubated at 65°C for 5 mins, then placed on ice for at least 1 min. cDNA 
Synthesis Mix was made up using 2μl 10X RT buffer, 4μl 25 mM MgCl2,  2μl 0.1 M 
DTT, 1 μl RNaseOUT (40 U/μl) and 1μl SuperScript III RT (200 U/μl). 10μl of cDNA 
Synthesis Mix was added to each 10l RNA sample, mixed, and briefly centrifuged. 
Oligo (dT)20
 oligonucleotide was annealed to template for 50 mins at 50°C. 
Termination of reaction was achieved at 85°C for 5 mins then chilled on ice. Each 
sample was incubated with 1μl of 5U/l RNase H (NEB) for 20 min at 37°C. 
EDM07494-FLAG was amplified from 2l cDNA mix using 3l 10 X Reaction 
Buffer, 0.6l 50mM MgCl2, 0.6l 100mM dNTP mix,1l Advantage Polymerase (1.1 
μg/μl) (Clontech), 1l (10M) each of oligonucleotide EDM07494-Forward and 
EDM07494-FLAG Reverse (Appendix II) and made up to 30l with DNase free 
water. PCRs were carried out in 0.2ml 96 well thin-walled PCR plate (ABgene) using 
a PTC-225 PCR machine (MJ Research). Amplification cycles comprised an initial 
DNA denaturation step for 5 min at 95°C, followed by 30 cycles of 30 sec 
denaturation step at 95°C, 1 min annealing step at 58°C and a 2 min elongation step 
at 72°C.  
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2.3.2 Purification of Amplified EDM07494-FLAG cDNA 
To purify PCR-products for cloning, they were size fractionated using 1% low 
melting agarose (Sigma)/TAE gel electrophoresis (Section 2.1.x) and glass wool 
centrifugation.  Specifically, PCR-products were visualised using a low ultra violet 
wavelength transilluminator (CAMLAB Ltd), to minimise possible damage to DNA, 
then excised from gel and placed on to a small amount of glass wool compacted into 
an 0.5ml Eppendorf tube with a pierced base. Samples were centrifuged at 5,000 
rpm to elute PCR-products from gel slices. Eluted PCR-products were washed with 
300l DNase-free water in Microcon YM-100 Centrifugal Filter Units (Millipore) at 
10,000rpm for 10 mins. 
 
2.3.3 Restriction Enzyme Digestion of EDM07494-FLAG cDNA and PcDNA4/TO 
Vector 
PcDNA4/TO vector (~2g) and EDM07494-FLAG cDNA PCR-product (~1g) 
were digested with 10U of Hind III (New England Biolabs) at 37 °C for 1 hour, 
according to the manufacturer‟s instructions.  Reactions were terminated by heat 
inactivation at 72°C for 20 mins. Samples were purified of small-sized cleaved DNA 
products and reaction buffer using Microcon 100 columns (Section 2.3.2) and 
restricted with EcoR1 to manufacturer‟s instructions. Desired products were purified 
by 1% low melting agarose/TAE gel electrophoresis plus glass wool filtration 
(Section 2.3.2) and purified of contaminates using Microcon 100 columns. 
 
2.3.4 Ligation of PcDNA4/TO vector EDM07494-FLAG cDNA 
Ligations were carried out in 10l containing differing ratios (i.e. 1:1, 2:1, 3:1, 
1:0.5, 0.5:2.5 and 0:1) of PcDNA4/TO vector (13 to 65.6ng) to EDM07494-FLAG 
cDNA (Figure 2.1), 1l (1U) T4 DNA Ligase and 1l 1X T4 DNA Ligase buffer to 
manufacturer‟s instructions (New England BioLab). Incubations were carried out at 
24°C for 16 hours. 
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2.3.5 Transformation of TOP10 bacterial cells with Plasmid DNA 
One Shot TOP10 Chemically Competent E. Coli cells (Invitrogen) were 
thawed on ice, divided into 50l aliquots and incubated with 5l of ligation mix for 30 
mins on ice. Bacteria plus ligation mix were “heat shocked” at 42°C for 30 secs, 
placed on ice for 2 mins, and then mixed with 250μl of pre-warmed Super Optimal 
Culture (S.O.C.) medium. Incubations were performed horizontally at 37°C for 1 hour 
at 225 rpm in a shaking incubator. Each transformation mix was spread (i.e. 20 and 
200 μl) on to a pre-warmed LB/agar containing 100g/ml of ampicillin in a petri dish. 
These were inverted and incubated overnight at 37°C.  
 
2.3.6 Growth of Transformed Bacterial Colonies 
Individual ampicillin-resistant bacterial colonies were inoculated into 5ml of LB 
medium containing 100g/ml ampicillin and incubated horizontally overnight at 37°C 
in a shaking incubator at 225 rpm. PcDNA4/TO vector containing EDM07494-FLAG 
cDNA was purified using QIAprep Miniprep (Qiagen) according to manufacturer‟s 
instructions. Essentially, bacteria were pelleted at 4°C, 8,000rpm for 5 mins in J2 
centrifuge, using JA-10 Beckman rotor.  Pelleted bacterial cells were re-suspended 
in 250μl Buffer P1 and transfered to a micro-centrifuge tube. To mix 250μl Buffer P2 
was added and mixed thoroughly by inverting the tube 4–6 times to avoid shearing of 
genomic DNA.  To lysed bacteria 350μl of Buffer N3 was mixed immediately and 
thoroughly by inverting the tube 4–6 times then centrifuged at 4oC for 10mins at 
13,000 rpm in an Eppendorf centrifuge. Supernatants were applied to QIAprep spin 
column and centrifuged for 1min. QIAprep spin column were washed by adding 
500l Buffer PB and centrifuged for 1 min. QIAprep spin columns were re-washed 
with 750l Buffer PE and centrifuged for 1 min. Flow-through was discarded and the 
spin column centrifuged for an additional 1 min to remove residual wash buffer. 
QIAprep columns were placed into 1.5 ml micro-centrifuge tubes and DNA was 
eluted by adding 50μl Buffer EB (10 mM Tris·Cl, pH 8.5) to the centre of each spin 
column, and centrifuged for 1 min. 
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Figure 2.1 EDM07494-FLAG Cloned into Expression Vector pcDNA4/TO. 
Restriction sites EcoR1 and HINDIII within Multiple Cloning Site (MCS) were used to 
ligate full length EDM07494-FLAG cDNA . Arrows indicate direction of transcription. 
EDM07494-FLAG cDNA is represented with large light blue arrow. Brown arrow 
represents Zeocin Resistance gene (ZeocinR). Green arrow represents the 
ampicillin-resistance gene (AmpR). Blue arrow contains the CMV promoter (PCMV) 
and the sequence for tetracycline-responsive operator (TetO). 
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2.3.7 Screening Constructs for EDM07494-FLAG Insert  
PCR‟s were performed (Section 2.3.1) on ~ 1g PcDNA4/TO 
vector/EDM07494-FLAG constructs in a final volume of 10 l. Reactions were 
analysed by agarose gel electrophoresis. Constructs were sequenced using forward 
PCDNA/F2, reverse PCDNA/R2, EDM07494-Forward and EDM07494-FLAG 
Reverse oligonucleotides (Appendix II) using automated fluorescent DNA ABI3730xl 
sequencer (Applied Biotech) through the Core CSC Genomics Laboratory. 
Sequence files were verified using ChromasPro v1.34 (Technelysium).  
 
2.3.8 High Yield Growth and Purification of EDM07494-FLAG Construct 
Individual colonies of transformed cells were inoculated into 15mls of sterile 
LB containing 100mg/ml of ampicillin. Cultures were incubated in a shaking incubator 
for 4 hours at 37°C then transferred to 500ml of sterile LB/ampicillin. Cultures were 
incubated overnight at 37°C in a shaking incubator. Plasmids were purified using 
QIAGEN Plasmid-Plus Maxi Kit to manufacturer‟s instructions (Section 2.1.1).  
Plasmid DNA concentration was quantified using 260-nm absorption and DNA purity 
was assessed using the 260 nm/280 nm ratio.  
 
2.3.9 Stable Cell line Rat 
Rat hepatoma McRH7777 cells stably transformed with pcDNA6/TR (Section 
2.2.3), were seeded at a density of 2 x 105 at passage number 5. Cells were 
incubated with 2ml of serum-free complete-D-MEM medium (SFM) in six-well culture 
dishes (NUNC). At 70% cell confluences, 3:2, 3:1, and 6:1 ratios of FuGENE 6 
Transfection Reagent (Roche) to PcDNA4/TO vector: EDM07494-FLAG DNA were 
inoculated into each well made up to a final volume of 1ml with SFM. Cells were 
incubated for 24 hours, until 70 % confluent. 
Cells were transferred to 9cm cell culture dishes (NUNC) and incubated in 
Complete D-MEM with selective antibiotics Zeocin (250g/ml) and Blasticidin 
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(3g/ml) (Section 2.2.3). Cells were incubated for ~5 days, with several changes of 
Complete D-MEM media until individual colonies were visible by eye. 
 
2.3.10 Isolation of Colonies 
Growth media were removed from 9cm cell culture plates and cell colonies 
were washed carefully with 5mls PBS. Using sterile, curved tip forceps, cloning 
cylinders (Millipore) were carefully dipped into autoclaved silicon grease (VWR), then 
placed greased-side down over the colony creating a seal between the cylinder and 
plate. Cloning cylinders were filled with 100l of 0.05 % Trypsin, 0.53 mM EDTA and 
incubated at room temperature for 2 mins. Trypsin and dissociated cells were 
removed and pipetted into 96 well cell culture plates (NUNC) with 500l of Complete 
D-MEM. Cells were incubated overnight at 37°C, followed by Complete D-MEM 
media change. Established cells were subsequently transferred to larger dishes (i.e. 
a six well plate until confluent, then transferred to a 9cm cell culture plate) (Section 
2.2.3).  
 
2.4 Microarray Methods  
2.4.1 RNA Extraction 
All centrifugations were carried out in an Eppendorf Centrifuge 5415C 
(Anderman) at ≥10,000 rpm. Total RNA extraction was carried out with the Qiagen 
RNeasy-Plus Mini Kit according to the manufacturer‟s instructions. This methodology 
was chosen because it selectively excludes RNAs <200 nucleotides such as 5.8S 
rRNA, 5S rRNA, and tRNAs and as such enriches for mRNAs. In brief, 2x106 cells 
were incubated on ice with 600l guanidine-isothiocyanate RLT buffer plus 6l β-
mercaptoethanol (14.3M) to inactivate RNAses and remove genomic DNA. Cells 
were homogenised on ice for 30 secs using a rotor-stator T25 homogeniser (Janke 
and Hunkel). The homogenate was transferred to a gDNA Eliminator spin column.  
Centrifugation was carried out for 2 mins at 10,000 rpm. The flow-through was mixed 
with 600µl of 70% ethanol and applied to an RNeasy spin column. Columns were 
centrifuged at 10,000rpm for 2 mins and developed with 700µl Buffer RW1 and two 
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500µl washes of Buffer RPE.  RNA was eluted by carefully adding 30l of room 
temperature RNase free water to the centre of the columns‟ membrane. Following 
the 2 min incubation period, RNA was recovered by centrifugation (2 mins at 14,000 
rpm).    
 
2.4.2 Quantitative and Qualitative Assessment of RNA  
RNAs were assessed by spectrophotometer analyses and on an Agilent 2100 
Bioanalyzer. In brief, RNA samples (2l) were mixed with 5 volumes of sample 
loading buffer (Sigma), heated to 65°C for 10 mins, chilled on ice and immediately 
then loaded onto a 1% agarose mini-gel alongside 1l of RNA ladder (Sigma). Gel 
electrophoresis was performed in 1 x Tris/Borate/EDTA (TBE) at 120V for 5 mins. 
Products were visualised on an InGenius Syngene Bio Imaging machine (SLS) using 
GeneSnap software. 
Spectrophotometer analyses were performed in RNAse-free quartz cuvettes. 
Cuvettes were cleaned with 0.1 M NaOH, 1 mM EDTA and rinsed in RNase-free 
water. Total RNA (1l) was diluted 1/250 with 150mM Tris buffer pH8.0.  OD 
readings at 260nm and 280nm were the formula 40 x A260 x dilution factor (250), 
where 1 unit at 260 nm corresponds to 40 µg of RNA per ml (A260 = 1 = 40 µg/ml) 
was applied. The 260: 280 ratios were also determined and for use in microarray 
experiments this ratio had to be > 1.6.  Further quantification was performed using 
RNA 6000 Nano-Chips filled with a gel-dye mixture (Agilent). 5μl of sample buffer 
was added to each sample well. Samples (1μl each) at 250ng/μl were loaded into 
chip A (n=7) and chip B (n=6). RNA 6000 ladder (Ambion) was denatured and l 
was loaded into the assigned ladder well. Decontaminating the Bioanalyser electrode 
of RNAses, RNaseZap was performed with Decontamination Solution (Ambion).  
RNA samples were diluted in RNAse-free water to 250ng/l, denatured at 
70°C for 2 mins with 1.2l RNA 6000 ladder, and immediately placed on ice. The 
RNA 6000 Nano Chip was placed in the chip-priming station and syringe-loaded with 
9l of gel-dye mix into the bottom of well G. An additional 9l of gel-dye was loaded 
into the remaining wells marked G. The remaining 13 empty wells, including the 
ladder well were filled with 5l of RNA 6000 Nano Marker (Agilent) and 1l of 
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denatured RNA 6000 ladder pipetted into ladder well. Denatured RNA samples were 
then loaded into the remaining 12 wells. The chip was vortexed for 1 min, placed in 
the Bioanalyser machine and the 18S and 18S ribosomal RNA intensity peaks were 
examined.   
 
2.4.3 First-Strand cDNA synthesis 
A buffer master mix was prepared for each reaction, this contained 4l (5x) 
First Strand Buffer (Invitrogen), 2l 0.1M dithiothreitol (DTT) (Invitrogen) and 1l 
10mM dNTPs (Invitrogen). 7l of master mix was mixed with 10g total RNA, 
100pmol T7-(T)24 and 1l Poly A+ Controls from a pre-synthesized mixture of lys, 
phe, dap, thr and trp RNA from modified B. subtilis genes were made up to a final 
volume of 11l with nuclease free water). Samples were pipette-mixed, incubated at 
65-70°C for 10 mins and then placed on ice. Samples were incubated at 42°C for 2 
mins, after which 2l of superscript II reverse transcriptase (Invitrogen) was added. 
Samples were gently mixed and incubated for 1 hour at 42°C, and immediately 
processed in the second strand synthesis reaction. 
 
2.4.4 Second-Strand cDNA synthesis 
Second-Strand cDNA master mix was prepared (130l) per sample and mixed 
with first-strand reactions. The master mix contained 30l (5X) Second Strand Buffer 
(Invitrogen), 3l (10mM) dNTPs (Invitrogen), 1l (10 Units) DNA Ligase (Invitrogen), 
4l DNA Pol1 (40 Units) (Invitrogen), 2l (2 Units) Rnase H (Invitrogen), and 90l 
nuclease-free water. Incubations were carried out for 2 hours at 16°C using a chilled 
lid on a G-Storm PCR Machine (GRI) to reduce condensation. Double-stranded 
cDNA was purified using the GeneChip Sample Cleanup Module (Affymetrix), as 
recommended by the manufacturer.  In brief, double-stranded cDNA was mixed with 
600l cDNA binding buffer, applied to a cDNA Cleanup Spin Column and centrifuged 
at > 10,000rpm for 1 min. The column was developed with 750l cDNA wash buffer 
with a 1 min centrifugation step at > 10,000rpm, followed by 5 mins of centrifugation 
at > 10,000rpm with the lid removed to dry the membrane. cDNA was eluted with 
14l of cDNA elution buffer, which was placed directly into middle of the spin column 
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membrane and left for 1 min at room temperature prior to a 1 min centrifugation at > 
10,000rpm.   
 
2.4.5 Preparation of cRNA 
All reagents were part of the Bioarray High Yield RNA Transcript Labelling Kit 
(Enzo).  For each in vitro transcription (IVT) reaction, 12l double-stranded cDNA 
was mixed with an IVT master mix containing 4l (10x) HY Reaction Buffer, 4l 
Biotin-labelled ribonucleotides, 4l DTT, 4l Rnase Inhibitor Mix, 2l T7 RNA 
Polymerase and 10l nuclease-free water. Reactions were incubated at 37°C for 5 
hours and agitated every hour to ensure even reaction conditions.  
Purification of cRNA was performed using the GeneChip Sample Cleanup 
Module (Affymetrix). In brief, 60l of nuclease-free water and 350l of IVT cRNA 
Binding buffer was mixed with each in-vitro transcription reaction.  The resulting 
mixture was applied to an IVT cRNA Cleanup Spin Column and subjected to a 15 
secs centrifugation at 10,000rpm. Spin columns were washed with 500l IVT cRNA 
Wash buffer followed by a 500l 80% ethanol wash, with each wash involving a 
centrifugation step (10,000rpm for 15 secs). Spin column membranes were air-dried 
at room temperature for 5 mins. cRNA was eluted in 11l of Rnase-free water (2 
mins at room temperature) applied directly onto the column membrane, and 
recovered  by centrifugation (10,000rpm for 1 min). This procedure was repeated 
using 10l of Rnase free water.  
 
2.4.6 Hybridisation and Staining Procedures 
cRNA fragmentation, hybridisation, staining and scanning procedures were 
kindly performed by Mr Anthony Brooks of the CSC/IC Microarray Centre (MaC).  
cRNA samples (20µg) were added to 4µl 5X fragmentation buffer (Affymetrix),  made 
up to final volumes of 20µl with RNase-free dH2O and incubated at 95°C for 35 mins. 
After incubation, samples were centrifuged for 2 mins at 10,000 rpm and 15µl of 
each reaction was used for hybridisation. Fragmented cRNAs were incubated at 
99°C for 5 mins, cooled at 45°C for 5 mins and resulting precipitants were removed 
by centrifugation (10,000rpm for 5 mins) and discarded. 
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Eukaryotic hybridisation controls (Affymetrix) and control oligonucleotide B2 
(Affymetrix) were incubated at 65°C for 5 mins. For each cRNA sample, the 
hybridization master mix contained 2150µl 2X hybridisation buffer, 5µl control 
oligonucleotide B2 (3nM), 15µl 20X eukaryotic hybridisation controls (BioB, BioC, 
BioD, Cre), 3µl (10mg/ml) herring sperm DNA (Promega), 3µl (50mg/ml) acetylated 
BSA (Invitrogen), 15µl purified cRNA (15µg) and 109µl RNase-free dH2O. cRNA 
hybridization mixes (200l) were loaded into pre-wetted (1x hybridisation buffer) 
GeneChip Rat Genome 230 2.0 Arrays (Affymetrix). Hybridisations were performed 
overnight at 45°C in an Affymetrix Hybridization Oven 640.   
 
2.4.7 GeneChip Wash and Staining Procedure 
Hybridization mixes were removed from GeneChip.  Arrays were washed 
each with 200l of Affymetrix Wash buffer A using the Affymetrix Fluidics 450 
automated washing station. During the wash procedure, Streptavidin-phycoerythrin 
(SAPE) stain master mix was prepared per array, using: 600l 2x stain Buffer; 540l 
RNase-free water; 48l (50mg/ml) acetylated BSA (Invitrogen) and 12l (1mg/ml) 
SAPE (Molecular Probes). A total volume of 600l of the SAPE stain mix was 
applied to each GeneChip by the automated fluidics station. GeneChips were 
washed with 200l of Affymetrix Wash buffer A and then incubated for overnight with 
600l of antibody mix containing per array: 300l 2x Stain Buffer; 266.4l RNase-
free water; 24l (50mg/ml) acetylated BSA; 6l (10mg/ml) normal goat IgG (Sigma) 
and 3.6l (0.5mg/ml) of biotinylated antibody (Vector Labs). GeneChips were 
repeatedly washed with 200l of Affymetrix Wash buffer A. GeneChips were 
scanned with the Affymetrix Scanner 3000, to produce a .dat file, which was 
converted to a .cel file. 
 
2.4.8 Analysis of Gene Chip Data 
Microarray image files (.cel) were imported into the Comprehensive R-based 
Microarray Analysis web server (CARMAweb;https:// CARMAweb.genome.tugraz.at 
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/CARMA/). Raw intensity values were normalised to remove any variation potentially 
attributable to non-biological effects. This involved applying the following: 
1) A “background correction” to remove non-specific background intensities on 
the scanned images;  
2) A “rma background correction”.  In brief, PM probe intensities are corrected 
by a global model for the distribution of probe intensities. The model is based 
on plots of the empirical distribution of probe intensities.  
3) A “Quantile normalization algorithm” designed to reduce undesired non-
biological differences between chips (Bolstad et al 2003). 
4) A “PM correction”, to minimize non-specific signal contributions such as 
unspecific binding or cross-hybridization of cRNA to Perfect Match (PM) 
probes. This was performed with the Affymetrix MAS 5 algorithm, which 
compares hybridization values of the mis-matched (MM) probes (i.e. probes 
with one or two nucleotides altered) with the signals for the perfect matched 
(PM) probes.  
5) A “summarization algorithm”, which combines multiple pre-processed probe 
intensities to a single expression value. Specifically, the “Liwong” method that 
applies a multi-chip model to each probe-set was used.   
 
 
2.4.9 Principle Component Analysis (PCA) 
PCA (Raychaudhuri et al 2000) is a multivariate statistical technique that 
allows the identification of key variables (or combinations of variables) in a multi-
dimensional data set. The goal of this PCA was to reduce the dimensionality of the 
data matrix across experiments to observe any variation of individual chips.  PCA 
was performed on A6DN91-FLAG1 (n=3), A6DN91-FLAG2 (n=3), Control 1 (n=3) 
and Control 2 (n=3) normalised data (n=31099 probe sets) using the cluster analysis 
module, GenesisWeb (https://CARMAweb.genome.tugraz.at/genesis/index2.html). 
Analysis was conducted across all experiments using an Eculidian distance 
parameter and viewed in 2 dimensions (x dimension). 
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2.4.10 Identifying Differentially Expressed Genes 
Significance Analysis of Microarray (SAM) algorithm was used on normalised 
data. In brief, SAM computed a statistic for each probe set, measuring the strength 
of the relationship between probe-sets values and the response variable (i.e. control 
versus test samples) using a permutation procedure. Cut-off values for significance 
were determined by a tuning parameter, the “delta value”, which defines the 
threshold of false positives in a validated data-set. The number of delta values was 
set at 50. A multiple testing “Benjamini & Hochberg” correlation was applied to 
correct for false positive results. Expression data were categorized in terms of false 
discovery rates (FDR) (Hochberg et al 1990). 
 
2.4.11 Annotation of Unknown Expressed Sequence Tags (ESTs) 
Annotation was performed using the NetAffx™ Analysis Centre 
(http://www.affymetrix.com/analysis/index.affx and the Basic Local Alignment Search 
Tool (BLASTN version 2.2.15) from the National Centre of Biotechnology Information 
(NCBI; http://www.ncbi.nlm.nih.gov/blast/).  
 
2.4.12 Gene Ontology (GO) 
Differentially expressed probe data-set (n=1934 probes, FDR = 0.0053) were 
analysed on the CARMAweb server using the Bioconductor Gostats package. 
Hyper-geometric p values were used to define over–represented probe sets in this 
data-set.  
 
2.4.13 Real Time Rt-PCR 
Total cellular RNAs were isolated from A6ND91-FLAG 1 (n=4), A6ND91-
FLAG 2 (n=4), Control 1 (n=4), and Control 2 (n=4), cells using Qiagen RNeasy 
purification kits (Qiagen) according to the manufacturer's instructions. To reduce 
DNA contamination, samples were treated with RNase-free DNase (10 U/μl, Qiagen) 
for 30 min at 20°C and then for 15 min at 65°C. cDNA synthesis was performed 
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using 1g total RNA and Qiagen cDNA synthesis kit to manufacturer‟s instructions. 
Reverse transcription was performed for 50 min at 42°C. Total cDNA was diluted in 
RNAse-free distilled water (Qiagen) and 5ng of diluted cDNA was used for each 
PCR reaction. RT-PCR was performed on Actb (QT00193473), Lcat (QT00184926), 
Fabp1 (QT00188783), Hao1 (QT01625834), Serping (QT01607326), Nars 
(QT01617084), Hao2 (QT00183554), Gpt1 (QT01083789), Ddah1 (QT00177513) 
and Cd36 (QT01830395) using QuantiTect Oligonucleotides (Qiagen) and 
specifically designed oligonucleotide for A6ND91-FLAG (Appendix II) on a 7300 RT 
PCR System (Applied Biosystems) using QuantiTect SYBR Green (Qiagen).  
Thermal cycling conditions consisted of 40 cycles at 95°C for 10 sec, 61°C for 
5 sec, 72°C for 10 sec. The fluorescence signal increase of SYBR-GREEN was 
automatically detected during the 72°C phase of the PCR. Analysis of the melting 
curve excluded the amplification of unspecific products. All PCRs were performed in 
duplicate. 
A standard curve was generated using 6 serial dilutions in duplicate to 
ascertain the efficiency of each target gene (i.e. A6ND91, Lcat, Fabp1, Hao1, 
Serping, Nars, Hao2, Gpt1, Ddah and Cd36) to the endogenous house-keeping gene 
-actin.  Standard curves were calculated by SDS software, and test samples were 
fitted to the generated curve (Applied Biosystems). Transcripts specific cycle 
threshold (Ct) signals were normalized to Ct signal of the house-keeping gene -
Actin using the 2-[][]Ct method.  
[][] Ct = []Ct, sample - []Ct, -Actin 
Oligonucleotide sequences are available in Appendix II. 
 
2.4.14 KEGG PATHWAY Analysis 
Differential probe-sets with p < 0.05 (n =10,986 probe-sets) displaying an 
Entrez Gene ID were imported into KEGG PATHWAY 
(http://www.genome.ad.jp/kegg/tool/color_pathway.html). Each Entrez Gene ID was 
tagged with a colour code representing fold-change values (e.g. RED for increased 
expression, GREEN for decreased expression). KEGG pathways were manually 
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filtered according to the significant categories termed by previous GO analysis 
(Section 2.4.11). 
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Chapter 3 Characterisation of Human A6ND91 and Rat EDM07494 
3.1 Introduction 
Important insights into the hepatic lipogenesis and secretion of VLDL have 
been derived from the study of animal models (Koteish et al 2002). In the well-
characterised orotic acid (OA) model of fatty liver, increases in total liver TG, 
cholesterol and phospholipids associate with decreases in serum VLDL (Cartwright 
et al 1993). Using a combined two-dimensional gel and proteomic analysis, our 
group identified a novel ~36KDa protein, EDM07494, from liver microsomes 
prepared from Kyoto rats fed OA (Section 2.1.1). At the one-day time point, 
EDM07494 was estimated to be increased ~ two-fold compared to ~ fifteen-fold at 
the 14-day time point as judged by silver-stained 2D gels (Section 1.4, Figure 1.6). 
Other proteins identified as being increased in this model included; a) Betaine 
homocysteine S-methyltransferase, Methylmalonate semialdehyde dehydrogenase, 
Ethylene-responsive catalase (ER60), Glucose-Regulated Protein, 78-KD (Grp78), 
Glucose-Regulated Protein, 94-KD (Grp94), Regucalcin, Alpha-2u-globulin and 
Carbonic anhydrase III (data not shown), all previously associated with hepatic lipid 
accumulation (Shibata el al 2003, Tanaka et al 2005, Morand et al 2005, Qiu et al 
2005, Nakashima et al 2006, Escrich et al 2004, Park at al 2004); and b) Ornithine 
transcarbamylase (Otc)  and Arginosuccinate Synthase (Asl), are two enzymes 
linked to urea cycle (Section 5.2.5.4, Figure 5.3).   
OA is synthesized from L-Glutamine, bicarbonate (HCO3) and L-Aspartate 
through a series of four enzymatic steps. As shown in Figure 3.0, the trifunctional 
protein, CAD, catalyses three enzymatic reactions via Carbamyl phosphate 
synthetase 2 (CPS 2),  L-Aspartate transcarbamylase and Dihydro-orotase. The first 
step is catalyzed by CPS2 which exists in two forms in animal cells (Hager et al 
1967). Cytosolic CPS is involved exclusively in pyrimidine biosynthesis (i.e. CPS2), 
and is ubiquitously expressed, preferring L-Glutamine as a source of NH3. The other 
form, CPS1, is located in mitochondria, and uses free NH3, synthesising carbamyl 
phosphate for the urea cycle. The next two enzymes, L-Aspartate transcarbamylase 
and Dihydro-orotase are complexed with the CPS2 (Jones et al 1980) in the 
cytoplasm, permitting transfer of intermediates (i.e. (1) carbamyl phosphate plus
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Figure 3.0 Synthesis Orotic Acid (OA). OA is synthesized from L-Glutamine, bicarbonate (HCO3), and L-Aspartate through a 
series of four enzymatic steps. The first 3 reactions are carried out by the tri-functional protein CAD that initiates and regulates de 
novo pyrimidine biosynthesis. CAD contains active sites for; 1. Carbamyl phosphate synthetase 2 (CPS2). 2. Aspartate 
carbamyltransferase and 3. Dihydro-orotase. The fourth enzyme, dihydro-orotate dehydrogenase (DHODH), catalyzes the oxidation 
of dihydro-orotate to orotic acid. DHODH is bound to the outer surface of the inner mitochondrial membrane permitting diffusion of 
substrates to and from the cytoplasm and mitochondria.  
 
 
6
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L-Aspartate forming (2) Dihyro-orotate). Dihydro-orotate is converted to OA by 
Dihydro-orotate dehydrogenase, which is bound to the outer surface of the inner 
mitochondrial membrane (Evans et al 2004), permitting diffusion of substrates to and 
from the cytoplasm and mitochondria. 
In-silico cloning of the homologous human A6ND91 cDNA, encoding 1-283 
amino acids (aa), predicts a protein of an estimated mass of ~30kDa, 6kDa smaller 
than rat EDM07494 isolated from the microsomes of OA treated rat. A6ND91 shares 
extensive sequence identity with an ancient family of proteins containing a domain of 
unknown function (DUF 108). Highly conserved residues are predicted to form a 
Rossmann fold that binds dinucleotides (i.e. nicotinamide adenine dinucleotide 
(NAD) and nicotinamide adenine dinucleotide phosphate (NADP)). Subsequently the 
co-ordination of dinucleotides NAD+/NADP+ was observed in a deep pocket in a 
crystal structure of a homologous protein from eubacterium Thermatoga maritime 
(TM1643) (Section 1.4, Figure 1.7) (Yang et al 2003). Yang et al showed that the 
putative dehydrogenase activity of TM1643 is highly specific for L-Aspartate and 
speculated that it produced the unstable intermediate iminoaspartate; contributing to 
de novo biosynthesis of NAD in bacteria and plants (Begley et al 2001). TM1643 in 
vitro had undetectable dehydrogenase activity against similar amino acids, such as 
L-Glutamate and L-Asparagine and did not possess L-Aspartate Oxidase activity. 
Based on these results, the enzyme was named "Aspartate Dehydrogenase" 
(AspDH).  
Mammalian cells are unable to syntheses the nicotinamide ring of NAD from 
L-Aspartate, obtaining this molecule in the diet as vitamin B3 or from the essential 
amino acid tryptophan (Katoh et al 2006; Foster et al 1980; Panozzo et al 2002) 
(Figure 3.1). Figure 3.1 shows iminoaspartate (i.e. Bacteria and Plants) is condensed 
with dihydroxyacetone phosphate producing quinolinate, a reaction catalyzed by 
NadA (quinolinate synthetase A). Iminoaspartate is very unstable in an aqueous 
solution and decomposes to the four-carbon dicarboxylic acid, oxaloacetate (OAA) 
plus ammonia. Figure 3.1 also shows OAA further decomposing to pyruvate and 
carbon dioxide by spontaneous decarboxylation.  
OAA is an intermediate of the Tricarboxcylic Acid (TCA) cycle and 
gluconeogenesis. The cytosolic isozyme Phosphoenolpyruvate carboxykinase 1 
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(PCK1), a rate limiting step of gluconeogensis in liver and kidney, decarboxylates 
and phosphorylates OAA to phosphoenolpyruvate and carbon dioxide (Pilkis et al 
1992). Mouse studies involving liver-specific over-expression of Pck1 causes 
excessive glucose production (Beale et al 2007). The authors also showed Pck1 
liver-specific knockouts have an inability to remove OAA from the TCA cycle, leading 
to fatty liver. Whole-body knockouts of Pck1 resulted in death probably due to 
reduced TCA cycle function, resulting from perturbations in gluconeogenesis, 
removal of excess OAA from the TCA cycle and glyceroneogenesis (i.e. synthesis of 
glycerol-3-phosphate as a precursor for fatty acid esterification into triglycerides).  
TM1643 showed a Michaelis constant (Km) for L-Aspartate was 20 times lower 
with NAD compared to NADP (Yang et al 2003). The lower Km for NAD, suggests 
that TM1643 uses NAD as a co-factor for the oxidation of L-Aspartate in vivo. This is 
also consistent the observation that NAD was co-crystallized with TM1643 (Yang et 
al 2003). In this redox reaction, energy is transferred to NAD+ by reduction forming 
NADH. In eukaryotes, electrons are carried by NADH (electron donor) from cytosolic 
reactions (i.e. glycolysis and gluconeogenesis) into the mitochondrion by 
mitochondrial shuttles, such as the malate-aspartate shuttle (Dawson et al 1982). 
NADH can be oxidized by the electron transport chain (Figure 3.2), which pumps 
protons across the mitochondrial membrane, generating adenosine triphosphate 
(ATP) through oxidative phosphorylation (Mitchell et al 1967).  
Figure 3.2 shows the energy released by the H+ ions of NADH generates a 
chemiosmotic potential by pumping H+ protons across the inner membrane of the 
mitochondrial cristae. This potential is then used to drive ATP synthase and produce 
ATP from ADP; producing on average around 29 to 30 ATP per glucose molecule. 
The electrons are finally transferred to exogenous oxygen, and with the addition of 
two protons, water is formed. 
To dissect the structure and potential function of A6ND91 a combined protein, 
metabolite and structural analysis were performed with the TM1643 human 
homologue A6ND91. This chapter describes A6ND91 in relation to the ancient family 
of proteins containing a domain of unknown function 108 (DUF 108) and mRNA 
expression in human tissue. The sub-cellular localisation of endogenous A6ND91 
and EDM07494 were identified using an A6ND91-FLAG polyclonal antibody,
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Figure 3.1 Synthesis of NAD in Mammals and Bacteria. Figure is adapted from the KEGG Nicotinate and Nicotinamide 
metabolism pathway (http://www.genome.jp/kegg/pathway/map/map00760.html) and associated literature (Yang et al 2003). 
Iminoaspartate product is unstable in aqueous solution and can decompose to oxaloacetate and pyruvate.  Arrows indicate flow of 
substrates through pathway. QPRT, Quinolinate phosphoribosyltransferase; NADSYN1, NAD synthetase 1; NMNAT2, Nicotinamide 
nucleotide adenylyltransferase; nadA, Quinolinate synthase ; nadB, L-Aspartate oxidase ; AspDH, Aspartate dehydrogenase; NP, 
Nucleoside phosphorylase; NRK, Nicotinamide riboside kinase; NAD, Nicotinamide adenine dinucleotide.
7
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Figure 3.2 Mitochondrial Electron Transfer Chain (ETC). Transfer of electrons 
(dark blue arrows) through the ETC is used to pump H+ protons (red arrows) from the 
mitochondrial matrix into the inter-membrane space, creating an electrochemical 
proton gradient across the mitochondrial inner membrane (IMM). This 
electrochemical proton gradient allows ATP synthase to use the flow of H + through 
the enzyme back into the matrix to generate adenosine triphosphate (ATP) from 
adenosine diphosphate (ADP) and inorganic phosphate (P). Complex I (NADH 
coenzyme Q reductase; labelled I) accepts electrons from the TCA cycle electron 
carrier nicotinamide adenine dinucleotide (NADH), and passes them to coenzyme Q 
(ubiquinone; labelled UQ), which also receives electrons from complex II (succinate 
dehydrogenase; labelled II). UQ passes electrons to complex III (cytochrome bc1 
complex; labelled III), which passes them to cytochrome c (Cyt c). Cyt c passes 
electrons to Complex IV (cytochrome c oxidase; labelled IV), which uses the 
electrons and hydrogen ions to reduce oxygen to H2O. 
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and both human A6ND91-FLAG and rat EDM07494-FLAG protein differences were 
compared using an in vitro cell system. The impact of A6ND91-FLAG expression on 
McRH7777 cells redox potential and ATP: ADP levels were addressed using NAD: 
NADH and NADP: NADPH plus ATP: ADP assays, respectively. 
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3.2 Results 
3.2.1 Protein Alignment of DUF 108 family 
A6ND91 shares extensive sequence homology with an ancient family of 
proteins containing a domain of unknown function 108 (DUF 108) (Figure 3.3).  It 
comprises complete proteins in Archea Methanothermobacter (AAB85469), 
Bordetella parapertussis (CAE37593), Thermatoga maritime (TM1643), Mus 
musculus (AAH19451), Rattus norvegicus (EDM07494), Homo sapiens (A6ND91), 
Danio rerio (AAH81519) and a single domain in a large C. Elegans (CAA84799). 
Comparison of human protein A6ND91 with TM1643 revealed 25.2% amino acid 
identity, whilst rat EDM07494 shared 25.0% amino acid identity, whilst human and 
rat proteins share 88.3% amino acid identity. 
Figure 3.3 shows the highly conserved residues (highlighted with *) that are 
predicted to form a Rossmann fold that binds dinucleotides, based on the crystal 
structure of TM1643 (Section 1.4, Figure 1.7) and ASA-DH (Yang et al 2003, 
Hadfield et al 2001). Rossmann folds are common in enzymes that use NAD in their 
reactions, suggesting that A6ND91 and EDM07494 may function as a 
dehydrogenase (Rao et al 1973).  
 
3.2.2 Expression of A6ND91 in Human Tissue 
Northern blot analysis established human mRNA is predominantly expressed 
in the liver, and to a lesser extent in kidney and brain (Figure 3.4). The transcript size 
of A6ND91 mRNA was determined to be ~1.1 kb consistent with the predicted Mw of 
1061 kb from human transcript NM_001114598. Expression of the housekeeping 
gene glyceraldehyde-3-phosphate-dehydrogenase mRNA (GAPDH) was detected 
uniformly in all tissues. 
 
3.2.3 Characterization of Human A6ND91-FLAG Polyclonal Antibody 
Characterization of the rabbit polyclonal human A6ND91-FLAG antibody was 
conducted by Western blot analysis using McRH7777 cells expressing  
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AAB85469        ------------------------ MILMMVGIVGCGAIAN-LITGFVRD-GRVPVKLGFF 34
CAE37593        ------------------------- MTHRIAFIGLGAIASDVAAGLLAD-AAQPCQLAAL 34
TM1643          --------------------------- MTVLIIGMGNIGK------------ KLVELGNF 21
AAH19451        ----------------- MATSTLPQVPYKVGVVGYGRLGQSLVSRLLAQGSELGLELVFV 43
EDM07494        ----------------- MDASMVPRVPHKVGVVGYGRLGQSLVSRLLAQGSELGLELVFV 43
A6ND91          --------------------- MADRGPWRVGVVGYGRLGQSLVSRLLAQGPELGLELVFV 39
AAH81519        --------------------- MADK-ALKVGIVGYGHLGQFLVEKIQSEGAEVGLQLAFV 38
CAA84799        MSAASEAVSGALFQH//FFLIELKMTKLRVGFIGYGHLGKFLVEKLRLLPEEF--EIVKI 478
: .:* * :.. ::  .
AAB85469        YDRDLERAENLASMVDGRAVLDVADMLPEVDLVVEAASPEAVRDLVPEILEAGKDVVVMS 94
CAE37593        TRNAADLPPALAGRVALLDGLP-GLLAWRPDLVVEAAGQQAIAEHAEGCLRAGLDMIICS 93
TM1643          EK--IYAYDRISKDIPGVVRLDEFQVPSDVSTVVECASPEAVKEYSLQILKNPVNYIIIS 79
AAH19451        WNRDPGRMAGSVPPALQLQDLTALEER-HPDLVVEVAHPKIIHESGAQILRH-ANLLVGS 101
EDM07494        WNRDPGRMAGSVPPALQLEDLTTLEER-HPDLVVEVAHPKIIHESGVQILRH-ANLLVGS 101
A6ND91          WNRDPGRMAGSVPPSLQLQNLAALGER-RPDLVVEVAHPKIIHESGAQILRH-ANLLVGS 97
AAH81519        WNRNADKLKDSLPKDLILHDLSDFTQR-DTDVIVEVCHPLIVKEFGVRFLSH-AHFLVGS 96
CAA84799        WNRSVG-----EPGVQGLETLTAENLK-DIDLVVEVAHPKIIADYGELILEH-CDLFAGS 531
* . :** . : :     * . . *
AAB85469        VGALMDPELREMLVELASLNDATIHVPSGAIVG-LDGLKAASMGNIESVKLITRKPPRSL 153
CAE37593        AGALADDALRARLIAAAEAGGARIRVPAGAIAG-LDYLQAVAGRDDAEVVYESRKPVAAW 152
TM1643          TSAFADEVFRERFFSELKNSPARVFFPSGAIGG-LDVLSSIK-DFVKNVRIETIKPPKSL 137
AAH19451        PSALADQTTEQQLLEASKRWGHTVFVARGALWGSEDISRLDAAGGLQSLRVTMATHPDGF 161
EDM07494        PSALADQTTERQLLEASNHWGHTVFVARGALWGCEDISRLDAAGGLQSLRVTMATHPDGF 161
A6ND91          PSALSDQTTERQLLEASQHWDHAVFVARGALWGAEDIRRLDAAGGLRSLRVTMATHPDGF 157
AAH81519        PSALSDGQLEQDLRTAAKQQGKTLYVPSGALWGGQDIQKMNDSGTLRALSIRMSKHPSCF 156
CAA84799        PTCFANQELLEKLTKLSLSHGKKLLIPAGALWGANDIQKMADVGSLKGLTVTMIKHPTSF 591
.: :      :          : .. **: * * :     .
AAB85469        GISMD------------- EKKVLYRGRASEAVKKFPLNIN--VAAALSLACD--RDVDVE 196
CAE37593        RAELPGMGIDPD---TLAESRTLFSGPAREAALRFPKNLN--VAATLALAGIGMTRTRVE 207
TM1643          GLDLKG------------- KTVVFEGSVEEASKLFPRNIN--VASTIGLIVG-FEKVKVT 181
AAH19451        RLEGPLAAAHS----SGP-RTVLYEGPVRGLCPLAPRNSNTMAAAALAAPSLGFDRVIGV 216
EDM07494        RLEGPLAAAHS----SGP-RTVLYEGPVRGLCPLAPRNSNTMAAAALAAPSLGFDRVIGV 216
A6ND91          RLEGPLAAAHS----PGP-CTVLYEGPVRGLCPFAPRNSNTMAAAALAAPSLGFDGVIGV 212
AAH81519        RLTGGLLSDWT----EGEGRRVLYRGSVAELCPLAPNNVNTMAAAAIAASKLGFHGVTGE 212
CAA84799        KLGSPLFEINEKAKLEETNETVLYEGSVRGLCPLAPNNVNTMAGGALAASNLGFDEVKAK 651
.:: * . * * * ...::. .
AAB85469        IIADP-AVDRNVHEVTVRGDFG------EFKTITEN--VRCSVNPKTSVMAAYSAIKLLK 247
CAE37593        VVVDP-RARGNQHRIQVRSPLG------EMQIELVN--APSPANPKTSWLVAQSVLATIR 258
TM1643          IVADP-AMDHNIHIVRISSAIG------NYEFKIEN--IPSPENPKTSMLTVYSILRTLR 232
AAH19451        LVADLSLTDMHVVDVELLGPPGPSGRSFAVHTHRENPAQPGAVTGSATVTAFWHSLLGCC 276
EDM07494        LVADLSLTDMHVVDVELTGPPGPTGRSFAVHTHRENPAQPGAVTGSATVTAFWHSLLGCC 276
A6ND91          LVADTSLTDMHVVDVELSGPRGPTGRSFAVHTRRENPAEPGAVTGSATVTAFWQSLLACC 272
AAH81519        IVSDTALADYHVVEVDVTGPDG-----FSVKTMRQNPAKLGAVTGKATYNSFWSSLLVCK 267
CAA84799        LISDPKMTDWHVVEVRVEGDDG-----FEVITRRNNPAKPGAVTGQLTYYSFLSSIKESR 706
:: * :   : : . * * . . . :       :    
AAB85469        SLSENIHIGT- 257
CAE37593        RHLARFTIG-- 267
TM1643          NLESKIIFG-- 241
AAH19451        QLTSRPGIHLC 287
EDM07494        QLPSRPGIRLC 287
A6ND91          QLPSRPGIHLC 283
AAH81519        GHGGR--VYLC 276
CAA84799        YKPIG--VQLC 715
.
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Figure 3.3 Alignment of Proposed L-Aspartate Dehydrogenase (DUF 108) using 
ClustalW 2.0.10. Amino acid alignment for proposed L-Aspartate dehydrogenase 
homologs from DUF 108 family; Archaebacteria (AAB85469), Yeast (CAE37593), 
Thermatoga maritime (TM1643), Mus musculus (AAH19451), Rattus norvegicus 
(EDM07494), Homo sapiens (A6ND91), Danio rerio (AAH81519) and a single 
domain in a large C. Elegans (CAA84799). Crystal structure of TM1643 is shown 
above amino acid sequence. Alignment parameters included Gonnet 250 Matrix. 
Identical residues (*), conservative amino acid substitutions (:), and semi-
conservative amino acid substitutions (.) are shown below the aligned sequences. 
Truncated sequence (//) and gaps (-) are also shown. Small residues (small+ 
hydrophobic (incl. aromatic -Y)) are shown in RED. Acidic residues are BLUE, Basic 
residues are MAGENTA and Hydroxyl + Amine + Basic residues are GREEN. 
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Figure 3.4 Tissue distribution of A6ND91 mRNA. Northern blot (Clontech) 
containing poly A+ mRNA from human tissues was hybridized with a 32P 
radiolabeled cDNA probe for A6ND91. Control experiments with a GAPDH probe 
revealed that mRNA was present in all tissues. A6ND91 mRNA is predominantly 
expressed in the liver and kidney and with small levels in the brain. 
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A6ND91-FLAG. Figure 3.5 shows the polyclonal antibody detected a distinct 
immuno-reactive product migrating at a molecular mass of ~30 kDa, consistent with 
the size of the immuno-reactive product detected in McRH7777 cell lines expressing 
human A6ND91-FLAG as detected monoclonal FLAG (M2) antibody (Figure 3.6).  
Figure 3.5 also shows endogenous rat EDM07494 from McRH7777 cells has 
an apparent mass of ~36KDa, ~6KDa larger than human A6ND91-FLAG and 
consistent with the estimated mass of rat EDM07494 isolated from rat liver 
microsomes (Section 1.4, Figure 1.6). To investigate the observed size difference 
between the rat and human proteins, Western blot analysis was performed on total 
liver protein from human and rat liver (Figure 3.7). Using the polyclonal antibody 
raised against human A6ND91-FLAG one distinct immuno-reactive product was 
observed in all individual samples. In human liver, a product of ~29KDa was 
detected. This slight size decrease compared to the 30KDa human A6ND91-FLAG is 
likely to be due to the FLAG epitope on the recombinant protein. By contrast, rat liver 
contained the distinct 36KDa product consistent with previous rat protein data. These 
data suggest that human and rat A6ND91 have different molecular masses, 30kDa 
and 36KDa, respectively. 
 
3.2.4 In vitro expression of A6ND91-FLAG and Rat EDM07494-FLAG 
To investigate whether the size difference between rat and human proteins 
was due to the rat transcript encoding a larger product, in-silico analysis of the rat 
transcript was performed. This revealed that the 5‟ end of transcript NM_001009643 
encoding rat protein EDM07494 contained an extra 12 coding nucleotides (i.e. four 
amino acids) compared to human A6ND91 (Section 3.2.1, Figure 3.3).  The 
estimated mass of the rat protein was 31,384 KDa compared to the human 
30,941KDa protein. 
Recombinant rat EDM07494-FLAG was stably transfected in McRH7777cells 
and examined by Western blot analysis using the monoclonal FLAG (M2) antibody. 
Western Blot detected an immuno-reactive product with an apparent molecular mass 
of 36KDa (Figure 3.8) suggesting that the polyclonal antibody raised against 
A6ND91-FLAG is detecting rat EDM07494-FLAG protein. 
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Figure 3.5 Western Blot Analysis of Human A6ND91-FLAG and Rat EDM07494 
from cells. Lane 1 corresponds to 10g of total protein from human A6ND91-FLAG 
expressing cell line. Lane 2 corresponds to 500g of total protein from control 
McRH7777cells.  Lane 3 contains 500g of total protein from human A6ND91-FLAG 
expressing cell line. Human A6ND91-FLAG and rat EDM07494, lane 1 and 2 
respectively, were detected using 1/500 rabbit polyclonal human A6ND91-FLAG 
antibody. Lane 3 was exposed to pre-immune rabbit serum. 
 
 
 
 
 
Figure 3.6 Western Blot Analysis of Human A6ND91-FLAG Expression from 
McRH7777 cell line +/- Tetracycline. Lanes 1, 2 and 3 correspond to 10g, 20g 
and 50g, respectively, of total protein from human A6ND91-FLAG cells without 
tetracycline. Lane 4, 5 and 6 corresponds to 1g, 5g and 10g, respectively, of total 
protein from human A6ND91-FLAG cells with tetracycline induction. Human 
A6ND91-FLAG protein was detected using 1/3000 mouse monoclonal Flag (M2) 
antibody.  
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Figure 3.7 Western Blot Analyses of Human A6ND91 and Rat EDM07494 
Proteins. Lane 1 and 2 correspond to 150g and 300g of total pooled human liver 
protein (n=22). Lane 3 and 4 corresponds to 150g and 300g of total pooled 
Sprague Dawley rat liver protein (n=93). A6ND91 and EDM07494 were detected 
using 1/500 rabbit polyclonal human A6ND91-FLAG antibody. 
 
 
 
 
Figure 3.8 Western Blot Analyses of Human A6ND91-FLAG and Rat EDM07494-
FLAG Expression from McRH7777 Cell Lines. Lanes 1, 2 and 3 correspond to 
100g, 150g and 200g, respectively of total protein from rat EDM07494-FLAG 
cells plus tetracycline. Lanes 4, 5 and 6 correspond to 100g, 150g and 200g, 
respectively, of total protein from rat control cells. Lanes 7, 8 and 9 correspond to 
100g, 150g and 200g, respectively of total protein from human A6ND91-FLAG 
cells without tetracycline. Human A6ND91-FLAG and rat EDM07494-FLAGproteins 
were detected using 1/3000 mouse monoclonal Flag (M2) antibody.  
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Figure 3.9. 2D electrophoresis and Western blot analysis of Human A6ND91-
FLAG. Total cellular protein (i.e.100g) from human A6ND91-FLAG expressing cells 
were separated by 2D SDS-PAGE. Western blot identified two immuno-reactive 
products, at 30KDa, proposed to be A6ND91-FLAG. Products where detected using 
1/500 rabbit polyclonal human A6ND91-FLAG antibody.  
 
 
 
 
 
Figure 3.10 2D Electrophoresis and Western blot Analysis of Rat EDM07494-
FLAG. Total cellular protein (i.e.100g) from rat EDM07494-FLAG expressing cells 
were separated by 2D SDS-PAGE. Western blot identified only one immuno-reactive 
product, at 36KDa, proposed to be EDM07494-FLAG. Products where detected 
using 1/3000 dilution monoclonal (M2) FLAG antibody.  
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3.2.5 Post Translational Modification of Human A6ND91-FLAG and Rat 
EDM07494-FLAG 
Total protein from cells expressing human A6ND91-FLAG and rat EDM07494-
FLAG were separated by 2D gel electrophoresis and analysed by Western blot using 
the monoclonal FLAG (M2) antibody (Figures 3.9 and 3.10). Two products at 30KDa 
were detected in cells expressing A6ND91-FLAG. The observed products had 
masses consistent with human A6ND91-FLAG.  The shift along the horizontal pH 
axis suggested that one of these products was post-translationally modified. Cells 
expressing rat EDM07494-FLAG produced only one immuno-reactive product.  
Analysis of A6ND91 and EDM07494 amino acid sequence using NetPhos 2.0 
identified possible phosphorylation motifs in both human and rat proteins (Table 3.0). 
Calculations based on rat and human-FLAG tagged polypeptides and the addition of 
one phosphate group to each protein gave predicted isoelectric points and molecular 
masses (Table 3.0) that are consistent with the observed 2D data for human 
A6ND91-FLAG but not for Rat EDM07494-FLAG (Figures 3.9 and 3.10).  
To evaluate the possibility that rat and human proteins may undergo 
phosphorylation, total cellular extracts were prepared from A6ND91-FLAG and Rat 
EDM07494-FLAG McA-RH7777 cell lines and treated with shrimp alkaline 
phosphatase (SAP). Additionally, a control experiment using inactivated SAP was 
performed. Western blot analysis of total cellular protein extracts from cell 
expressing A6ND91-FLAG treated with active SAP revealed a single protein spot on 
2-dimensional SDS-PAGE gel (Figure 3.11A1), while two protein spots were 
identified in the control experiment (Figure 3.11A2).  
Treatment of rat total cellular extract expressing EDM07494-FLAG with active 
SAP produced two immuno-reactive products, one migrating at an apparent mass of 
~30KDa with a more basic pI and the other migrating at a similar size to the control 
EDM07494-FLAG (i.e. ~36KDa) (Figures 3.11B1 and 3.11B2). The loss of 6KDa is 
predicted to correspond with the removal of over 60 phosphates (Table 3.0). This 
degree of phosphorylation seems unlikely, suggesting that the behaviour of 
phosphorylated EDM07494-FLAG as determined by SDS-PAGE is aberrant, as 
observed for phospholamban (Wegener et al 1984) and human adenovirus ElA 
proteins (Smith et al 1989).   
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Protein Phosphorylation pI Mw 
Human  0 phosphate 
              1 phosphate 
              2 phosphates 
              3 phosphates 
6.19 
6.04  
5.90 
5.76 
30947 
31025 
31103 
31181 
Rat        0 phosphate 
              1 phosphate 
              2 phosphates 
              3 phosphates 
            60 phosphates 
5.98 
5.87 
5.76 
5.65 
2.34 
31389 
31467 
31545 
31623 
36067 
 
Table 3.0 Effect of Phosphorylation on Iso-Electric Point and Molecular Mass. 
Prediction of the effect of phosphorylations on rat EDM07494-FLAG and human 
A6ND91-FLAG using Scansite Molecular Weight & Isoelectric Point Calculator 
(http://scansite.mit.edu/cgi-bin/calcpi) using the dissociation constant (pKa = 2.12 for 
first ionization and pKa = 7.21 for the second on the molecular weight (Mw) and iso-
electric point (pI). 
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Figure 3.11 Dephosphorylation Assay of Human A6ND91-FLAG and Rat 
EDM07494-FLAG proteins. Total cellular protein at 10g (1) aliquots for human 
A6ND91-FLAG (figure 3.11A1) and 200ug of rat EDM07494-FLAG (figure 3.11B1) 
were incubated with 500 units shrimp alkaline phosphatase (SAP) and inactivated 
SAP 65oC (figure 3.11A2 and figure 3.11B2). Results were analyzed by 2D SDS-
PAGE and immuno-blotting with anti-FLAG as described under "Experimental 
Procedures." Horizontal scale refers to the apparent isoelectric point (pI). Control 
assay for A6ND91-FLAG identified two immuno-reactive spots (figure 3.11A1) and a 
single immuno-reactive spot in rat EDM07494-FLAG cells (figure 3.11B1). Treatment 
with 500 units SAP shifts the pI of the proposed phosphorylated A6ND91-FLAG 
protein spot to a single spot of a more basic charge. The single rat EDM07494-FLAG 
protein spot shifted to a lower Mr of 30KDa with a more basic charge. Molecular size 
markers in kDa are shown on the left.  
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Mass spectrophotometry analysis was performed on 2D separated A6ND91-
FLAG and EDM07494-FLAG proteins. Excised gel spots were subjected to mass 
spectrometry (Ms/Ms) analysis, as described in Methods 2.1.8 and 2.1.9. Analysis of 
A6ND91-FLAG peptides produced an overall sequence coverage of 31% (Figure 
3.12A) and revealed a single serine phospho-peptide, 
LEGPLAAAH(pS)PGPCTVLYEGPVR. This was located at amino acid residue168 
(Ser168) (Figure 3.13A). This residue was unphosphorylated in the A6ND91-FLAG 
protein displaying the more basic pI (Figure 3.12B).  
Ms/Ms sequence analysis of the proposed phosphorylated rat FLAG-tagged 
protein failed to identify a phosphorylation site, despite 71% peptide coverage. 
Protein sequence coverage ruled out Ser168 as being phosphorylated. However, 
looking at mass differences between unmatched experimental peptide masses and 
theoretical peptide masses (http://www.expasy.ch/tools/findmod/) calculated from 
EDM07494-FLAG protein sequence identified a potential phosphorylation located at 
amino acid residue 139 (Ser139) (Figure 3.13B). This residue is the highest scoring 
residue (= 0.947) as predicted by NetPhos 2.0 and is not conserved in human 
A6ND91.  Peptide fragment GALWGCEDIS(pS)R has a theoretical mass of 1286.51, 
potentially matching unassigned peptide experimental masses of 1287.5752, 
1286.5098, 1286.512, 1286.5227 and 1287.5402.  Figure 3.13B shows protein 
coverage of rat EDM07494-FLAG achieved by Ms/Ms and the proposed 
phosphorylated residue as identified by the FindMod program.  
Using NetPhosK 1.0, predictions of kinase specific sites was performed on 
both human Ser168 and rat Ser139 plus surrounding residues. Table 3.1 shows the 
highest scoring kinase achieved for human A6ND91 Ser168 was Glycogen Synthase 
Kinase 3 (GSK3) (= 0.51) and for rat EDM07494 Ser139 was Cell Division Cycle 2 
(Cdc2) (= 0.50).  Table 3.1 also shows three predicted kinase sites (i.e. CaM-II, Cdc2 
and GSK3) that may phosphorylated both human and rat phosphorylated residues. 
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Figure 3.12 Detection of A6ND91-FLAG phospho-peptide by MS/MS. FLAG-
tagged A6ND91 protein was expressed in DH7777 cells and separated on 2D SDS-
PAGE and trypsin digested (see Experimental procedures). The resulting peptides 
were subjected to mass spectrometry (MS/MS). MS/MS spectrum and sequence of 
the Ser168 phosphorylated peptide (LEGPLAAAHSPGPCTVLYEGPVR) of A6ND91-
FLAG (aa. 159-181), as identified by MASCOT software. The b-ion ladder is shown 
is represented by b and the y-ion ladder represented by y. Distances between peaks 
on the horizontal mass-to-charge (m/z) axis can be used to infer partial sequences of 
the peptide. Yellow star represents ser168 (y10) in phosphorylated form (Figure A) 
and unphosphorylated form (Figure B). 
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Figure 3.13 Peptide Sequence Coverage of A6ND91 and EDM07494-FLAG 
tagged Proteins. 2D gel separated A6ND91 and EDM07494 protein were typsin 
digested and protein fragments (shown in yellow).  Figure A shows each of the 
independently identified tryptic peptides from A6ND91-FLAG highlighted in red. The 
phospho-peptide fragment LEGPLAAAHSPGPCTVLYEGPVR is underlined in red, 
with phosphorylated Ser168 highlighted with yellow star. Figure B shows peptide 
coverage from rat EDM07494-FLAG. Identified tryptic peptides analysed using 
Ms/Ms from EDM07494-FLAG are highlighted in red. NetPhos 2.0 phosphorylation 
sites above the threshold value (0.500) and not ruled out by Ms/Ms data are 
represented. Yellow stars indicate the potentially phosphorylated residue (i.e. Ser222 
= 0.865 and Thr240 = 0.877).  
 
 
 
 MADRGPWRVGVVGYGRLGQSLVSRLLAQGPELGLELVFVWNRDPGR
MAGSVPPSLQLQNLAALGERRPDLVVEVAHPKIIHESGAQILRHANLLV
GSPSALSDQTTERQLLEASQHWDHAVFVARGALWGAEDIRRLDAAGG
LRSLRVTMATHPDGFRLEGPLAAAHSPGPCTVLYEGPVRGLCPFAPRN
SNTMAAAALAAPSLGFDGVIGVLVADTSLTDMHVVDVELSGPRGPTGR
SFAVHTRRENPAEPGAVTGSATVTAFWQSLLACCQLPSRPGIHLC 
 
 MDASMVPRVPHKVGVVGYGRLGQSLVSRLLAQGSELGLELVFVWNRDP
GRMAGSVPPALQLEDLTTLEERHPDLVVEVAHPKIIHESGVQILRHANLLV
GSPSALADQTTERQLLEASNHWGHTVFVARGALWGCEDISRLDAAGGL
QSLRVTMATHPDGFRLEGPLAAAHSSGPRTVLYEGPVRGLCPLAPRNS
NTMAAAALAAPSLGFDRVIGVLVADLSLTDMHVVDVELTGPPGPTGRSF
AVHTHRENPAQPGAVTGSATVTAFWHSLLGCCQLPSRPGIRLC 
 
B 
A 
1                                                                                                                                                     46 
47                                                                                                                                                     95 
96                                                                                                                                                     142 
143                                                                                                                                                     190 
191                                                                                                                                                     238 
239                                                                                                                                          283 
1                                                                                                                                                     48 
49                                                                                                                                                     99 
100                                                                                                                                                    147 
148                                                                                                                                                    195 
196                                                                                                                                                    244 
245                                                                                                                                  287 
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Table 3.1 Predicted NetPhos 2.0 Phosphorylated Residues of A6ND91 and 
EDM07494 proteins. Pos, position of the residue analyzed. Sequence shows a 9 
residue sequence centred on the residue being analyzed. Score represents output 
score (value in the range [0.000-1.000]). Ms/Ms identified human A6ND91 
phosphorylated residue Ser168 is highlighted in RED. Predicted rat phosphorylated 
residue is shown in YELLOW. 
 
 
SERINE THREONINE TYROSINE 
Pos Sequence Score Pos Sequence Score Pos Sequence Score 
HUMAN A9ND91 
20           
23 
50  
54  
83    
97   
99   
102          
114 
145  
168        
191 
203          
218            
230    
239 
258  
267   
276 
RLGQSLVSR 
QSLVSRLLA 
RMAGSVPPS  
SVPPSLQLQ   
IIHESGAQI        
LLVGSPSAL 
VGSPSALSD  
PSALSDQTT  
LLEASQHWD          
GGLRSLRVT           
AAAHSPGPC   
APRNSNTMA  
LAAPSLGFD  
VADTSLTDM  
DVELSGPRG  
PTGRSFAVH  
AVTGSATVT  
AFWQSLLAC  
CQLPSRPGI  
0.014    
0.031    
0.073    
0.022    
0.012    
0.157    
0.013    
0.897  
0.039    
0.182    
0.340    
0.822  
0.072    
0.919  
0.607  
0.018  
0.052      
0.003    
0.004     
105   
106
149
152
173
193 
217   
220
236
244
256
260
262 
 
LSDQTTERQ  
SDQTTERQL  
SLRVTMATH  
VTMATHPDG               
PGPCTVLYE  
RNSNTMAAA  
LVADTSLTD   
DTSLTDMHV     
PRGPTGRSF  
FAVHTRREN  
PGAVTGSAT  
TGSATVTAF  
SATVTAFWQ   
0.230    
0.883  
0.016    
0.164    
0.035    
0.035    
0.085    
0.108    
0.960  
0.855  
0.414    
0.040    
0.067 
14 
176    
GVVGYGRLG         
CTVLYEGPV   
      
     
      
 
0.120    
0.208     
RAT EDM07494 
4 
24 
27 
34 
54 
87 
101 
103 
118 
139 
149 
172 
173 
195 
207 
222 
243 
262 
271 
280 
-MDASMVPR  
RLGQSLVSR  
QSLVSRLLA 
 LAQGSELGL 
 RMAGSVPPA 
 IIHESGVQI 
 LLVGSPSAL 
 VGSPSALAD 
 LLEASNHWG 
 CEDISRLDA 
 GGLQSLRVT 
 AAAHSSGPR 
 AAHSSGPRT 
 APRNSNTMA 
 LAAPSLGFD 
 VADLSLTDM 
  PTGRSFAVH 
 AVTGSATVT 
 AFWHSLLGC 
 CQLPSRPGI 
0.003 
0.014 
0.031 
0.016 
0.054 
0.023 
0.128 
0.011 
0.013 
0.947  
0.056 
0.051 
0.333 
0.454 
0.322 
0.865 
0.018 
0.052 
0.009 
0.008 
65 
66 
109 
110 
124      
153      
156      
177      
197      
224      
234      
240      
248      
260      
264      
266      
 
LEDLTTLEE  
EDLTTLEER  
LADQTTERQ  
ADQTTERQL 
HWGHTVFVA  
SLRVTMATH  
VTMATHPDG  
SGPRTVLYE  
RNSNTMAAA  
DLSLTDMHV 
DVELTGPPG  
PPGPTGRSF 
FAVHTHREN  
PGAVTGSAT 
TGSATVTAF  
SATVTAFWH 
 
0.414 
0.450 
0.323 
0.776 
0.355 
0.016 
0.164 
0.027 
0.035 
0.035 
0.322 
0.877 
0.902 
0.414 
0.040 
0.067 
18 
180 
GVVGYGRLG   
RTVLYEGPV   
      
      
     
      
 
0.120 
0.182 
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Table 3.2 NetPhosK 1.0 Kinase prediction results. Predicted kinase (above the 
threshold 0.40) for phosphorylated A6ND91 Ser168 residue identified five possible 
kinase binding motifs (i.e. GSK3, p38MAPK, cdc2, CaM-II and CKI). For the 
predicted rat phosphorylation Ser139 four possible kinase motifs (i.e. cdc2, CKII, 
GSK3, CaM II) were identified.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HUMAN A6ND91 RAT EDM07494 
Position Kinase Score Position Kinase Score 
S168 GSK3 0.51 S139 
 
cdc2     0.50 
p38MAPK 0.49 CKII     0.49 
cdc2 0.45 GSK3     0.45 
CaM-II     0.43 CaM II 0.43 
CKI     0.41  
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3.2.6 A6ND91 is Predominantly Cytosolic 
Human and rat proteins are predicted to be cytosolic (http://psort.ims.u-
tokyo.ac.jp). To assess intracellular localisation of human and rat proteins, Western 
blot analysis using the polyclonal human A6ND91-FLAG antibody was performed on 
human total liver, microsomal and cytosolic fractions (Figure 3.14).  Rat liver 
fractions, mitochondria, microsomes, cytosol from OA treated and untreated animals 
were also examined (Figure 3.15). 
 In human liver, A6ND91 was predominantly localised to the cytosolic fraction. 
A small amount of A6ND91 was also observed in the microsomal fraction. In rat liver 
a distinct immuno-reactive product with a molecular mass of ~36 KDa was 
predominantly seen in the cytosolic fraction. There was no marked difference in the 
concentration between the cytosolic fractions from rats fed OA and controls. The 
same size product was observed in OA treated microsomal fraction but was not 
detectable in the untreated fraction. These data are consistent with the 2D gels 
detecting a differential expressed 36KDa protein in the microsome fraction of OA 
treated rats. 
 
3.3.7 NAD: NADH and NADP: NADPH assay 
To address the possibility that A6ND91 may be involved in the synthesis of 
NAD (Yang et al 2003), cells expressing high levels of A6DN91-FLAG were assayed 
for the total amounts of NAD plus NADH, NADP plus NADPH and the ratio of NAD+ 
to NADH plus NADP+ to NADPH. Figure 3.16A, shows the mean total amount of 
NAD plus NADH was not significantly altered between control cells (i.e. 131.02± 
112.95 pmol/g) and A6ND91-FLAG 1 cells (i.e. 111.25± 81.19 pmol/g) and 
A6ND91-FLAG 2 cells (i.e. 66.26 +/- 27.11 pmol/g). Figure 3.16B shows the mean 
total amount of NADP+ plus NADPH was not significantly changed between control 
cells (i.e. 165.35 +/- 141.70 pmol/g) and A6ND91-FLAG 1 cells (i.e. 141.41+/- 
108.65pmol/g) and A6ND91-FLAG 2 cells (i.e. 84.19 +/- 49.26 pmol/g).   
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Figure 3.14 Cellular Localisation of Human A6ND91.  Lanes 1-3 corresponds to 
g, 200g, 300g total protein from pooled human liver (n=22). Lane 4-6 
corresponds to 100g, 200g, 300g cytosolic protein from pooled human liver 
(n=20). Lane 7-9 corresponds to 100g, 200g, 300g of microsomal protein from 
pooled human liver (n=15). 
 
 
 
 
 
 
Figure 3.15 Cellular Localisation Rat EDM07494.  Lane 1 and 2 corresponds to 
100g of mitochondrial fraction protein from control and treated Wistar rats, 
respectively (n=3). Lane 3 and 4 corresponds to 100g of cytosolic protein from 
control and treated rats, respectively (n=3). Lane 5 and 6 corresponds to 100g of 
microsomal protein from control and treated rats, respectively (n=3). Human and rat 
proteins were detected using 1/500 rabbit polyclonal human A6ND91-FLAG antibody 
and visualised as described in the methods. 
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Figure 3.16 assays measuring mean total NAD+ plus NADH and NADP+ plus 
NADPH. Two cell lines (A; n=3 and B; n=3) expressing A6ND91-FLAG and Control 
cells (n=3). Total cellular NAD+ plus NADH levels were mot significantly altered as 
were total NADP+ plus NADPH levels in A6ND91-FLAG cells compared to Control 
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Figure 3.16A shows mean NAD concentrations in control cells were 85.33 +/- 
79.50pmol/g; 38.45 +/- 41.76pmol/g in A6ND91-FLAG 1 cells and 33.50 +/- 
27.11g/l in A6ND91-FLAG 2 cells. The NAD: NADH ratio was 3.42 +/- 1.48 in 
control cells; 0.96 +/- 0.57 in (p = 0.02762) in A6ND91-FLAG 1 cells and 1.25 +/- 
0.34 in (p = 0.03439) A6ND91-FLAG 2 cells (Figure 3.17A). The results indicate that 
A6ND91-FLAG expression reduced the intracellular NAD: NADH ratio.  
Cell extracts were also analysed using the NADP cycling protocol. Figure 
3.16B shows the results revealed that NADP concentration was 57.73 +/- 
36.07pmol/g in control treated cells (n=3); 46.16 +/- 23.41 pmol/g in A6ND91-
FLAG 1 (n=3) cells and 32.04 +/- 32.36 pmol/g in A6ND91-FLAG (B) cells (n=3). 
The NADP: NADPH ratio was 2.91+/- 1.48 in control cells; 2.21± 1.05 in (p = 
0.26991) A6ND91-FLAG 1 cells and 3.16 +/- 2.42 in (p = 0.44229) A6ND91-FLAG 2 
cells (Figure 3.17B). The results indicate that A6ND91-FLAG did not alter the 
intracellular NADP: NADPH ratio.   
 
3.3.8 ATP: ADP Ratio in A6ND91-FLAG expressing Cells 
NADH donates H+ ions for mitochondrial oxidative phosphorylation and the 
synthesis of ATP. Total cellular amounts of ATP and ADP plus the ATP: ADP ratio in 
cellular extracts from control (n=3), A6ND91-FLAG 1 (n=3) and A6ND91-FLAG 2 
(n=3) cells were assessed. Nucleotides were separated by ion-exchange 
chromatography on a Mini Q column (0.1ml) attached to a SMART System 
(Amersham Biosciences). ATP and ADP levels in perchloric acid extracts of 
A6ND91-FLAG 1 cells, A6ND91-FLAG 2 cells and control cells were determined by 
ion-exchange chromatography (Figure 3.18A). Areas under the ADP and ATP peaks 
were quantified by integration using SMART System software and used to calculate 
the ATP: ADP ratios. Mean total amounts of ATP and ADP are shown in Figure 
3.18A. Control cells achieved mean total ATP and ADP peak area value (arbitrary 
unit) of 12.11 +/- 4.71 and 87.45 +/- 18.65, respectively. Cells expressing A6ND91-
FLAG 1 achieved mean total ADP and ATP peak area value (arbitrary unit) of 17.62 
+/- 12.36 and 109.01 +/- 48.61, respectively and cells expressing A6ND91-FLAG 2 
achieved mean total ATP and ADP peak area value (arbitrary unit) of 16.01 +/-  9.96  
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Figure 3.17 NAD+ / NADH and NADP+ / NADPH Ratio in cells expressing 
A6ND91-FLAG. Assays measuring NAD+ / NADH ratio established increased 
NADH compared to NAD+ in two cell lines (A; n=3 and B; n=3) expressing A6ND91-
FLAG. The NAD+ / NADH ratio were significantly altered, whereas NADP+ / NADPH 
assays did not identify and significant change in A6ND91-FLAG cells compared to 
Controls (n=3).  
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and 87.90 +/- 34.16, respectively. Although experimental cells displayed higher 
levels of ATP and/or ADP, these increases did not achieve significance (i.e. ATP-
A6ND91-FLAG 1 (p = 0.24088) and ATP-A6ND91-FLAG 2 (p = 0.49040) ADP-
A6ND91-FLAG 1 (p = 0.20462) and ADP-A6ND91-FLAG 2 (p = 0.20594)). 
I was not able to determine accurately AMP concentrations, owing to the 
levels being undetectable by the SMART System software. Therefore I used the 
ATP: ADP ratio as a measure of the energy charge within the cell. Figure 3.17B 
shows the ATP: ADP ratio was 7.71+/- 1.68 in control cells (n=4), 6.90 +/- 1.46 in 
A6ND91-FLAG 1 (n=11) and 6.14 +/- 1.37 A6ND91-FLAG 2 (n=8). Expression of 
A6ND91-FLAG did not significantly alter the ATP: ADP ratio in A6ND91-FLAG 1 (p = 
0.19021) and A6ND91-FLAG 2 (p = 0.05626) when compared to control cells. 
Although the ATP: ADP ratio in A6ND91-FLAG 2 cells compared to control cells 
appeared lower, this may achieve significance if more samples were analysed.  
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Figure 3.18 Total cellular and ratio of ATP / ADP levels in A6ND91-FLAG Cells. 
Assays measuring adenine nucleotide (i.e. ADP and ATP) in perchloric acid extracts 
from A6ND91-FLAG (A) and (B) and Control cells were analysed by ion-exchange 
chromatography. Areas under the ADP and ATP peaks were analysed using SMART 
System software and used to calculate the ATP / ADP ratio. Data are the mean of four 
independent experiments. 
p = 0.201 p = 0.210 
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3.3 Discussion  
This chapter addresses the structural and functional characteristics of human 
A6ND91 and rat EDM07494 proteins. Both proteins share extensive sequence 
identity with an ancient family of proteins containing a domain of unknown function 
108 (DUF 108). Highly conserved residues within this family of proteins are predicted 
to form a Rossmann fold (Figure 3.3). Subsequently the co-ordination of 
dinucleotides NAD+/NADP+ was observed in a crystal structure of a homologous 
protein from eubacterium Thermatoga maritime (TM1643) (Yang et al 2003).  
Enzymatic characterization by Yang et al revealed that TM1643 possesses 
dehydrogenase activity toward L-Aspartate forming iminoaspartate, which rapidly 
degrades to oxaloacetate plus ammonia. Additionally, a homologous protein 
AF1838, whose predicted amino acid sequence exhibits 38% identity with that of 
TM1643 acts as a highly thermostable L-Aspartate dehydrogenase (Yoneda et al 
2007). The group identified that a citrate molecule could be also modelled into 
AF1838. Human A6ND91 shares 30% amino acid identity with TM1643. These data 
suggest that the mammalian form of this protein may influence metabolic processes 
involving NAD, L-Aspartate, oxaloacetate and/or citrate.  
Human A6ND91 mRNA is abundantly expressed in liver and kidney, with 
marginal expression detected in total brain tissues (Figure 3.4). These tissues are 
important in the metabolism of amino acids and glucose. The liver and kidney have 
been studied extensively since 1972 in relation to gluconeogenesis (Exton et al 
1972). However, brain tissue also is capable of small amounts of gluconeogenesis 
(Sun et al 2006, Davis et al 1995). Gluconeogenesis occurs mainly in the liver with a 
small amount also occurring in the cortex of the kidney (Stanley et al 1981, Zorzano 
et al 1984).The enzymes which operate within gluconeogenesis from the substrate 
oxaloacetate onwards are localised to the cytosol. Results from Western Blot 
analysis suggest that both human A6ND91 (Figure 3.14) and rat EDM07494 proteins 
(Figure 3.15) localise predominantly to the cytosolic fraction in liver (Peng et al 
1973). It should be noted that proteins were immuno-blotted using a human 
A6ND91-FLAG polyclonal antibody.  
 
 
99 
 
Polyclonal antibodies have been known to react with other proteins by cross-
reactivity, especially across different species. Western blots suggest the specificity of 
the A6ND91-FLAG polyclonal antibody was accurate, as the estimated 36KDa rat 
immuno-reactive product is consistent with the 36KDa EDM07494 isolated by 2D gel 
electrophoresis (Section 1.4, Figure 1.6). Also, high levels of the immuno-reactive 
product was detected in the microsomal fraction of livers from Orotic Acid treated 
rats (Figure 3.15); consistent with the OA rat model EDM07494 was isolated from.  
The detection of a 6KDa size difference between human A6ND91 and rat 
EDM07494 proteins required further investigation. To confirm that the rat protein did 
not contain a 5‟ mRNA extension, full length rat EDM07494-FLAG mRNA, encoding 
287 amino acids was expressed in a hepatoma cell line. Immuno-reactive products 
detected by the highly specific monoclonal M2 FLAG antibody resolved at 36KDa on 
SDS-PAGE. These results show that the size difference between human A6ND91 
and EDM07494 is not due to an alternative initiating ATG. The most likely cause of 
altered size difference between human and rat proteins is a post-translational 
modification. 
To assess potential post-translational modifications, I adopted 2D gel 
analysis. This technique separates proteins by charge (i.e. Isoelectric point (pI)) and 
mass, thus providing a platform to observe any charge difference elicited by a post-
translational modification. 2D gel electrophoresis of A6ND91-FLAG cell lysate 
identified two, 30KDa immuno-reactive products migrating with differing pI‟s (Figure 
3.9).  The small shift in pI with no discernable alteration in mass indicated a 
phosphorylation (Patton et al 1999). No altered pI was detected for EDM07494-
FLAG protein (Figure 3.10). 
Dephosphorylation assays (i.e. SAP assays) were performed in conjunction 
with Ms/Ms on A6ND91-FLAG and EDM07494-FLAG proteins. Both proteins showed 
altered migration after SAP treatment (Figure 3.11). Following SAP treatment human 
A6ND91-FLAG revealed one immuno-reactive product, again indicating the removal 
of a phosphate(s). This shift if pI is usual with the removal of a phosphate. Ms/Ms 
identified the more acidic A6ND91-FLAG protein is phosphorylated at Serine 168 
(Figure 3.12). The more basic A6ND91-FLAG protein did not reveal a 
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phosphorylated Serine-168 residue, even though sequence coverage included 
Serine 168 (Figure 3.12) 
 Rat EDM07494-FLAG protein revealed two immuno-reactive products after 
SAP treatment; a more acidic pI 36KDa and a more basic pI at 30KDa. The 
alteration in pI is indicative of phosphate removal however this is inconsistent with 
such a large mass change (i.e. ~6KDa). Large mass changes as detected by SDS-
PAGE have been observed with phosphorylated proteins, such as phospholamban 
(Wegener et al 1984) and human adenovirus ElA proteins (Smith et al 1989). Ms/Ms 
failed to identify EDM07494 phosphorylation, even though 71% peptide coverage 
was achieved. Protein sequence coverage ruled out Ser168 as being 
phosphorylated. However, analysis of unmatched experimental peptide masses and 
theoretical peptide masses (http://www.expasy.ch/tools/findmod/) calculated from 
EDM07494-FLAG protein sequence suggested a potential phosphorylation at Serine 
139 (Figure 3.13b). This residue was the highest scoring residue (= 0.947) as 
predicted by NetPhos 2.0 and is not conserved in human A6ND91. To identify the 
potential phosphorylated residue one may adopt a phosphopeptide enrichment step 
prior to Ms/Ms analysis. However, the possibility that the phosphorylated peptide 
may not “fly” well during Ms/Ms analysis must be considered. Altering the size of the 
phosphorylated peptide fragment by digestion with an alternative enzyme (i.e. low-
specificity chemotrypsn, Pepsin or Proteinase K) may aid the identification of the 
phosphorylated residue by Ms/Ms. However one must also consider that EDM07494 
may contain a post-translational modification other than a phosphorylation (e.g. 
Glycosylation). This would need further investigation failing identification of a 
phosphorylation.  
In-silico analysis of A6ND91 amino acid sequence surrounding the 
phosphorylated Serine 168 residue predicts a Glycogen Synthase Kinase 3 (GSK3) 
motif. GSK3 is considered to be a kinase of broad range specificity, capable of 
phosphorylating a large range of candidate substrates in-vitro (Doble et al 2003). 
GSK3 was initially identified as the kinase responsible for phosphorylating the 
enzyme Glycogen Synthase (GS) (Embi et al 1980, Woodgett et al 1990). This 
enzyme plays an important role in the conversion of excess glucose into glycogen 
(Kollberg et al 2007). GS is a key enzyme in glycogenesis and is highly regulated by 
allosteric binding of glucose-6-phosphate (Bouskila et al 2008), insulin (Petersen et 
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al 2002) as well as GSK3 phosphorylation (Roach et al 2002). GS requires a 
“docking” phosphorylation prior to GS phosphorylation. This docking phosphorylation 
needs an available Serine within the GSK3 motif. I identified only one 
phosphorylated Serine residue (Figure 3.11 and Figure 3.12) within the proposed 
A6ND91-GSK3 motif, suggesting no GSK3 “docking” phosphorylation was present. 
This “docking” phosphorylation is not essentially for all GSK3 phosphorylations. The 
complex -Catenine, Axin and APC involved in Wnt signalling pathway (Akiyama et 
al 2000), does not use a priming phosphorylation for GSK3 docking (Hart et al 1998). 
The identification of the kinase responsible for A6ND91 phosphorylation will aid the 
discovery of regulatory mechanisms governing A6ND91 expression and/or activity. 
One may adopt in-vitro kinase assays to determine the kinase responsible for 
A6ND91 phosphorylation (Kawaguchi et al 2003, Kato et al 2003). 
Yang et al identified that homologous TM1643 possessed dehydrogenase 
activity towards L-Aspartate, preferentially binding to NAD+ over NADP+. They 
propose the dehydrogenation of L-Aspartate produces iminoaspartate, a key 
metabolite in the synthesis of NAD+. To address the possibility that human A6ND91 
may alter the synthesis of NAD+, assays were performed to measure NAD+/NADH 
and NADP+/NADPH total cellular levels and the respective ratios. Although total 
levels of NAD+/NADH and NADP+/NADPH in A6ND91-FLAG cells were slightly lower 
then controls, this was not significant.  However the ratio of NAD+ to NADH was 
significantly altered between A6ND91-FLAG and controls cells, with results showing 
more NADH to NAD+. No altered NADP+/NADPH ratio were detected in A6ND91-
FLAG cells. This increase in NADH to NAD+ maybe due to A6ND91 functioning as a 
dehydrogenase, preferentially binding to NAD+ over NADP+ (Yang et al 2003). An 
increased ratio of cytosolic free NADH/NAD+ causes cytosolic reductive stress, this 
is found in animal models of diabetes (Williamson et al 1993). This redox change is 
caused by increased oxidation of substrates coupled to reduction of the cofactor 
NAD+ to NADH (Williamson et al 1993). Cytosolic reductive stress from increased 
NADH/NAD+ due to increased oxidation of glucose metabolites appears to play an 
important role in diabetes (Ido et al 1997).  
NADH supplied by glucose, fatty acids and amino acids is the main substrate 
for oxidative phosphorylation, stimulating ATP synthesis (Brown et al 1992). The 
impact of increased cytosolic NADH levels in relation to ATP production in A6ND91-
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FLAG cells was assessed by SMART analysis. No significant change was detected 
in total ATP: ADP levels and ATP: ADP ratio in A6ND91-FLAG cells compared to 
controls. The near-complete lack of cytosolic NADH to oxidative ATP production has 
been documented before in chicken livers and cardiomyocytes (Allred et al 1969 and 
O'Donnell et al 2004).  Although not significant (i.e. p = 0.05626), the ratio of ATP: 
ADP was lower in A6ND91-FLAG(B) cells compared to control cells, indicating less 
ATP to ADP. The reduced ATP: ADP in A6ND91-FLAG(B) cells could be explained 
by two different mechanisms: a decrease in energy production or an increase in 
some ATP-consuming processes (i.e. gluconeogenesis or ureagenesis).Decreases 
in ATP: ADP ratio is known to affect balance between glucose, lactate and pyruvate 
production, in almitrine treated hepatocytes (Leverve et al 1994). Williamson et al 
showed that as glucose production is halted, decreases in the ratio ATP: ADP plus 
decreased levels of citrate, isocitrate, malate, and glutamate, were coupled to 
increases in pyruvate and oxaloacetate (Williamson et al 1970). Examination of 
cellular metabolites in A6ND91-FLAG cells through techniques such as Nuclear 
Magnetic Resonance (NMR) may identify perturbed metabolic substrates/pathways 
which influence lipogenic pathways.  
This chapter provides evidence that human A6ND91 is related to an ancient 
family of proteins which contain an NAD binding domain (DUF 108). Yang et al 
provides evidence that this family of proteins dehydrogenate L-Aspartate, 
preferentially binding to NAD over NADP, producing iminoasparate, which rapidly 
degrades to oxaloacetate (Yang et al 2003). The rat EDM07494 protein was 
originally isolated from the livers of OA fed rats, characterised by hepatic lipid 
accumulation and increased glucose (Rooney et al 2003, Griffin et al 2004). The 
proposed L-Aspartate dehydrogenase activity of A6ND91 is supported by; 1. 
A6ND91 is expressed in tissues important in glucose and amino acid metabolism 
(i.e. liver, kidney and brain); 2. Human and rat proteins localizes predominantly to the 
cytosolic fraction were glycolysis and gluconeogenesis pathways operate; 3. Human 
A6ND91 is phosphorylated by the proposed kinase GSK3, which controls the activity 
of GS a key enzyme in the metabolism of glucose; 4. NAD: NADH assays show 
A6ND91 expression in two rat hepatoma cell lines increase the NADH/NAD ratio, 
possibly from NAD dehydrogenation of L-Aspartate releasing the by-product NADH. 
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Collectively, results suggest that human A6ND91 may still function as an L-
Aspartate Dehydrogenase altering levels of cytosolic oxaloacetate, impacting on 
glycolysis and gluconeogenesis metabolic pathways. 
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Chapter 4 Microarray Analysis of A6ND91-FLAG Cell Lines 
4.1 Introduction 
A genome-wide microarray study was performed to identify the biochemical 
pathways perturbed in cells expressing human A6ND91-FLAG. This technology has 
become an important tool in biochemical research, allowing the simultaneous 
measurement of thousands of expressed genes in a single experiment. Studies 
adopting this technique have been widely used to identify various perturbed 
biochemical pathways due to aberrant gene expression. Pircher et al demonstrated 
the power of microarray analysis, specifically identifying a number of genes 
regulating cholesterol and bile acid metabolism in rat livers (Pircher et al 2003). 
Microarray analysis identified genes induced by nuclear receptor Farnesoid X 
Receptor, namely bile acid-CoA synthetase and bile acid-CoA: amino acid N-
acetyltransferase. These genes play a critical role in the regulation of cholesterol and 
bile acid metabolism in the liver.  
RNA from two rat hepatoma cell lines expressing human A6ND91-FLAG 
(A6ND91-FLAG 1 and A6ND91-FLAG 2) and two control hepatoma cell lines 
(Control 1 and Control 2) were hybridised to Affymetrix GeneChip Rat Genome 230 
2.0 Arrays. This technology uses oligonucleotide probes, 20 to 25 nucleotides in 
length that are synthesized via photo lithography and combinatorial chemistry 
techniques (Barone et al 2001). The array contains more than 31,000 probe sets, 
analysing over 30,000 expressed sequence tag (EST) and transcripts from 
approximately 28,000 well-substantiated rat genes. Each transcript is represented on 
the array by 16-20 probe pairs, consisting of a perfect match (PM) and a mismatch 
(MM) oligonucleotide that differs from the perfect match by only a single base in the 
centre position. The purpose of the MM sequence is to capture the non-specific 
binding that distorts the measured intensity level of the PM (Lipshutz et al 1999. 
Lockhart et al 2000).  
In this chapter, the emphasis is placed upon the quality control parameters 
used to assess total RNA and cRNA prior to hybridisation, and also upon 
normalisation parameters used to generate a “meaningful” data-set. The quality of 
gene expression data was also analysed by unsupervised principal component 
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analysis (PCA) to explore any sample variables (or combinations of variables) in 
experiments versus gene expression (Raychaudhuri et al 2000).  
Analysis of microarray by the online resource CARMAweb (Rainer et al 2006) 
allowed the identification of differentially expressed genes, with estimates of False 
Discovery Rates (FDR) being performed by Significant Analysis of Microarray (SAM) 
methodology (Tusher et al 2001). As microarray experiments generate large multiple 
testing problems due to thousands of hypotheses being tested simultaneously within 
one experiment (Nadon et al 2002), an adjustment of calculated p values was also 
performed. Adjustment of p values using Benjamini and Hochberg algorithm 
(Hochberg et al 1990) provides strong control of the FDR. 
To classify differentially expressed data-sets according to common biological 
paths and activities, Gene Ontology (GO) is often used (Kluger et al 2004, Mash et al 
2007). GO classification (Ashburner et al 2000, Harris et al 2004, Zhang et al 1999) 
seeks to provide a consistent set of shared structured vocabularies for annotating 
biological characteristics across organisms. GO analyses uses three ontology‟s to 
describe molecular function (MF), biological process (BP), and cellular component 
(CC). These classifications were chosen because they represent information sets 
common to all living forms. Briefly, MF describes the actions of gene-products at a 
biochemical level. BP describes a broad biological function. CC describes the 
location(s) of a gene product within cellular structures and macromolecular 
complexes. 
To validate microarray data quality real-time reverse transcription PCR (RT-
PCR) (Bustin et al 2000) is typically carried out on a small selection of differentially 
expressed transcripts. This is important because probe sets derived from short 
Expressed Sequences Tags (EST) can sometimes contain sequence errors resulting 
in inaccurate hybridization with target mRNAs (Boguski et al 1993). RT-PCR is a 
sensitive in-vitro technique used to amplify and quantitate RNA (Wang and Brown 
1999). 
This chapter presents results of pre-processed and normalised microarray 
data-set from cell lines expressing A6ND91-FLAG and control cells. Normalised data 
were analysed using SAM to identify transcripts that were significantly differentially 
expressed between two A6ND91-FLAG cell lines compared to two control cell lines. 
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Selected transcripts were classified using GO, helping identify biological pathways 
perturbed in rat hepatoma cells expressing high levels of A6ND91-FLAG.   
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4.2 Results 
 
4.2.1 Expression of Human A6ND91-FLAG as identified by Western Blot 
Western blot analysis using monoclonal anti-FLAG antibody shows that the 
expression of human A6ND91-FLAG at the time of RNA extraction was comparable 
between the two experimental cell lines (Figure 4.0). No human A6ND91-FLAG 
protein was detected in both Control 1 and Control 2 cells. 
 
4.2.2 Quality Control of total RNA, cDNA and cRNA  
Total RNA was extracted from two A6ND91-FLAG cell lines and two control 
cell lines, at cell densities of 2x106 per dish. Table 4.0, Figure 4.1 and Figure 4.3 
show the total yield and quality of total RNA and cRNA assessed by 
spectrophotometry and Agilent Bioanalyser chip analyses respectively. 
  Spectrophotometric measurements were performed at wavelengths of 260nm 
and 280nm on total RNA for all samples (Table 4.0). The yield of total RNA extracted 
from 2x106 cells ranged from 678ng/μL to 1518ng/μL (988.8 +/- 281.7ng/μL). The 
A260/A280 ratio ranged from 2.1 to 4.2 (for pure RNA the ratio should be between 1.6 
and 2.0). The ratio measurements were higher then the recommended 2.0 cut off 
value, indicating contamination and/or a poorly calibrated spectrophotometer. 
Samples (2.5ng/l) were also assessed on pico chips using an Agilent 2100 
Bioanalyser (Figure 4.1). All samples achieved a RNA integrity number (RIN) score 
above 8 (9.6 +/- 0.4), indicating good quality RNA (Table 4.0). The concentration of 
total RNA (Table 4.1) was comparable between all samples, ranging from 1504pg/l 
to 3163pg/l (2455.1 +/- 478.1pg/l). The range of total RNA concentration is fairly 
consistent with the spectrophotometric measurements. Figure 4.3 shows the 
Bioanalyzer Electropherogram profiles for total RNA isolated from 13 samples, all 
samples separate well, showing two distinct ribosomal peaks corresponding to 18S 
and 28S ribosomes, and no identifiable “smears” between 28S and 18S ribosomal 
bands.  
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Figure 4.0 Western Blot of A6ND91-FLAG from A6ND91-FLAG 1, A6ND91-FLAG 
2 and Control Cell Lines. Lane 1, 2 and 3 corresponds to 4g, 6g and 10g 
respectively, of total cellular protein from A6ND91-FLAG 1 cells. Lane 4, 5 and 6 
corresponds to 4g, 6g and 10g, respectively, of total cellular protein from 
A6ND91-FLAG 2 cells. Lane 7, 8 and 9 corresponds to 4g, 6g and 10g, 
respectively, of total cellular protein from Control 1 cells. Lane 10, 11 and 12 
corresponds to 4g, 6g and 10g, respectively, of total cellular protein from 
Control 2 cells. All cells were incubated in the Complete D-MEM plus tetracycline for 
16 hours. Human A6ND91-FLAG protein was detected using 1/3000 dilution mouse 
monoclonal Flag (M2) antibody and visualised with 1/3000 goat anti-mouse IgG 
horseradish peroxidase conjugated secondary antibody, followed by enhanced 
chemiluminescence. Protein concentrations were determined in duplicate with Bio-
Rad DC protein assay. Migration of pre-stained molecular weight standards are 
indicated on the left hand side in kilo Daltons (kDa). 
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Figure 4.1 Agilent 2100 Bioanalyzer Scans of Total RNA from 13 Samples. RNA 
6000 Nano Chips (Section 2.4.2) containing denatured total RNA, chip A (n=7) and 
chip B (n=6). 1l of denatured RNA 6000 ladder was loaded into assigned ladder 
well. Fluorescence Units (FU) (y axis) is plotted against nucleotide (nt) (x axis). The 
scan shows total RNA is of good quality with a 28S:18S rRNA ratio of 2.0. The trace 
shows two distinct peaks are visible, a larger 28S ribosomal RNA band and a smaller 
18S rRNA band with a flat baseline between the two peaks. The intensity of the 28S 
band is double the intensity of the 18S band in all the 13 samples. Calculations were 
performed using Biosizing software. 
 
 
  Ladder                             A6ND91 - F LAG1.1                A6ND91 - FLAG1.2      
         A6ND91 - F LAG1.3              A6ND91 - F LAG2.1               A6ND91 - FLAG2.2      
        A 6ND91 - F LAG2.3               A6ND91 - FLAG2.4                     
L adder                                Control 1 .1                             Control 1 .2     
    Control 1 .3                             Control 2 .1                             Control 2 .2      
   Control 2 .3      
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 Spectrophotometer Agilent 2100 Bionanalyser 
260/280nm 
ratio 
Total RNA 
yield (g) 
RIN 
 
Total RNA 
(pg/l) 
cRNA yield (g) 
A6ND91-FLAG1.1 2.2 1080 9.7 2253 71.1 
A6ND91-FLAG1.2 2.7 900 9.6 2517 51.9 
A6ND91-FLAG1.3 2.3 948 9.5 2355 56.2 
A6ND91-FLAG2.1 2.9 648 9.8 2650 48.8 
A6ND91-FLAG2.2 2.8 825 9.7 2629 56.2 
A6ND91-FLAG2.3 3.0 1020 9.3 2234 52.3 
A6ND91-FLAG2.4 3.0 858 9.6 1504 43.9 
Control 1.1 2.5 1371 8.5 2018 52.7 
Control 1.2 2.9 1518 9.9 1918 37.2 
Control 1.3 2.1 1395 9.8 3162 53.5 
Control 2.1 4.2 708 9.7 2802 38.5 
Control 2.2 2.8 906 9.8 2711 55.6 
Control 2.3 3.2 678 9.8 3163 47.1 
Mean +/- SD 2.8 +/- 0.5 988.8 +/- 281.7 9.6 +/- 0.4 2455.1 +/- 478.1 55.2 +/- 8.7 
 
Table 4.0 Spectrophotometry and Bioanalyser Analyse of Total RNA and cRNA. 
Optical density measurements at a wavelength of 260nm and 280nm were 
performed using total RNA diluted 1/250 with 150mM Tris buffer pH8.0. OD readings 
at 260nm and 280nm were documented and A260/A280 ratios determined. The formula 
40 x A260 x 250 (dilution factor) was used to determine total RNA concentrations. 
Bioanalyser RNA Integrity Number (RIN) for total RNA ranged from 9.9 to 8.5 (9.6 +/- 
0.4) with concentrations ranging from 1504pg/l to 3163pg/l (2455.1 +/- 478.1). The 
total yield of cRNA is indicated in the end column, ranging from 71.1g to 37.2g 
(55.2 +/-8.7). Mean standard deviation (SD) for each column is shown in the final 
row. 
+
 The ratio of the readings at 260 nm and 280 nm (A260/A280). 
++ 
An absorbance of 1 unit at 260 nm corresponds to 40μg/ml of RNA (A260= 1= >40 μg/ml). 
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Figure 4.2 Agilent 2100 Bioanalyzer Electropherogram for Total RNA from All 
samples. The first lane (L) corresponds to the RNA 6000 ladder. The 28S RNA band 
is twice the intensity of the 18S RNA band in nearly all samples (A6ND91-FLAG2.3 
and Control 2.1 shows slightly less intense 28s and 18s bands) and there are no 
major extraneous background bands, or „smears‟. Electropherograms were created 
by Biosizing software. 
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A total of 10g of total RNA was used to synthesise cDNA and then cRNA. 
The synthesis and fragmentation of cRNA was assessed using pico chip analysis on 
the bioanalyser. Table 4.0 shows the final yields of cRNA for each of the samples 
ranging from 37.2g to 71.1g (55.2 +/- 8.7g). The total yield of cRNA from Control 
1.2 and Control 2.1, was slightly lower than the recommended 40g, however they 
still provided sufficient amounts of cRNA for array hybridisation (i.e. a minimum of 
15g required).  
 
4.2.3 Hybridisation to Affymetrix GeneChip Rat Genome 230 2.0 Array 
A pre-synthesized mixture of lys, phe, dap, thr and trp PolyA+ RNA controls 
(from modified B. subtilis genes) were spiked into each total RNA sample in 
staggered concentrations prior to cRNA synthesis and labelling. Figure 4.4, shows 
hybridization intensity values of the PolyA+ controls to all samples. An increasing 
signal value in the following order: trp>thr>dap>phe>lys is evident. This increase 
represents the spike in concentration of each PolyA+ control.  
To evaluate hybridisation efficiency, a mixture of biotin-labelled cRNA 
transcripts of bioB, bioC, bioD and cre, were prepared in staggered concentrations. 
Figure 4.5, shows the intensity observed in each hybridised sample. The signal value 
is shown to increase, with Cre the lowest, followed by BioB, then BioC and finally 
BioD transcripts. The relative increases reflect their spiked concentrations.  
 
4.2.4 Quality of Hybridisation  
To determine the overall quality of gene expression data, .CEL intensity 
images from the 13 GeneChip Affymetrix Arrays were analysed using Bioconductor 
(BioC Release 1.9) open source software. Analysis of .CELs images highlighted only 
one outlier, A6ND91-FLAG 2.3 (Figure 4.6 and Table 4.1). Table 4.1 represents a 
series of quality control parameters associated with assay and hybridisation 
performance. The average background shows A6ND91-FLAG 2.3 exceeds the 
acceptable threshold; the remainder of the arrays fell within the acceptable threshold 
values and were comparable. 
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Figure 4.3  Agilent 2100 Bioanalyzer Scan of cRNA from 13 Samples. RNA 6000 
ladder was denatured and 1l was loaded into the assigned ladder well. 
Fluorescence Units (FU) on the y axis is plotted against nucleotide (nt) size on the x 
axis. The scan shows bioanalyser traces characterised by a small hump at ~ 150 
nucleotides (nt = 28 seconds) followed by a broader hump that plateaus between 
~800 (nt = 34 seconds) and 1500 nucleotides (nt = 40 seconds). Calculations were 
performed using Biosizing software. 
 
Ladder                                    A6ND91-FLAG1.1                     A6ND91-FLAG1.2    
        A6ND91-FLAG1.3                    A6ND91-FLAG2.1                     A6ND91-FLAG2.2    
       A6ND91-FLAG2.3                           
Ladder                                   A6ND91-FLAG2.4                      Control 1.1                                      
Control 1.2                                  Control 1.3                                 Control 2.1                                      
  Control 2.2                                  Control 2.3    
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Figure 4.4 Bar graph of Signal Intensity of PolyA+ Controls. RNA polyA+ 
controls TrpX (14.7 ng/ml), ThrX (39.1 ng/ml), DapX (108.9 ng/ml), PheX (260.0 
ng/ml) and LysX (591.1 ng/ml) were spiked into all samples. The correlation between 
their concentration and raw signal value (log2 intensity) achieves a R
2 greater than 
0.95 in all samples.  
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Figure 4.5 Bar graph of Signal Intensity of Hybridisation Controls. cRNA 
hybridisation controls BioB (1.5 pico moles (pM), BioC (5 pM), BioD (25 pM) and Cre 
(100 pM) were spiked into all samples prior to array hybridisation.  
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Figure 4.6 Probe-Intensity Distributions of Gene Chip data. The 13 gene chip 
arrays are represented as a smoothed histogram. The log2 probe intensities for each 
array before normalisation (i.e. unprocessed data) are shown against frequency.  
Array A6ND912.3 is shown to be the outlier displaying a bimodal distribution that is 
usually indicative of a spatial artefact. The abnormally high frequency value is the 
result of an entire section of the array having distorted values. Skewing of the 
histogram towards the high end of the log2 intensity scale could also indicate 
saturation of probes. The remaining chips are positively skewed (long right tail) and 
similar to each other in a sample set, indicating that they fall into the criteria for 
further analysis. 
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Table 4.1 Quality of cRNA Hybridisation to Affymetrix Chips. Hybridised 
samples returned average background values ranging from 67.18 to 110.31, 
excluding A6ND91-FLAG2.3 (highlighted in red), which exceed this threshold at 
596.28. The remainder of arrays fell within acceptable threshold values and were 
comparable. The percent present (%P) values ranged from 43.50% to 45.37%, again 
excluding array A6ND91-FLAG2.3 which returned a lower %P value (i.e. 33.28) 
when compared to other arrays, indicating RNA degradation. The remainder of 
arrays have similar %P value. RawQ values range from 2.83 to 3.98, excluding array 
A6ND91-FLAG 2.3 which has a high RawQ (i.e. 13.06). This is probably due to the 
sample quality, not electrical noise of the scanner, as all chips were scanned on the 
same scanner in two batches. 
+ 
Average Background is the mean average signal value of the lowest 2% probes and measuring 
array surface auto-fluorescence as well as non-specific binding of target or SAPE stain molecules.  
++ 
Percent Present (%P) is a measure of the percent of probes on the array that are marked as being 
expressed (were the Perfect Match (PM) probe signal is significantly higher than the Mismatch (MM) 
probe signal). Acceptable values for whole genome arrays is ~50%, low %P values might indicate 
reduced RNA quality and are usually seen with high non-specific binding, (were the MM probe may be 
giving a signal value closer to PM probe signal value).  
+++
 Noise (Raw Q) is a measure of pixel-to-pixel variation of probe cells on the array. The two main 
factors that contribute to noise are electrical noise of the scanner and sample quality. Since a 
significant portion of Noise (Raw Q) is electrical noise, values among scanners will vary. 
 
 
Cell Line Average 
Background 
 
Percent Present 
(%P) 
RawQ 
A6ND91-FLAG1.1 67.18 43.65 2.83 
A6ND91-FLAG1.2 90.57 44.62 3.39 
A6ND91-FLAG1.3 89.44 45.37 3.37 
A6ND91-FLAG2.1 98.19 44.58 3.60 
A6ND91-FLAG2.2 94.32 44.43 3.48 
A6ND91-FLAG2.3 596.28 33.28 13.06 
A6ND91-FLAG2.4 94.04 45.18 3.44 
Control 1.1 88.64 43.78 3.28 
Control 1.2 85.33 45.04 3.19 
Control 1.3 73.13 45.11 2.96 
Control 2.1 110.31 44.44 3.98 
Control 2.2 101.62 44.25 3.66 
Control 2.3 92.75 43.50 3.39 
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Figure 4.7 Histogram (density plots) of Raw (A) and Normalised (B) Intensities 
of A6ND91-FLAG1, A6ND91-FLAG2, Control 1 and Control 2 cells. Affymetrix 
.CEL files were uploaded into web application, CarmaWeb. Quantile normalisation 
was performed across the 12 arrays using Robust Microarray Analysis (RMA) 
background correction, Perfect Match/Mis-Match correction (pmonly) and liwong 
summarization. Data was plotted on the x axis as either density (RAW) or counts 
(NORMALISED) against a Log2 intensity value (y axis). It is apparent that 
normalisation brings the data closer together. 
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4.2.5 Normalisation of data using CARMAWeb 
Normalisation parameters are described in Methods (Section 2.4.7). 
Affymetrix .CEL files were uploaded into web application, CARMAWeb. Pre-
processing (i.e. background correction, normalisation of expression values within 
each array and between the arrays, and adjusting expression values across arrays) 
were performed on 12 arrays. The aim of data pre-processing step is to remove the 
technical variance and systematic errors without altering biological variance within 
the data-set. Figure 4.7A and 4.7B show raw and normalised data intensities. It is 
apparent that normalisation brings the data closer together, consistent with the 
removal of experimental variation. 
 
4.2.6 Differentially expressed probe sets identified by Principle Component 
Analysis (PCA) and Significance Analysis of Microarrays (SAM).  
PCA analysis was performed on normalised data. Figure 4.8, shows A6ND91-
FLAG 1 and A6ND91-FLAG 2 cell lines are most similar in terms of transcript 
expression. The control cells cluster away from both A6ND91-FLAG experimental 
cell lines, indicating clear differences in transcriptional expression. 
Due to the high level of similarity between both A6ND91-FLAG cell lines and both 
Control cell lines, statistical analyses were performed on combined data sets (i.e. 
A6ND91-FLAG 1 (n=3) plus A6ND91-FLAG 2 (n=3) versus Control 1 (n=3) plus 
Control 2 (n=3)), as well as on data from individual cell lines.  
Table 4.2 shows that when A6ND91-FLAG 1 and A6ND91-FLAG 2 were grouped 
together (n=6) in the SAM analysis, a False Detection Rate (FDR) of 0.00521 
(BOLD) returned 1934 probe sets as being significantly differentially expressed with 
24 being called false positives. However, when A6ND91-FLAG cells were analysed 
separately versus combined Control 1 and Control 2 (n=6), only identified 26 probe 
sets were called for A6ND91-FLAG1 (n=3) at a comparable FDR (0.0053). Only 20 
probe sets were called as significantly differentially expressed in A6ND91-FLAG 2 
cells (n=3) compared to combined Control 1 and Control 2 (n=6) at a FDR of 0.0066.  
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Figure 4.8 Principle Component Analysis (PCA) Plot of A6ND91-FLAG1, 
A6ND91-FLAG2, Control 1 AND Control 2 cell lines. Cells expressing human 
A6ND91-FLAG1 (n=3) and A6ND91-FLAG2 (n=3) are shown to cluster together; 
implying they are similar to each other in terms of probe set expression values. 
Control 1 (n=3) and Control 2 (n=3) cells cluster away from A6ND91-FLAG 1 and 
A6ND91-FLAG 2 cells on both axis; suggesting differential expression of transcripts 
between control cells and A6ND91 cells. Both Control 1 and Control 2 cells also 
show slight differences between each other. 
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Table 4.2 SAM Analysis of A6ND91-FLAG 1, A6ND91-FLAG 2, Control 1&2 
Data-sets. The results of the top ten SAM analyses are represented in this table. 
The top ten delta values and the corresponding number of “Called” genes detected 
(within a specific FDR) are shown. The column “False” contains the number of false 
positive genes contained within the dataset, and the column “Called” represents the 
number of genes that were found significant with the specific delta. 
 
 
 
Figure 4.9 Expression of human A6ND91-FLAG transcripts detected by probe 
set 1378819_at. Normalised expression values of 1378819_at in all 12 samples is 
shown against corresponding chromatic scale (red = 3 -fold over-expressed, to green 
= 3-fold under expressed). 
 
 
 A6ND91-FLAG1 vs Control 1&2 
 
A6ND91-FLAG1 vs Control 1&2 A6ND91-FLAG2 vs Control 1&2 
Delta FALSE Called FDR Delta FALSE Called FDR Delta FALSE Called FDR 
1 0.1 23114 27577 0.3496 0.1 21858 26956 0.3460 0.1 19685 24525 0.4227 
2 0.8 773 8484 0.0380 0.7 1662 9452 0.0750 0.6 734 4503 0.0858 
3 1.5 24 1934 0.0052 1.2 151 2285 0.0281 1.2 48 916 0.0276 
4 2.3 2 623 0.0015 1.8 22 639 0.0145 1.7 10 363 0.0147 
5 3.0 1 263 0.0010 2.4 5 244 0.0094 2.2 3 176 0.0100 
6 3.7 0 131 0.0009 2.9 2 131 0.0075 2.7 2 100 0.0082 
7 4.4 0 90 0.0009 3.5 1 88 0.0065 3.3 1 50 0.0077 
8 5.1 0 52 0.0009 4.1 1 59 0.0058 3.8 1 39 0.0072 
9 5.8 0 35 0.0009 4.6 1 44 0.0054 4.3 0 25 0.0068 
10 6.6 0 23 0.0008 5.2 0 26 0.0053 4.9 0 20 0.0066 
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4.2.7 Human A6ND91-FLAG RNA expression 
Figure 4.9 shows the expression of human A6ND91-FLAG mRNA in A6ND91-FLAG 
1, A6ND91-FLAG 2, Control 1 and Control 2 cells. Human A6ND91-FLAG transcripts 
were detected by probe-set 1378819_at, which corresponds to the homologous rat 
A6ND91 mRNA, AW435096. The observed cross-species hybridisation is not 
unusual, as the percent identity between human and rat mRNA is 88% as identified 
by Basic Local Alignment Search Tool nucleotide (BLASTn version 2.2.15). Levels of 
human A6ND91-FLAG mRNA in the two experimental cell lines are comparable, 
consistent with the analysis of A6ND91-FLAG protein by Western Blot (Section 4.2.1, 
Figure 4.0). 
  
4.2.8 Functional annotation 
The 1934 differentially expressed probe sets included 1595 known and 339 
unknown transcripts. Annotation was performed on the unknown transcripts using 
the NetAffx Analysis Centre (http://www.affymetrix.com/analysis) and BLASTn 
(version 2.2.15). Comparative analysis against the BLAST multiple species non-
redundant database, revealed the identity of 119 of these transcripts. No confident 
gene assignments could be made for the remaining 220 transcripts.   
 
4.2.9 GO Classification 
Nearly half (n=917) of the 1934 perturbed transcripts (FDR=0.005211) were 
assigned a “parent” GO term: 720 were assigned to a BP, 763 to a MF and 693 to a 
CC (Figure 4.10). Figure 4.10 shows that 522 of the differentially expressed 
transcripts were classified by all three parent terms. Additionally, between BP and 
MF, 635 transcripts were shared, compared to 570 between BP and CC and 590 
between MF and CC.  
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Figure 4.10 Venn Diagram Showing the Number of Genes Contributing to 
Biological Process, Molecular Function and Cellular Component Ontology’s. 
720 genes are assigned to BP, 693 genes are assigned to CC and 763 genes are 
assigned to MF. Between BP and CC 570 genes were shared, BP and MF shared 
635 of genes and MF and CC shared 590 genes. In total, 522 genes were shared 
between all the three ontology‟s. 
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Table 4.3 shows that transcripts assigned to the BP grouping represented 
nine clear, meaningful, biological processes. These include cholesterol biosynthetic 
process (p = 0.0003), xenobiotic metabolic process (p = 0.0003), carboxylic acid 
metabolic process (p = 0.0013), sterol metabolic process (p = 0.0013), complement 
activation (p = 0.0023), acute inflammatory response (p = 0.0027), urea cycle (p = 
0.0043), glycine metabolic process (p = 0.0061) and amino acid and derivative 
metabolic process (p = 0.0077). 
The most significantly enriched CC and MF groupings are shown in Tables 
4.4 and 4.5, respectively. The CC parent grouping were most significantly enriched 
for mitochondrion (p = 0.0008), peroxisome (p = 0.0012), GOLGI apparatus (p = 
0.0044), cytosol (p = 0.0054), microsome (p = 0.0083), rough endoplasmic reticulum 
(p = 0.0084). The MF grouping highlighted significant over-representation in four 
categories, the most significant being enoyl-CoA hydratase activity (p = 0.0006), then 
sodium: phosphate symporter activity (p = 0.0033) and arylsulfatase activity (p = 
0.0043). 
 
4.2.10 Real Time RT-PCR 
Transcript values for a series of differentially expressed genes (i.e. Lcat, 
Fabp1, Hao1, Serping1, Nars, Hao2, Gpt1, Ddah and Cd36) were selected on the 
basis of GO analysis and determined by RT-PCR, alongside the house keeping gene 
-actin and A6ND91-FLAG transcript. Each cell line was re-grown in quadruplicate 
and total RNA prepared. Ct values for -actin highlighted one outlier A6ND91-FLAG 
2.3 (i.e. Avg Ct = 16.27 +/- 0.39 compared to outlier A6ND91 2.3 = 18.46) and was 
removed from further comparative []Ct analysis. Table 4.6 shows []Ct values for 
each transcript plus their corresponding microarray levels.  With the exception of 
Hao1, avg[]Ct fold-change profiles were consistent with microarray D fold-changes. 
Good correlation between RT-PCR and microarray fold-changes were observed 
(Figure 4.11, Table 4.6), with an R2 value of 0.8355 for all transcript data points.  
This increased to a value of 0.9767 (data not shown) when the outlier (i.e. Hao1) 
was removed.
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GO:ID Term p value Count Size 
GO:0045184 establishment of protein localization 0.0002 54 316 
GO:0006695 cholesterol biosynthetic process 0.0003 8 18 
GO:0008152 metabolic process 0.0003 425 3612 
GO:0006805 xenobiotic metabolic process 0.0003 9 23 
GO:0019752 carboxylic acid metabolic process 0.0013 57 364 
GO:0016125 sterol metabolic process 0.0013 13 49 
GO:0006886 intracellular protein transport 0.0015 44 266 
GO:0006956 complement activation 0.0023 7 19 
GO:0002526 acute inflammatory response 0.0027 11 41 
GO:0006903 vesicle targeting 0.0035 5 11 
GO:0000050 urea cycle 0.0043 3 4 
GO:0051649 establishment of cellular localization 0.0048 63 434 
GO:0051648 vesicle localization 0.0055 5 12 
GO:0006544 glycine metabolic process 0.0061 4 8 
GO:0006519 amino acid and derivative metabolic process 0.0077 39 250 
GO:0008284 positive regulation of cell proliferation 0.0086 30 182 
 
Table 4.3 Mapping of Significantly Altered Transcripts to Biological Process 
Gene Ontology. Over-represented GO terms for Biological Processes (p = < 0.01) 
are shown in order of their significance with their GO identification. GO terms 
enriched within A6ND91-FLAG cell lines compared to control cell lines are shown 
achieving a p value smaller than 0.01. “Count” column represent the number of 
target genes from data-set placed within GO term. “Size” represents global the 
number of genes that are included in associated GO term.  
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GO:ID Term p value Count Size 
GO:0005737 cytoplasm 4x10
-6
 320 2484 
GO:0005622 intracellular 0.0006 451 3855 
GO:0005739 mitochondrion 0.0008 81 543 
GO:0005777 peroxisome 0.0012 14 54 
GO:0043229 intracellular organelle 0.0028 363 3077 
GO:0044431 Golgi apparatus part 0.0044 23 122 
GO:0005829 cytosol 0.0054 55 368 
GO:0005792 microsome 0.0083 22 121 
GO:0005791 rough endoplasmic reticulum 0.0084 5 13 
GO:0031090 organelle membrane 0.0088 67 475 
 
 
Table 4.4 Mapping of Significantly Altered Transcripts to Cellular Component 
Gene Ontology. Over-represented GO terms for Cellular Component (p = < 0.01) 
are shown in order of their significance.  See Table 4.3 for explanation of contents. 
 
 
 
 
 
 
Table 4.5 Mapping of Significantly Altered Transcripts to Molecular Function 
Gene Ontology. Over-represented GO terms for Molecular Function (p = < 0.01) are 
shown in order of their significance.  See table 4.3 for explanation of contents. 
 
 
GO:ID Term p value Odds Count Size 
GO:0004300 enoyl-CoA hydratase activity 0.0006 33.98 4 5 
GO:0008565 protein transporter activity 0.0013 2.60 17 73 
GO:0005436 sodium:phosphate symporter activity 0.0033 11.32 4 7 
GO:0004065 arylsulfatase activity 0.0043 25.45 3 4 
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Figure 4.11 RT-PCR versus Affymetrix GeneChip Fold-Changes. Real-time RT-
PCR (Avg[]Ct fold-changes) results are plotted versus expression levels (D fold-
changes) determined by Affymetrix GeneChip results for A6ND91 (1378819_at), 
Lcat (1367887_at), Fabp1 (1369111_at), Hao1 (1394112_at), Serping (1372254_at), 
Nars (1374437_at), Hao2 (1387139_at), Gpt1 (1387052_at), Ddah (1387111_at) and 
Cd36 (1386901_at). The fold-change values determined by the two independent 
methods achieved a correlation value (R2=0.8355). One outlier (i.e. Hao1) is circled 
in red, indicating conflicting fold-change expression value. 
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Table 4.6 RT-PCR and Affymetrix Fold-change Values for GO Selected Transcripts. Comparative []Ct values for A6ND91-
FLAG (NM_001114598), Lcat (NM_017024), Fabp1 (NM_012556), Hao1 (XM_001081256), Serping1 (NM_199093), Nars 
(NM_001025635), Hao2 (NM_032082), Gpt1 (NM_031039), Ddah (NM_022297) and Cd36 (NM_031561). A6ND91-FLAG 1 (n=4), 
A6ND91-FLAG 2 (n=3), Control1 (n=4) and Control2 (n=4) were normalized to rat -actin (NM_031144). Using comparative Ct 
method (Section 2.4.12) average (Avg)[]Ct values were obtained for Control 1 plus 2 cells (n=8) and A6ND91-FLAG 1 plus 2 cells 
(n=7), standard deviation (SD) and p values were calculated. []Ct fold-changes were calculated for A6ND91-FLAG vs Control cell 
lines. Affymetrix D fold-changes plus p values are shown for; A6ND91-FLAG (1378819_at), Lcat (1367887_at), Fabp1 
(1369111_at), Hao1 (1394112_at), Serping (1372254_at), Nars (1374437_at), Hao2 (1387139_at), Gpt1 (1387052_at), Ddah 
(1387111_at) and Cd36 (1386901_at).
Gene Name Gene ID Control1 
(Ct) 
 
Control2 
(Ct) 
 
A6ND91 
-FLAG1 
(Ct) 
A6ND91 
-FLAG2 
(Ct) 
Control1/2 
Avg 
Ct) 
SD 
Control1/2 
Avg(Ct) 
A6ND91-
Flag1/2 
AvgCt) 
SD 
Flag1/2 
Avg(Ct) 
p Value 
(Ct) 
Fold-
change 
(Ct) 
Affymetrix 
Fold 
Change 
Affymetrix 
p  Value 
Homologous L-Aspartate  
Dehydrogenase 
A6ND91 0.000040 0.000028 0.006061 0.016000 0.000040 0.001937 0.011031 0.010313 0.007660 273 17.25 0.0000001 
Lecithin-cholesterol  
acyltransferase 
Lcat 0.000040 0.000101 0.000121 0.000126 0.000070 0.000039 0.000124 0.000025 0.004687 1.76 9.14 0.0000013 
Fatty acid binding protein 1 Fabp1 0.000061 0.000347 0.000280 0.000239 0.000204 0.000165 0.000259 0.000058 0.195537 1.27 7.29 0.0000029 
Hydroxyacid oxidase 1 Hao1 0.000023 0.000063 0.000043 0.000038 0.000043 0.000026 0.000040 0.000009 0.410909 -1.07 7.28 0.0000031 
Serine (cysteine) peptidase i 
inhibitor, clade G, member 1 
Serping 0.000003 0.000002 0.000005 0.000004 0.000002 0.000001 0.000005 0.000002 0.001653 2.09 7.15 0.0000033 
Asparaginyl-tRNA synthetase Nars 0.000300 0.000520 0.000623 0.000557 0.000410 0.000153 0.000590 0.000146 0.016449 1.44 7.01 0.0000037 
Hydroxyacid oxidase 2 Hao2 0.000051 0.000041 0.000079 0.000090 0.000046 0.000016 0.000084 0.000022 0.001052 1.84 6.98 0.0000038 
Glutamate Pyruvate  
Transaminase 1 
Gpt1 0.000021 0.000015 0.000010 0.000011 0.000018 0.000006 0.000010 0.000003 0.003446 -1.78 -5.41 0.0000094 
Dimethylarginine  
dimethylamino-hydrolase 
Ddah 0.000143 0.000104 0.000048 0.000066 0.000124 0.000040 0.000057 0.000017 0.000544 -2.17 -5.73 0.0000077 
Cluster of Differentiation 36 Cd36 0.000028 0.000015 0.000003 0.000006 0.000021 0.000009 0.000005 0.000002 0.000119 -4.46 -11.73 0.0000005 
1
28
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4.3 Discussion  
Large-scale gene expression analysis with microarray enables a high number 
of genes to be analyzed in a single experiment. Experimental design in microarray 
studies is crucial, since thousands of measurements are made simultaneously and if 
not well designed the significance of each measurement is poor. Hence, a major 
focus of this chapter was the experimental design of the microarray analysis. To take 
in to account potential biological variability, two cell lines over-expressing human 
A6ND91-FLAG were compared to two control cell lines. The two cell lines expressed 
similar amounts of human A6ND91-FLAG (Figure 4.0), providing a good in-vitro 
model to observe total cellular transcriptional changes. Additionally three samples 
per cell line were analysed, reducing the impact of experimental variation throughout 
sample preparation and hybridisation procedures.   
Total RNA extracted from 2x106 hepatoma cell lines were assessed at an 
absorbance of 260nm/280nm. Although yields were sufficient for cDNA synthesis, 
absorbance ratios were generally higher than expected (Table 4.0). The ratio 
between the absorbance at 260/280 nm gives a rough estimate of RNA purity with 
respect to contaminants, the high ratio may be the result of alcohol or protein 
contamination.  However, as an absorbance spectrum of 200nm to 360nm within a 
10 second window was not performed it was impossible to ascertain the 
contaminant. The spectrum would have highlighted at 230nm, organics, such as 
thiocyanates or phenolate ions, 270nm phenol, 280nm protein and 330nm particulate 
matter. I chose to validate the integrity and quality of total and fragmented cRNA 
using a more sensitive approach using the 2100 Agilent Bioanalyzer. The 
bioanalyzer provides sequential analysis through a single separation channel for 12 
samples. This methodology provides information regarding ribosomal RNA 
contamination or potential degradation by nucleases during the purification process. 
Total RNA for all samples showed good results with clear 18S and 28S rRNA peaks 
with a low small RNAs presence relative to the rRNA peaks (5S, transfer RNA and 
miRNA) (Miller et al 2004, Schoor et al 2003). All samples had a flat base line in the 
fast-migrating region with a RIN score above ~7 (Figure 4.1 and Table 4.0). The 
bioanalyser also showed good cRNA fragmentation (Figure 4. 3), consisting of a 
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smear of products with a characteristic main peak between 800-1500nt and a small 
fragment 'bump' around 150-200nt.   
Overall, the Bioanalyser results for total RNA suggest the spectrophotometry 
ratios are incorrect, which may be due to a poorly calibrated spectrophotometer 
instead of the presence of contaminants. Supporting this contention, cDNA and 
cRNA synthesis was not impaired, which would be expected if contaminants were 
present. Moreover, the pre-synthesized mixture of lys, phe, dap, thr and trp RNA 
controls showed good hybridisation performance, indicative of efficient synthesis of 
cDNA, cRNA and labelling (Figure 4.4). For these analyses, hybridisation was 
monitored by the spike in controls bioB, bioC, bioD (genes in the biotin synthesis 
pathway of E.coli) and cre (recombinase gene from P1 bacteriophage) (Figure 4.5). 
This analysis signified good hybridisation with concentrations after hybridisation 
giving consistent increasing signal values, reflecting their relative spiked 
concentration. 
Several analyses were performed to determine the overall quality of gene 
expression data from hybridisation images (i.e. .Cel files). One outlier, A6ND91-
FLAG 2.3 (Figure 4.6 and Table 4.1) showed inconsistent results with the rest of the 
data-set, possibly due to the array becoming saturated with SAPE stain molecules or 
non-specific binding of target cRNA. The latter is the more likely explanation as the 
abnormally low percent present call and the high RawQ value suggests poor sample 
quality, indicating RNA degradation. A6ND91-FLAG 2.3 was removed from the data-
set prior to normalisation, avoiding an adverse effect on the other arrays. 
Array images were imported into CARMAweb and normalisation was 
performed to help remove technical variation and systematic errors without altering 
biological variance within the data. In Figure 4.7 raw data intensities are compared to 
normalised data intensities. It is apparent that the normalisation procedure brings the 
data closer together, as was expected. Normalised data were analysed using PCA, 
making the data more accessible for visualization and further analyses. PCA showed 
considerable overlap between all A6ND91-FLAG samples, clearly separating them 
from the controls. This suggests the expression profile is very similar between 
A6ND91-FLAG 1 (n=3) and A6ND91-FLAG 2 (n=3) cells. Control 1 (n=3) and Control 
2 cells (n=3) did not overlap with each other as much, indicating slight variation 
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between the two control cell lines, and the importance of using more than one control 
cell line in such experiments.  
To identify significantly differentially expressed genes in a set of microarray 
experiments I chose to analyse the data-set with SAM (Significance Analysis of 
Microarrays). This statistical technique method (Tusher et al 2001), measures the 
strength of the relationship between gene expression and the response variable (i.e. 
A6ND91 vs. Control cell lines), and uses repeated permutations of data to determine 
whether the expression of any gene is significantly related to the response. SAM p-
values were further adjusted by multiple hypothesis testing (Hochberg et al 1990) for 
strong control of false discovery rate (FDR). Table 4.2 shows that combining the two 
A6ND91-FLAG (n=6) and Control cells lines (n=6) a much larger data-set became 
available for further analyses (i.e. 1934 probe-sets with less then 25 false positives 
(i.e. 24.16)). A6ND91-FLAG 1 (n=3) versus Control 1 and Control 2 at a FDR of 
0.0053, only 26 probe sets were identified with less then 1 false positive (i.e. 0.32), 
whereas A6ND91-FLAG 2 cells (n=3) versus Control 1 and Control 2 at a FDR of 
0.0066, only 20 probe sets were identified with less then 1 false positive (i.e. 
0.25).The disadvantage of combining data in this fashion is introducing increase 
error into the data-set. However, when comparing the number of probe-sets obtained 
from each analysis it became apparent that the combined data-set provided much 
more information at a similar FDR.  
Gene Ontology (GO) classification was performed on 1934 probe-sets derived 
from the annotated SAM data-set (i.e. FDR = 0.005211). Prior to GO analysis, 339 
unknown transcripts identified within the 1934 data-set were annotated using 
methods such as sequence similarity searches and functional and structural 
predictions through NetAffx Analysis Centre (http://www.affymetrix.com/analysis) and 
Basic Local Alignment Search Tool nucleotide (BLASTn version 2.2.15) (Altschul et 
al 1990). Comparative analysis of 339 unknown transcripts against BLAST multiple 
species non-redundant database, identified 119 as known transcripts. These 
transcripts were updated with an appropriate Entrez Gene ID (URL: 
http://www.ncbi.nlm.nih.gov/Entrez/) (Tatusova et al 1999) as GO analysis requires 
this information to calculate p values.  
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GO identified the most meaningful over-represented BP categories were 
enrichment of cholesterol biosynthetic process (p = 0.0003), xenobiotic metabolic 
process (p = 0.0003), carboxylic acid metabolic process (p = 0.0013), sterol 
metabolic process (p = 0.0013), complement activation (p = 0.0023), acute 
inflammatory response (p = 0.0027), urea cycle (p = 0.0043), glycine metabolic 
process (p = 0.0061) and amino acid and derivative metabolic process (p = 0.0077) 
(Table 4.3); CC categories were mitochondrion (p = 0.0008), peroxisome (p = 
0.0012), GOLGI apparatus part (p = 0.0044), cytosol (p = 0.0054), microsome (p = 
0.0083) and rough endoplasmic reticulum (p = 0.0084) (Table 4.4); MFcategories 
were enoyl-CoA hydratase activity (p = 0.0006), sodium:phosphate symporter activity 
(p = 0.0033) and arylsulfatase activity (p = 0.0043) (Table 4.5). 
The GO database provides a useful tool to annotate and analyse the functions 
of large numbers of genes. GO classification lists biological processes, molecular 
function and cellular components that are significantly over-represented. Data may 
be viewed as  directed acyclic graphs (DAGs) that represent a network in which each 
term may be a “child” (more specialized term) of one or more than one “parent” (less 
specialized term). I did not use DAGs to view my data, instead opting for a 
complementary approach viewing data at the level of known biological processes, 
making it possible to generate new hypotheses and identify pathways that warrant 
more detailed investigation (Chapter 5). Although GO is very helpful in defining the 
process, function and localisation of a gene it is limited to well-characterized genes 
resulting in more than 47 percent of the probe-sets remaining unassigned  (i.e. only 
917 out of 1934 probe-sets were recognised by GO). Therefore in Chapter 5 further 
efforts were pursued to annotate the remaining genes and assign function.  
A common problem in GO analysis is the considerable overlap of genes within 
parent GO terms, thus often parent GO terms are called significant, because most of 
its child nodes are enriched. This is due to the hierarchical structure of the GO 
parent nodes that inherit all genes annotated at their more specific child nodes. To 
alleviate this problem I ignored the more general terms, such as BP process (p = 
0.0003), intracellular protein transport (p = 0.0015) and establishment of cellular 
localization (p = 0.0048) (Table 4.3); MF protein transporter activity (p = 0.0013) 
(Table x); CC cytoplasm (p = 4x10-6), intracellular (p = 0.0006), intracellular organelle 
(p = 0.0028) and organelle membrane (p = 0.0088) (Table 4.4), only focusing on the 
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more specific and enriched child terms. Additionally, to improve the quality of the 
associations between genes and GO terms, all annotations based solely on 
computational sequence similarity searches or inferred from electronic annotation 
(IEA) can be excluded from the analysis. I did not perform IEA exclusion as the data 
obtained from GO analysis overlapped with the altered phenotypic profile (i.e. 
increased cholesterol, triglyceride, fatty acid synthesis and secretion of triglyceride-
rich VLDLs) (Section 1.4, Figure 1.9 and 1.10) identified in cells expressing A6ND91-
FLAG. 
 Based on transcript function, relative mRNA values were determined for a 
selection of the identified differentially expressed genes (Bustin et al 2000, Wang et 
al 1999). A high correlation (R2=0.8355) was observed between microarray and Real 
Time RT-PCR transcript values, as charted in Figure 4.11 and Table 4.6. 
Inconsistency was detected with the transcript Hao1, with only the microarray 
analyses indicating up-regulation.  Considering, the relatively low expression of Hao1 
detected by RT-PCR (i.e. -1.07) and the high p value (p = 0.410909) returned, further 
analyses will be required to establish whether Hao1 (or a specific Hao1 mRNA 
species) is consistently over-expressed in cells expressing high levels of A6ND91-
FLAG.  
In conclusion, the microarray dataset presented in this chapter provides a 
robust platform to analyse the perturbed biological pathways in cells expressing 
A6ND91-FLAG, and as such the justification for further dissection of the significant 
enriched BP GO categories (Chapter 5). 
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Chapter 5 Perturbed Metabolic Pathways in Cells Expressing 
A6ND91 
5.1 Introduction 
The major challenge after computational analysis of microarray data is to 
establish biological meaning. The list of significantly perturbed transcripts should not 
be simply viewed as an end in itself but should be systematically investigated to 
dissect out the complex gene networks operating in a given physiological 
environment. In order to understand the biology of these data it may be relevant to 
include physiological information on the genes in the study. Combination of 
microarray and pathway data can highlight metabolic processes which occur in the 
cell. Several methods are currently available to search for biological relevance within 
microarray data. Clustering, (such as Hierarchical and K-means clustering) groups 
genes based on similarity in their expression profile, providing new gene-gene 
associations (Wen X et al 1998, Tavazoie et al 1998). Other methods including 
Principal Component Analysis (PCA) (Raychaudhuri et al 2000,  Holter et al 2000) 
(Section 5.2.6) allows the identification of key variables (or combinations of 
variables) in a multidimensional data-set that may best explain differences between 
observations but implies little about actual perturbed metabolic pathways. Gene 
Ontology (GO) (Section 4.2.9) provides information on perturbed biological 
processes (BP), molecular function (MF) and cellular components (CC) in the 
experimental system. GO does not show perturbed genes in terms of known 
metabolic pathways. Instead data is organized as a directed acyclic graph (DAG) or 
a list, which is a hierarchical structure similar to a tree (Khatri et al 2005).  
An alternative method is to analyze gene expression data in the context of 
known metabolic pathways, as in the Kyoto Encyclopaedia of Genes and Genomes 
(KEGG) (Kanehisa et al 2002, Ogata et al 1999). KEGG comprises manually drawn 
maps of metabolic pathways; representing knowledge on molecular interaction and 
networks of reactions including metabolism, genetic information processing, 
environmental information processing, other cellular processes, human diseases and 
drug development. KEGG is a bioinformatic resource linking gene-products to 
biological systems (www.genome.jp/kegg/) and consists of genes and proteins 
(KEGG GENES), endogenous and exogenous substances (KEGG LIGAND), 
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molecular wiring diagrams of interaction and reaction networks (KEGG PATHWAY), 
and hierarchies and relationships of biological objects (KEGG BRITE). Data can be 
analysed in a species-specific manor or viewed in general biological pathways called 
“reference pathways”. Thus, KEGG PATHWAY provides a platform to map species-
specific gene expression data to corresponding elements of available pathways.  
Results from Carmaweb‟s GOstats and GOpackage (GO analysis) can be 
readily coupled to KEGG PATHWAY as significantly over-represented GO terms are 
associated with EntrezGene gene identifiers. Entrez (Schuler et al 1996, Tatusova et 
al 1999) is a powerful online database 
(http://www.ncbi.nlm.nih.gov/sites/entrez?db=gene) that integrates scientific 
literature, DNA and protein sequence databases, 3D protein structure and protein 
domain data, population study datasets, expression data, assemblies of complete 
genomes, and taxonomic information into a tightly interlinked system. 
GO classifications (Section 4.2.9) as identified by analysis of data at a FDR = 
0.005211 (i.e. Xenobiotics, Cholesterol, Carboxylic Acid and Complement Activation 
pathways), were used as a template for KEGG PATHWAY analysis. Due to the 
limited number of KEGG recognised genes from 1934 probe-sets (i.e. n =878), a 
larger microarray dataset (p < 0.05, n =10,986 probe-sets) was selected and 
analyzed in the context of GO representative pathways providing a more complete 
overview of the cellular processes altered by A6ND91-FLAG expression. This 
chapter presents results of a combined GO and KEGG PATHWAY analysis 
identifying biological pathway‟s perturbed in rat hepatoma cells expressing A6ND91-
FLAG.  
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5.2 Results  
5.2.1 Mapping Differentially Expressed Genes to Metabolic Pathways  
The most informative GO category to analyse perturbed metabolic pathways 
was Biological Processes (BP). Significantly enriched GO BP classifications (i.e. BP 
categories; Cholesterol biosynthetic process (p = 0.0003), Xenobiotic metabolic 
process (p = 0.0003), Carboxylic acid metabolic process (p = 0.0013), Sterol 
metabolic process (p = 0.0013), Complement activation (p = 0.0023), Acute 
inflammatory response (p = 0.0027), Urea cycle (p = 0.0043), Glycine metabolic 
process (p = 0.0061) and Amino acid and derivative metabolic process (p = 0.0077)). 
were further analysed by KEGG PATHWAY 
(http://www.genome.ad.jp/kegg/tool/color_pathway.html). This online resource 
places differentially expressed gene-products onto annotated KEGG PATHWAYs. 
The program requires probes to have an Entrez Gene ID (URL: 
http://www.ncbi.nlm.nih.gov/Entrez/) and a colour tag representing fold-change 
values (e.g. RED for increased expression, GREEN for decreased expression, and 
GREY for unaltered expression).  
To extract more information from the microarray data-set in terms of GO BP 
categories, I increased the number transcripts by analysing all differential probe-sets 
with p < 0.05 (n =10,986 probe-sets). Out of 10,986 probe-sets, 8524 were 
represented with an Entrez Gene ID and a total of 5890 transcripts were recognised 
by KEGG PATHWAY.  
 
5.2.2 Cholesterol and Steroid Metabolism  
GO (n=14) coupled with KEGG PATHWAY (n=13) analysis and surrounding 
literature (n=8) identified 41 probe-sets, representing 35 genes involved in regulation 
of Cholesterol and Steroid Biosynthesis (Table 5.0, Figure 5.0). Additional probe-sets 
shown in both Figure 5.0 and Table 5.0 were included because of their known roles 
in cholesterol metabolism.   
The major rate-limiting step in non-sterol isoprenoids and cholesterol 
synthesis is HMG-CoA reductase (Hmgcr) (Goldstein and Brown 1990, Illingworth 
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and Tobert 2001). Unaltered expression values were returned for the probe-sets 
representing Hmgcr. Expression values were also unaltered for the probes 
representing Lanosterol 14-demethylase cytochrome P450 (Cyp51), which in 
mammals generates a reaction intermediate (14-carboxyaldexyde derivative of 
lanosterol) that down-regulates cholesterol biosynthesis via suppression of Hmgcr 
translation (Lepesheva GI et al 2007). By contrast, increased probe values were 
returned for Lanosterol synthase (Lss), required for generating the first sterol 
intermediate of cholesterol biosynthesis (i.e. lanosterol) and promotion of Insig-
mediated degradation of Hmgcr (Song et al 2005, Cao et al 2007). Like-wise 
A6ND91-FLAG expression was associated with increased transcript probe values for 
Insulin-induced gene (Insig1/2), Autocrine motility factor receptor (Gp78) and 
ubiquitin fusion degradation 1(Ufd1), also required for sterol-accelerated degradation 
of Hmgcr (Sever et al 2003 (A), Sever et al 2003 (B) Cao et al 2007).  Probe-sets 
representing SREBF2 displayed increased expression values. SREBF-2 over-
expression induces all 12 enzymes of the cholesterol biosynthetic pathway 
[Sakakura et al 2001], most notably the mRNA for Hmgcr (Horton et al 1998). 
Collectively, these results display the complex regulation of Hmgcr transcription and 
regulation. Expression of Hmgcr mRNA as detected by probe-sets 1387848_at and 
1375852_at do not provide insights into the regulation of cholesterol biosynthesis in 
cells expressing A6ND91-FLAG. 
Increased expression values were returned for probes representing 
Mevalonate kinase (Mvk), which metabolises Hmgcr synthesised mevalonate.  
Expression values were also increased for probe-sets representing Melavonate 
diphosphate decarboxylase (Mvd), Isopentenyl diphosphate; Dimethyl diphosphate 
isomerase (Idi1) and Farnesyl diphosphate synthetase (Fdps), which generate 
physiological inhibitors (i.e. isopentenyl-diphosphate; di-methyl-diphosphate and 
generanyl-diphosphate) of Mevalonate kinase (Hinson et al 1997). By contrast, 
expression values for probes representing Phosphomevalonate kinase (Pmvk), 
which generates the non-inhibitory intermediate, mevalonate diphosphate, (Hinson et 
al 1997) were unaltered. Collectively, these data suggest that A6ND91-FLAG 
expression may influence regulation of the metabolic pathways controlling de novo 
production of non-sterol isoprenes from acetyl-CoA. These data are supported by 
assays (Figure 1.9) that showed increases in de novo synthesised cholesterol.  
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Figure 5.0 Schematic Representation of Cholesterol Biosynthesis. Figure is 
adapted from KEGG steroid metabolism pathway and associated literature. Steroids 
are synthesized de novo from Acetyl-CoA. Cont’d page 138. 
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Cont’d Figure 5.0 Schematic Representation of Cholesterol Biosynthesis. 
HMG-CoA reductase (Hmgcr) is a rate-limiting enzyme controlling synthesis of 
mevalonate from 3-hydroxy-3-methylglutaryl-CoA (Goldstein et al 1990). Mevalonate 
is a precursor of isoprenoids, such as farnesyl diphosphate which is a branch point 
for biosynthesis of squalene by Farnesyl diphosphate farnesyl transferase 1 (Fdft1). 
This is the first specific enzyme in cholesterol biosynthesis catalyzing the 
condensation of farnesyl diphosphate to presqualene, then reducing presqualene to 
squalene. Lanosterol is synthesised from squalene by the action of Squalene 
epoxidase (Sqle) and Lanosterol sythetase (Lss). Lanosterol-to-cholesterol 
conversion involves oxidative removal of three methyl groups by Cytochrome P450, 
family 51 (Cyp51), reduction of double bonds and migration of lanosterol double 
bond to a new position in cholesterol. Cellular cholesterol is either incorporated into 
lipoproteins (i.e. very low density and high density lipoproteins (VLDL, HDL)) and 
secreted or enters bile acid biosynthesis by Cytochrome P450, family 7,subfamily a, 
polypeptide 1 (Cyp7a1). Additionally, oxysterol binding proteins (i.e. Osbp1a) bind to 
cholesterol derivatives eliciting control over cellular cholesterol levels. Arrows 
indicate flow of substrates through pathway. Connections to other metabolic 
processes are shown in text boxes. Transcripts displaying differential expression in 
McRH7777 cell lines expressing A6ND91-FLAG are shown in red (increased) and 
green (decreased) ovals. See Table 5.0 and Section 5.2.2 for gene names, 
expression fold-changes and p values. Transcripts in grey ovals had expression 
values that did not reach statistical significance. Transcripts in blue ovals are 
unidentified in the rat genome (i.e. Geranylgeranyl reductase (Chlp). 
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Probe ID Name Gene 
Symbol 
Program 
ID 
Fold 
Change 
P Value 
1394490_at
  
ATP-binding cassette, sub-family A, 
member 1 
Abca1 KEGG -1.50 0.021492 
1383416_at 
1367763_at 
Acetyl-Coenzyme A acetyltransferase 
1 (Mitochondrial) 
Acat1 KEGG 3.54 
3.21 
0.000089 
0.000169 
1372462_at Acetyl-Coenzyme A acetyltransferase 
2 (Cytosolic) 
Acat2 GO 3.64 0.000076 
1368335_at Apolipoprotein A-I Apoa1 GO 5.03 0.000013 
1368520_at
  
Apolipoprotein A-IV Apoa4 MAN
#
 -1.39 0.029814 
1369011_at Apolipoprotein A-V Apoa5 MAN
#
 1.29 0.041188 
1384417_at
  
Apolipoprotein C-IV Apoc4 MAN
#
 2.26 0.002041 
1370862_at Apolipoprotein E Apoe MAN
#
 2.14 0.002942 
1388190_at Apolipoprotein B Apob MAN
#
 1.63 0.014232 
1368587_at
  
Apolipoprotein C-I Apoc1 MAN
#
 2.62 0.000709 
1393139_at
  
Apolipoprotein C-II  Apoc2 MAN
#
 2.60 0.000755 
1372012_at 24-dehydracholesterol reductase Dhcr24 KEGG 1.70 0.011310 
1368189_at Dehydrocholesterol reductase Dhcr7 KEGG 2.35 0.001581 
1389725_at Delta14 sterol reductase Tm7sf2 KEGG 1.57 0.016840 
1367839_at Farnesyl diphosphate farnesyl 
transferase 1 
Fdftl GO 3.37 0.000121 
1367667_at Farnesyl diphosphate synthase Fdps KEGG 2.15 0.002863 
1367932_at 3-hydroxy-3-methylglutaryl-Coenzyme 
A synthase 1 
Hmgcs1 KEGG 2.17 0.002719 
1387233_at Hydroxysteroid (17-beta) 
dehydrogenase 7 
Hsd17b7 GO 2.75 0.000497 
1368878_at 
1388872_at 
Isopentenyl-diphosphate delta 
isomerase 
Idi1 GO 
 
3.76 
3.51 
0.000062 
0.000093 
1368086_a_at Lanosterol sythetase Lss KEGG 2.04 0.004069 
1367887_at Lecithin cholesterol acyltransferase Lcat GO 9.14 0.000001 
1391745_at Low density lipoprotein receptor Ldlr MAN
#
 -1.43 0.026735 
1368020_at Mevalonate (diphospho) 
decarboxylase 
Mvd GO 3.69 0.000069 
1368232_at 
1387119_at 
Mevalonate kinase Mvk GO 
 
3.00 
2.60 
0.000264 
0.000744 
1387599_a_at NAD(p)H dehydrogenase, quinone 1 Nqo1 KEGG 1.30 0.039186 
1392604_at 
1392988_at 
NAD(p) dependent steroid 
dehydrogenase-like 
Nsdhl GO 
 
4.97 
3.24 
0.000014 
0.000159 
1383633_at Oxysterol binding protein-like 1A Osbpl1a GO -3.04 0.000239 
1371050_at Paraoxonase 1 Pon1 GO 2.55 0.000860 
1386990_at Phenylalklamineca
2†  
antagonist 
(emopamil) binding protein 
Ebp KEGG 2.43 0.001221 
1385640_at Proprotein convertase subtilisin/kexin 
type 9   
Pcsk9 MAN
#
 1.94 0.005455 
1369104_at Protein kinase, AMP-activated, alpha 1 
catalytic subunit 
Prkaa1 GO 2.89 0.000346 
1373952_at 
1383122_at 
Protein kinase, AMP-activated, gamma 
2 non-catalytic subunit 
Prkag2 GO 
 
-4.78 
-2.97 
0.000017 
0.000287 
1387017_at Squalene epoxidose Sqle KEGG 2.05 0.003944 
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Probe ID Name Gene 
Symbol 
Program 
ID 
Fold 
Change 
P Value 
1390777_at 
1387926_at 
Sterol-C5-desaturase Sc5d GO 2.57 
4.13 
0.000832 
0.000033 
1368275_at Sterol-C4-methyloxidase-like Sc4mol KEGG 2.24 0.002170 
1388330_at Vitamin K epoxide reductase complex 
subunit 1 
Vkorc1 KEGG 3.70 0.000068 
1393621_at 
1380590_at 
Vitamin K epoxide reductase complex, 
subunit 1-like 1 
Vkorc1l1 KEGG 1.70 
1.56 
0.011362 
0.017849 
 
Table 5.0 Significantly Perturbed Transcripts of Cholesterol and Steroid 
Metabolism. The table shows a list of differentially expressed genes involved in 
Cholesterol and Steroid Metabolism (p < 0.05) from cells expressing A6ND91-FLAG. 
Affymetrix probe-set ID is shown in column Probe ID. Program ID, represents either 
GO, KEGG-PATHWAY analysis or literature identified transcripts (Section 5.2.2); 
Fold-change and p values (p < 0.05) are shown.  
# 
Program ID = MAN, shows transcripts searched for manually (i.e. not recognised by either GO or 
KEGG-PATHWAY analysis). 
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To substantiate the evidence that A6ND91-FLAG expression perturbs the 
regulation of non-sterol isoprenoid metabolism, expression data for additional genes 
were examined. Decreased expression values were returned for Dehydrodolichyl 
diphosphate synthase (Dhdds), which catalyses the sequential condensation of 
isopentenyl diphosphate with farnesyl diphosphate in the synthesis of the 
biosynthetic precursor of dolichol (i.e. dehydrodolichyl diphosphate). Decreased 
values were also obtained for the probes representing the -and -subunits of 
Geranylgeranyltransferase II (i.e. Rabggta, Rabggtb), which catalyses the 
attachment of 20 carbon-long prenyl lipid anchors to non-CaaX motif proteins 
(Maurer-Stroh et al 2003). By contrast, increased expression values were returned 
for the -subunit of Geranylgeranyltransferase I (Pggt1b), which prenylates CaaX 
motif proteins. Probes representing -subunit of Farnesyltransferase (Fnta), which 
competes with the -subunit of Geranylgeranyltransferase I for binding to the 
common -subunit (Fnta), were decreased. Fnta probe values were unaltered. 
Finally, Figure 5.0 shows that probe values were increased for two further non-sterol 
components (i.e. Vkorc1 and Nqo1) of the KEGG Steroid Metabolism Pathway. 
These data provide further evidence that A6ND91-FLAG expression perturbs 
expression of genes regulating non-sterol isoprenoid metabolism.   
Data in Figure 5.0 and Table 5.0 show that probe values were increased for 
most of the transcripts representing gene-products obligatory for cholesterol and 
steroid biosynthesis, plus the first step of bile-acid biosynthesis (Section 5.2.6). 
Probe values were also increased for lipoprotein-associated gene-products (e.g. 
ApoB and ApoA1) that promote cellular removal of cholesterol (Dixon et al 1991, 
Boisvert et al 1999). However, probe values were not increased for Abca1 (ATP-
binding cassette transporter A1), which effluxes cellular cholesterol onto ApoA1 for 
HDL particle formation (Boadu et al 2008).   
Decreased expression values were returned for probes representing Low 
density lipoprotein receptor (Ldlr), which mediates cellular cholesterol uptake (Brown 
et al 1981 (A), Brown et al 1981 (B)). Additionally, increased values were returned 
for probes representing proprotein convertase subtilisin/kexin type 9 (Pcsk9), a 
secretory protein that promotes degradation of the LDL-receptor (Zhang et al 2008).  
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5.2.3 Xenobiotic Metabolism 
A total of 26 transcripts classified by GO (n=10) analysis and KEGG 
PATHWAY (n=16) falling under Xenobiotic Metabolism are shown in Table 5.1, with 
their respective fold-changes and p values. Four of the GO transcripts; Aldehyde 
oxidase 1(Aox1), Flavin containing mono-oxygenase 4 (Fmo4), UDP 
glycosyltransferase 2 family, member 3 (Ugt2b3) and Cytochrome P450, family 2, 
subfamily c, polypeptide 23 (Cyp2c23) cluster on KEGG PATHWAY Drug 
Metabolism by Cytochrome P450. KEGG PATHWAY analysis placed a further 16 
transcripts on Drug Metabolism by Cytochrome P450 pathway. Table 5.2 shows the 
drugs metabolised by the respective gene-products as identified by KEGG. 
Four GO identified transcripts (i.e. Ahr, Bucs1, Ephx2 and Akr1c12) were 
supported by scientific literature in metabolism of Xenobiotics. Increased expression 
values were returned for probes encoding Aryl hydrocarbon receptor (Ahr), Butyryl 
Coenzyme A synthetase 1 (Bucs1) and Epoxide hydrolase 2, cytoplasmic (Ephx2). 
Ahr, a ligand-activated transcription factor is involved in binding of aromatic 
hydrocarbons (Lusska et al 1991, Okey et al 1994) and controls the expression of 
CYP1A1, CYP1A2 and CYP1B1, as well as glutathione S-transferase (GST) and 
UDP-glucuronosyltransferase (UGT) (Vrzal et al 2004). Bucs1 is a xenobiotic 
/medium-chain fatty acid: CoA ligase (XM-ligases), catalysing the formation of 
carboxylic acid-CoA thioesters from xenobiotic carboxylic acids and medium-chain 
fatty acids (Vessey et al 2003). Ephx2 catalyzes the hydrolysis of fatty acid derived 
epoxides to glycol or dihydro-diols (Sandberg et al 2000). Decreased probe 
expression was returned for Aldo-keto reductase family 1, member C12 (Akr1c12), 
which metabolises a range of xenobiotic carbonyl compounds including the 
oxidisation of 17-hydroxysteroids, -dicarbonyl compounds and aromatic aldehydes 
(Matsunaga et al 2006). Two GO identified gene-products (i.e. Pter and Laptm4a) 
failed to provide evidence in the role of Xenobiotic Metabolism. 
Closer examination of the genes (n=13) involved in Drug Metabolism by 
Cytochrome P450, identified shared activities involved in Carboxylic Acid metabolism 
(Section 5.2.4). Table 5.3 shows the overlap with carboxylic acid metabolism. 
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Probe ID Name Gene 
Symbol 
Program 
ID 
Fold 
Change 
P Value 
1368021_at Alcohol dehydrogenase 1 (class I) Adh1 KEGG -1.27 0.042990 
1369863_at Alcohol dehydrogenase 4 (class II), pi 
polypeptide 
Adh4 KEGG -1.84 0.007356 
1387376_at Aldehyde oxidase 1 Aox1 GO 3.87 0.000050 
1398612_at 
Aldo-keto reductase family 1, member 
C12 
Akr1c12 GO -4.15 0.000033 
1369146_a_at Aryl hydrocarbon receptor Ahr GO 3.38 0.000753 
1384499_at Butyryl Coenzyme A synthetase 1 Bucs1 GO 2.60 0.000753 
1387243_at Cytochrome P450, family 1, subfamily 
a, polypeptide 2 
Cyp1a2 KEGG -1.90 0.006213 
1368155_at Cytochrome P450, family 2, subfamily 
c, polypeptide 12 
Cyp2c12 KEGG -1.26 0.044615 
1367988_at Cytochrome P450, family 2, subfamily 
c, polypeptide 23 
Cyp2c23 GO 3.04 0.000241 
1370241_at Cytochrome P450, family 2, subfamily 
c, polypeptide 7 
Cyp2c7 KEGG -2.20 0.002437 
1370387_at Cytochrome P450, family 3, subfamily 
a, polypeptide 9 
Cyp3a9 KEGG 1.87 0.006728 
1369663_at Epoxide hydrolase 2, cytoplasmic Ephx2 GO 3.26 0.001537 
1379885_at 
Flavin containing mono-oxygenase 4
    
Fmo4 GO -2.74 0.000514 
1388748_at 
Lysosomal-associated protein 
transmembrane 4A 
Laptm4a GO 2.98 0.000277 
1367774_at Glutathione S-transferase A3 Gsta3 KEGG 2.43 0.001251 
1368180_s_at Glutathione-S-transferase, alpha type2 Gsta2 KEGG -4.90 0.000015 
1368354_at Glutathione S-transferase theta 1 Gstt1 KEGG 5.02 0.000013 
1368409_at Glutathione S-transferase, theta 2 Gstt2 KEGG 3.39 0.000117 
1398378_at Glutathione S-transferase kappa 1 Gstk1 KEGG -8.27 0.000002 
1387023_at Glutathione S-transferase, mu type 3 Gstm3 KEGG 2.31 0.001777 
1370813_at Glutathione S-transferase, mu 5 Gstm5 KEGG 3.21 0.000169 
1387851_at Phosphotriesterase-related Pter GO 5.46 0.000009 
1377831_at 
1370678_s_at 
Monoamine oxidase A Maoa KEGG 2.29 
2.17 
0.001862 
0.002738 
1369850_at 
UDP glucuronosyltransferase 2 family, 
polypeptide A1  
Ugt2a1 KEGG 2.31 0.001774 
1387955_at 
UDP glycosyltransferase 2 family, 
member 3 
Ugt2b3 GO -7.39 0.000003 
1370698_at 
UDP glucuronosyltransferase 2 family, 
polypeptide B17 
Ugt2b17 KEGG 1.39 0.029760 
 
Table 5.1 Significantly Perturbed Transcripts of Xenobiotic Metabolism. 
Differentially expressed genes involved in Xenobiotic Metabolism (p < 0.05) from 
cells expressing A6ND91-FLAG. See Table 5.0 for Table description.  
 
 
 
145 
 
 
Name Gene 
Symbol 
Drug Target Fold 
Change 
Alcohol dehydrogenase 1 (class I) Adh1 Cyclophosphamide/Ifosfamide 
Felbamate 
-1.27 
Alcohol dehydrogenase 4 (class II), pi 
polypeptide 
Adh4 Cyclophosphamide/Ifosfamide 
Felbamate 
-1.84 
Aldehyde oxidase 1 Aox1 Citalopram 3.87 
Cytochrome P450, family 1, subfamily a, 
polypeptide 2 
Cyp1a2 Lidocaine -1.90 
Cytochrome P450, family 2, subfamily c, 
polypeptide 12 
Cyp2c12 Cyclophosphamide/Ifosfamide 
Citalopram 
Carbamazepine 
Valproic acid 
-1.26 
Cytochrome P450, family 2, subfamily c, 
polypeptide 23 
Cyp2c23 Cyclophosphamide/Ifosfamide 
Citalopram 
Carbamazepine 
Valproic acid 
3.04 
Cytochrome P450, family 2, subfamily c, 
polypeptide 7 
Cyp2c7 Cyclophosphamide/Ifosfamide 
Citalopram 
Carbamazepine 
Valproic acid 
-2.20 
Cytochrome P450, family 3, subfamily a, 
polypeptide 9 
Cyp3a9 Tamoxifen 
Cyclophosphamide/Ifosfamide 
Codeine/Morphine 
Methadone 
Lidocaine 
Felbamate 
Carbamazepine 
1.87 
Flavin containing mono-oxygenase 4 
   
Fmo4 Tamoxifen -2.74 
Glutathione S-transferase A3 Gsta3 Cyclophosphamide/Ifosfamide 2.43 
Glutathione-S-transferase, alpha type2 Gsta2 Cyclophosphamide/Ifosfamide -4.90 
Glutathione S-transferase, theta 1 Gstt1 Cyclophosphamide/Ifosfamide 5.02 
Glutathione S-transferase, theta 2 Gstt2 Cyclophosphamide/Ifosfamide 3.39 
Glutathione S-transferase, kappa 1 Gstk1 Cyclophosphamide/Ifosfamide -8.27 
Glutathione S-transferase, mu type 3 Gstm3 Cyclophosphamide/Ifosfamide 2.31 
Glutathione S-transferase, mu 5 Gstm5 Cyclophosphamide/Ifosfamide 3.21 
Monoamine oxidase A Maoa Citalopram 2.29 
2.17 
UDP glucuronosyltransferase 2 family, 
polypeptide A1  
Ugt2a1 Codeine/Morphine 2.31 
UDP glycosyltransferase 2 family, member 3 Ugt2b3 Codeine/Morphine -7.39 
UDP glucuronosyltransferase 2 family, 
polypeptide B17 
Ugt2b17 Codeine/Morphine 1.39 
 
Table 5.2 Xenobiotic Identified Transcripts and Their Target Drugs. Transcripts 
from cells expressing A6ND91-FLAG that are identified to operate on KEGG 
pathway Drug Metabolism by Cytochrome P450 are shown with their respective drug 
target and fold-change values.  
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Additionally, seven genes (i.e. Gsta2 - 3, Gstt1 – 2, Gstk, Gstm3 - 5) are involved in 
Glutathione Metabolism, a pathway responsive to cellular stress. GSTs catalyse the 
conjugation of reduced glutathione to oxidised lipids (Yang et al 2001), as well as a 
broad range of xenobiotics (Bull et al 2002) and may transport bilirubin bile acids and 
heme proteins (Board et al 1987).  
 
5.2.4 Carboxylic Acid Metabolism 
The 58 probes grouped by GO into Carboxylic Acid Metabolism represents 
gene-products involved in metabolism of organic acids containing one or more 
carboxyl (COOH) groups or anions (COO-). Table 5.4 shows some examples of 
common carboxylic acids in mammalian metabolism, while Table 5.5 shows the GO 
parent category contained 8 child terms. Using KEGG PATHWAY analysis, 52 of the 
58 GO-identified genes were assigned to a metabolic pathway. KEGG PATHWAY 
analysis also implicated potential involvement of an additional 116 differentially 
expressed gene-products in carboxylic acid metabolism (Table 5.6). The pathways 
on which these gene-products cluster are shown in Table 5.5. 
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Gene 
Symbol 
KEGG Carboxylic Acid Pathway Section 
Adh1 Bile Acid  
Fatty Acid  
Glycolysis and Gluconeogensis 
5.2.4.8 
5.2.4.9 
5.2.4.10 
Adh4 Bile Acid  
Fatty Acid  
Glycolysis and Gluconeogensis 
5.2.4.8 
5.2.4.9 
5.2.4.10 
Aox1 Valine, Leucine and Isoleucine 5.2.4.5 
Cyp1a2 Linoleic Acid 5.2.4.9 
Cyp2c12 Arachinoic Acid 
Linoleic Acid 
5.2.4.9 
5.2.4.9 
Cyp2c23 Arachinoic Acid 
Linoleic Acid 
5.2.4.9 
5.2.4.9 
Cyp2c7 Arachinoic Acid 
Linoleic Acid 
5.2.4.9 
5.2.4.9 
Cyp3a9 Linoleic Acid 5.2.4.9 
Ephx2 Arachinoic Acid 5.2.4.9 
Maoa Urea Cycle 
Glycine, Serine and Threonine 
5.2.4.4 
5.2.4.6 
Ugt2a1 Glucuronate 5.2.4.10 
Ugt2b3 Glucuronate 5.2.4.10 
Ugt2b17 Glucuronate 5.2.4.10 
 
Table 5.3 Overlap of Transcripts Both Identified in Xenobiotic and Carboxylic 
Acid Metabolism. The table shows a list of differentially expressed genes as 
identified in Xenobiotic metabolism (p < 0.05) from cells expressing A6ND91-FLAG 
and overlap with Carboxylic Acid metabolism. 
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Table 5.4 Common Carboxylic Acids in Mammalian Metabolism.   
 
 
Common 
name 
Molecular Structure Chemical formula Example 
Pathway 
 
Amino acids 
 
 
Formic acid 
 
Acetic acid 
 
Butyric acid 
 
Palmitic acid 
 
Stearic acid 
 
 
Pyruvic acid  
 
 
Acetoacetic 
acid  
 
Succinic acid 
 
 
Lactic acid  
 
 
 
 
 
 
 
 
 
 
 
 
NH2CH(R)COOH 
 
 
HCOOH 
 
CH3COOH 
 
CH3(CH2)2COOH 
 
CH3(CH2)14COOH 
 
CH3(CH2)16COOH 
 
 
CH3C(O)COOH 
 
 
CH3C(O)CH2COOH 
 
 
COOH(CH2)2COOH 
 
 
CH3CH(OH)COOH 
 
Amino acid 
 
 
Glyoxylate 
 
Pyruvate 
 
Ketone Body 
 
Fatty Acid 
 
Fatty Acid 
 
 
Pyruvate 
 
 
Ketone Body 
 
 
TCA Cycle 
 
 
Pyruvate 
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Table 5.5 Carboxylic Acid Component Child Terms. 
 
 
 
 
 
Carboxylic Acid Metabolism 
Amino Acid Metabolism 
Alanine and Aspartate  
Valine, Leucine and Isoleucine  
Glycine, Serine and Threonine  
Arginine and Proline  
Glutamate  
Bile Acid Metabolism 
Carboxylic Acid Biosynthesis 
Glyoxylate and Dicarboxylate 
Creatine Metabolism 
Arginine and Proline  
Fatty Acid Metabolism  
Carnitine Metabolism 
Folate Metabolism   
Pyruvate Metabolism 
      Citrate (TCA) cycle 
Glycolysis and Gluconeogenesis 
      Uronic Acid Metabolism 
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Probe ID Name Carboxylic Acid 
Metabolism 
Gene 
Symbol 
Program 
ID 
Fold 
Change 
P Value 
1370147_at 2-amino-3-carboxymuconate-
6-semialdehyde 
decarboxylase 
Acmsd KEGG -1.27 0.044126 
1370310_at 3-hydroxy-3-methylglutaryl-
Coenzyme A synthase 2 
Hmgcs2 KEGG 1.31 0.038870 
1368387_at 3-hydroxybutyrate 
dehydrogenase, type 1 
Bdh1 KEGG 3.40 0.000114 
1367811_at 3-phosphoglycerate 
dehydrogenase 
Phgdh KEGG 2.30 0.001811 
1368794_at 3-hydroxyanthranilate 3,4-
dioxygenase 
Haao KEGG 2.60 0.000764 
1388118_at 3-hydroxyisobutyrate 
dehydrogenase 
Hibadh GO -2.77 0.000476 
1373564_at 3-hydroxyisobutyryl-
Coenzyme A hydrolase 
Hibch KEGG 4.23 0.000030 
1368188_at 4-hydroxyphenylpyruvic acid 
dioxygenase 
Hpd KEGG -2.15 0.002880 
1384370_at 
1392719_at 
1381768_at 
5,10-
methenyltetrahydrofolate 
synthetase (5-
formyltetrahydrofolate cyclo-
ligase) 
 
Mthfs 
 
GO 3.56 
2.76 
      1.57
  
0.000085 
0.000487 
0.017082 
1372847_at ACN9 homolog (S. 
cerevisiae) 
Acn9 GO     -3.19 0.000176 
1387215_at Alanine-glyoxylate 
aminotransferase 
Agxt KEGG 1.32 0.036753 
1367763_at 
1383416_at 
Acetyl-coenzyme A 
acetyltransferase 1 
Acat1 KEGG 3.21 
3.54 
0.000169 
0.000089 
1387783_a_at Acetyl-Coenzyme A 
acyltransferase 1 
Acaa1 KEGG 1.97 0.005045 
1380504_at 
1386880_at 
Acetyl-Coenzyme A 
acyltransferase 2 
(mitochondrial) 
Acaa2 KEGG -2.64 
1.89 
0.000663 
0.006327 
1367702_at Acetyl-Coenzyme A 
dehydrogenase, medium 
chain 
Acadm KEGG 2.13 0.003093 
1370939_at Acyl-CoA synthetase long-
chain family member 1 
Acsl1 KEGG -1.57 0.017069 
1367897_at Acyl-Coenzyme A 
dehydrogenase, very long 
chain 
Acadvl KEGG 2.25 0.002087 
1386916_at Aconitase 1 Aco1 KEGG -1.61 0.015088 
1367589_at Aconitase 2, mitochondrial Aco2 KEGG 1.36 0.032764 
1388394_at Alanyl-tRNA synthetase Aars GO 4.74 0.000017 
1368021_at Alcohol dehydrogenase 1 
(class I) 
Adh1 KEGG -1.27 0.042989 
1369863_at Alcohol dehydrogenase 4 
(class II), pi polypeptide 
Adh4 KEGG -1.84 0.007356 
1372246_at 
1387867_at 
Aldehyde dehydrogenase 
family 9, subfamily A1 
Aldh9a1 KEGG 1.31 
1.62 
0.037924 
0.014768 
1387344_at Aldehyde dehydrogenase 
family 6, subfamily A1 
Aldh6a1 GO 3.65 0.000074 
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Probe ID Name Carboxylic Acid 
Metabolism 
Gene 
Symbol 
Program 
ID 
Fold 
Change 
P Value 
1387376_at Aldehyde oxidase 1 Aox1 KEGG 3.87 0.000050 
1370299_at Aldolase B Aldob GO 4.65 0.000018 
1398753_at Aldo-keto reductase family 1, 
member A1 
Akr1a1 KEGG 1.81 0.008034 
1367734_at Aldo-keto reductase family 1, 
member B4 
Akr1b4 KEGG -1.29 0.040344 
1367775_at Alpha-methylacyl-CoA 
racemase 
Amacr GO 4.40 0.000023 
1368139_s_at Alkaline phosphatase, tissue-
nonspecific 
Alpl KEGG -1.57 0.017135 
1381322_at Amiloride binding protein 1 
(amine oxidase, copper-
containing) 
Abp1 KEGG -1.34 0.034737 
1383920_at Aminomethyltransferase 
(glycine cleavage system 
protein T) 
Amt KEGG 1.54 0.018826 
1368916_at Argininosuccinate lyase Asl GO 3.54 0.000089 
1374871_at 
1387966_at 
Asparaginase like 1 Asrgl1 KEGG -2.72 
-3.86 
0.000546 
0.000051 
1374437_at Asparaginyl-tRNA synthetase Nars GO 7.01 0.000004 
1387508_at Bile acid-Coenzyme A: amino 
acid N-acyltransferase 
Baat GO 5.75 0.000008 
1369520_a_at Branched chain 
aminotransferase 1, cytosolic 
Bcat1 KEGG 1.94 0.005429 
1386928_at Branched chain 
aminotransferase 2, 
mitochondrial 
Bcat2 KEGG 2.51 0.000985 
1380557_at Branched chain keto acid 
dehydrogenase E1, alpha 
polypeptide 
Bckdha KEGG -2.21 0.002360 
1370906_at Branched chain keto acid 
dehydrogenase E1, beta 
polypeptide 
Bckdhb KEGG 1.81 0.008131 
1370842_at Branched chain keto acid 
dehydrogenase kinase 
Bckdk GO 3.07 0.000225 
1390822_at Cadherin 16 Cdh16 GO 4.03 0.000040 
1370151_at 
1384334_at 
Carbamyl-phosphate 
synthetase 1, mitochondrial 
Cps1 KEGG -2.90 
-4.80 
0.000338 
0.000016 
1367742_at Carnitine palmitoyltransferase 
1b, muscle 
Cpt1b KEGG -1.47 0.023380 
1369738_s_at cAMP responsive element 
modulator 
Crem GO 2.78 0.000457 
1368826_at Catechol-O-
methyltransferase 
Comt GO 3.59 0.000082 
1396168_at Catalase Cat KEGG 1.26 0.045191 
1398827_at CD 81 antigen CD81 GO 3.50 0.000094 
1368692_a_at Choline kinase alpha Chka KEGG 2.40 0.001342 
1384201_at Citrate synthase Cs KEGG -1.55 0.018362 
1387243_at Cytochrome P450, family 1, 
subfamily a, polypeptide 2 
Cyp1a2 KEGG -1.90 0.006212 
1368990_at Cytochrome P450, family 1, 
subfamily b, polypeptide 1 
Cyp1b1 KEGG -2.84 0.000399 
1367988_at Cytochrome P450, family 2, 
subfamily c, polypeptide 23 
Cyp2c2
3 
GO 3.04 0.000241 
1387118_at Cytochrome P450, family 3, 
subfamily a, polypeptide23/ 1 
Cyp3a2
3/1 
KEGG 2.32 0.001717 
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1394844_s_at Cytochrome P450, family 4, 
subfamily a, polypeptide 2/3 
Cyp4a2/
3 
GO -3.31 0.000137 
1368458_at Cytochrome P450, family 7, 
subfamily a, polypeptide 1 
Cyp7a1 KEGG 1.48 0.022793 
1387914_at Cytochrome P450, family 27, 
subfamily a, polypeptide 1 
Cyp27a
1 
KEGG 2.13 0.003057 
1367838_at Cystathionase (cystathionine 
gamma-lyase) 
Cth KEGG 1.82 0.007802 
1373667_at Cysteine conjugate- lyase 1 Ccbl1 KEGG 1.86 0.007002 
1367626_at Creatine kinase, muscle Ckm KEGG 2.02 0.004245 
1369491_at D-amino acid oxidase 1 Dao1 KEGG -1.94 0.005616 
1391889_at DEAD (Asp-Glu-Ala-Asp) box 
polypeptide 52 
Ddx52 KEGG -1.28 0.041879 
1397508_at 
1377945_at 
DEAD (Asp-Glu-Ala-Asp) box 
polypeptide 18 
Ddx18 KEGG -1.33 
-1.33 
0.036335 
0.035635 
1370075_at 
1383536_at 
Dihydrofolate reductase Dhfr GO 2.24 
3.82 
0.002163 
0.000054 
1388194_at Dihydrolipoamide S-
acetyltransferase (E2 
component of pyruvate 
dehydrogenase complex) 
Dlat KEGG 1.46 0.024241 
1387111_at Dimethylarginine 
dimethylaminohydrolase 1 
Ddah1 GO -5.73 0.000008 
1367659_s_at Dodecenoyl-coenzyme A 
delta isomerase 
Dci KEGG 1.75 0.009848 
1380212_at Enolase 2, gamma Eno2 KEGG -1.36 0.032382 
1386885_at Enoyl coenzyme A hydratase 
1, peroxisomal 
Ech1 GO 4.02 0.000040 
1367829_at Enoyl Coenzyme A 
hydratase, short chain, 1, 
mitochondrial 
Echs1 GO 3.18 0.000182 
1385413_at  Epidermal growth factor 
receptor 
Egfr GO 3.15 0.000192 
1369663_at  Epoxide hydrolase 2, 
cytoplasmic 
Ephx2 GO 3.26 0.001537 
1369111_at Fatty acid binding protein 1, 
liver 
Fabp1 GO 7.29 0.000003 
1376522_at Fatty acid binding protein 3
    
Fabp3 KEGG 1.46 0.024404 
1370024_at 
1381732_at 
Fatty acid binding protein 7, 
brain    
   
  
Fabp7  KEGG 3.14 
1.60 
0.000198 
0.015662 
1367707_at Fatty acid synthase Fasn KEGG -1.86 0.006894 
1367670_at Fumarate hydratase 1 Fh1 KEGG 1.57 0.017044 
1368092_at Fumarylacetoacetate 
hydrolase 
Fah GO 2.54 0.000906 
1385072_at Galactose mutarotase Galm KEGG 1.40 0.029004 
1370725_a_at Glucose-6-phosphatase, 
catalytic 
G6pc KEGG 1.86 0.006882 
1382040_at 
1373418_at 
Glutamyl-prolyl-tRNA 
synthetase 
Eprs KEGG 2.47 
1.63 
0.001102 
0.014192 
1377761_at Glutamine-fructose-6-
phosphate transaminase 2 
Gfpt2 KEGG -1.95 0.005210 
1370375_at Glutaminase 2 (liver, 
mitochondrial) 
Gls2 KEGG -1.55 0.018027 
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1367805_at Glutaminase Gls KEGG 1.58 0.016420 
1369462_at Glutamate decarboxylase 2 Gad2 KEGG -1.52 0.019715 
1367819_at Glutamate oxaloacetate 
transaminase 2, 
mitochondrial 
Got2 KEGG 1.27 0.043864 
1370030_at Glutamate cysteine ligase, 
modifier subunit 
Gclm GO -2.85 0.000388 
1370200_at 
1387878_at 
Glutamate dehydrogenase 1 Glud1 GO 3.27 
3.45 
0.000148 
0.000103 
1367632_at 
1367633_at 
1386870_at 
Glutamate-ammonia ligase 
(glutamine synthase) 
Glul GO 2.52 
3.24 
3.10 
0.000957 
0.000158 
0.000212 
1387052_at Glutamic pyruvic 
transaminase 1, soluble 
Gpt1 GO -5.41 0.000009 
1388788_at 
1397526_at 
Glutaryl-Coenzyme A 
dehydrogenase  
Gcdh GO 3.30 
3.26 
0.000140 
0.000154 
1369061_at Glutathione reductase Gsr KEGG 1.75 0.009779 
1370365_at Glutathione synthetase Gss KEGG 1.78 0.008997 
AFFX_Rat_GAPDH_5
_at 
AFFX_Rat_GAPDH_
M_at 
Glyceraldehyde-3-phosphate 
dehydrogenase 
Gapdh KEGG 1.64 
 
1.23 
0.013727 
 
0.048527 
1368890_at Glyceronephosphate O-
acyltransferase 
Gnpat GO 3.40 0.000113 
1377784_at Glycine amidinotransferase 
(L-arginine:glycine 
amidinotransferase) 
Gatm KEGG 1.47 0.023423 
1367908_at Glycine cleavage system 
protein H (aminomethyl 
carrier) 
Gcsh GO 2.76 0.000481 
1371358_at Glycoprotein, synaptic 2 Gpsn2 KEGG 4.54 0.000021 
1399098_at Glyoxylase 1 Glo1 KEGG 1.59 0.015807 
1368503_at 
1387221_at 
GTP cyclohydrolase 1 Gch KEGG 2.16 
1.77 
0.002747 
0.009317 
1368009_at Glucosamine Gne GO -3.96 0.000044 
1368253_at Guanidinoacetate 
methyltransferase 
Gamt GO 2.86 0.000374 
1380373_at Guanine monophosphate 
synthetase 
Gmps KEGG 2.39 0.001371 
1386929_at 
AFFX_Hexokinase_3
_at 
Hexokinase 1 Hk1 KEGG 1.26 
2.12 
0.044884 
0.003195 
1367662_at Hydroxyacyl-Coenzyme A 
dehydrogenase type II 
Hadh2 KEGG 2.98 0.000279 
1370164_at Hydroxyacyl-Coenzyme A 
dehydrogenase/3-ketoacyl-
Coenzyme A thiolase/enoyl-
Coenzyme A hydratase 
(trifunctional protein), alpha 
subunit 
Hadha KEGG 1.26 0.044336 
1367694_at Hydroxyacyl-Coenzyme A 
dehydrogenase/3-ketoacyl-
Coenzyme A thiolase 
Hadhb GO 3.13 0.000199 
1370433_at Hydroxy-delta-5-steroid 
dehydrogenase, 3 beta- and 
steroid delta-isomerase 7 
Hsd3b7 KEGG 3.14 0.000196 
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1367672_at Hydroxysteroid (17-beta) 
dehydrogenase 4 
Hsd17b
4 
KEGG 3.08 0.000220 
1376418_a_at Isoleucine-tRNA synthetase  Iars KEGG 1.56 0.017481 
1397170_at Kynurenine 3-
monooxygenase (kynurenine 
3-hydroxylase) 
Kmo KEGG 1.34 0.034460 
1389922_at 
1392328_at 
1370237_at 
L-3-hydroxyacyl-Coenzyme A 
dehydrogenase, short chain 
Hadhsc KEGG 1.60 
1.27 
1.69 
0.015393 
0.044031 
0.011588 
1387725_at 
1369837_at 
L-gulonolactone oxidase Gulo GO 9.57 
10.52 
0.000001 
0.000001 
1389406_at Lactate dehydrogenase A-like 
6B 
Ldhal6b KEGG 1.28 0.042369 
1370218_at Lactate dehydrogenase B Ldhb KEGG -1.82 0.007843 
1387216_at Lactate dehydrogenase C Ldhc KEGG 1.81 0.008089 
1376579_at Leucine aminopeptidase 3 Lap3 KEGG 2.45 0.001167 
1367653_a_at Malate dehydrogenase 1, 
NAD (soluble) 
Mdh1 KEGG 2.29 0.001894 
1369927_at Malate dehydrogenase 2, 
NAD (mitochondrial) 
Mdh2 KEGG 2.40 0.001359 
1370067_at 
1370870_at 
Malic enzyme 1 Me1 GO 3.24 
4.13 
0.000160 
0.000034 
1387531_at Methionine sulfoxide 
reductase A 
Msra GO 3.46 0.000101 
1389733_at 
1395363_at 
Methionine-tRNA synthetase 
1 (cytosolic)  
Mars1 GO 1.81 
3.46 
0.008077
0.000101 
1377287_at Methionine-tRNA synthetase 
2 (mitochondrial)  
Mars2 KEGG -4.73 0.000017 
1397176_at Methyltransferase like 6 Mettl6 KEGG -1.50 0.022017 
1376852_at Methylcrotonoyl-Coenzyme A 
carboxylase 1 (alpha) 
Mccc1 KEGG 1.95 0.005288 
1369906_s_at Multiple coagulation factor 
deficiency 2 
Mcfd2 GO -4.73 0.000017 
1369077_at 
1374770_at 
N-acylsphingosine 
amidohydrolase 1 
Asah1 GO 2.81 
2.57 
0.000424 
0.000825 
1373939_at N-acetylglucosamine kinase Nagk KEGG -1.53 0.019306 
1367729_at Ornithine aminotransferase Oat KEGG 2.26 0.002055 
1390020_at 
1398072_at 
Oxoglutarate dehydrogenase 
(lipoamide) 
LOC360
975 
KEGG 1.97 
1.40 
0.004923 
0.028963 
1371054_at Phenylethanolamine-N-
methyltransferase 
Pnmt KEGG 2.02 0.004255 
1372264_at Phosphoenolpyruvate 
carboxykinase 1 
Pck1 KEGG 1.43 0.026117 
1376247_at Phosphoenolpyruvate 
carboxykinase 2 
(mitochondrial)  
Pck2 KEGG 1.27 0.043411 
1388634_at Phosphoglucomutase 1 Pgm1 KEGG -2.32 0.001729 
1387361_s_at Phosphoglycerate kinase 1 Pgk1 KEGG 1.63 0.014021 
1384632_at Phosphofructokinase, muscle Pfkm KEGG -1.71 0.011169 
1372665_at Phosphoserine 
aminotransferase 1 
Psat1 GO 2.78 0.000460 
1375964_at Phosphoserine phosphatase Psph GO 4.25 0.000029 
1369581_at Phosphatidylethanolamine N-
methyltransferase 
Pemt KEGG 2.00 0.004582 
1370427_at Platelet derived growth factor, 
alpha 
Pdgfa GO 2.62 0.000716 
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1387616_at Platelet-derived growth 
factor, C polypeptide 
Pdgfc GO  3.81 0.000057 
1367807_at Procollagen-lysine, 2-
oxoglutarate 5-dioxygenase 1 
Plod1 KEGG 3.19 0.000179 
1372920_at Proline oxidase, 
mitochondrial precursor 
(proline dehydrogenase) 
LOC680
409 
KEGG -1.80 0.008484 
1370187_at Propionyl coenzyme A 
carboxylase, beta polypeptide 
Pccb KEGG -1.25 0.046545 
1369104_at Protein kinase, AMP-
activated, alpha 1 catalytic 
subunit 
Prkaa1 GO 2.89 0.000346 
1373952_at 
1383122_at 
Protein kinase, AMP-
activated, gamma 2 non-
catalytic subunit 
Prkag2 GO -4.78 
-2.97 
0.000017 
0.000287 
1374393_at Protein tyrosine 
phosphatase-like  
Ptplb KEGG 3.26 0.000154 
1372485_at Pterin 4 alpha carbinolamine 
dehydratase/dimerization 
cofactor of hepatocyte 
nuclear factor 1 alpha (TCF1) 
1 
Pcbd1 GO  3.84 0.000053 
1387271_at 
1393245_at 
Phytanoyl-CoA hydroxylase 
 
Phyh GO 5.26 
 4.54 
0.000011 
0.000021 
1383698_at 
1371380_at 
Pyruvate dehydrogenase E1 
alpha 1 
Pdha1 GO 3.76 
2.52 
0.000062 
0.000960 
1368651_at Pyruvate kinase, liver and red 
blood cell 
Pklr KEGG 3.10 0.000214 
1369931_at Pyruvate kinase, muscle Pkm2 KEGG -4.14 0.000033 
1367695_at Quinoid dihydropteridine 
reductase 
Qdpr KEGG 1.88 0.006499 
1388098_at Resection-induced TPI  Rs11 KEGG 1.39 0.030107 
1370573_at Sarcosine dehydrogenase Sardh KEGG 1.86 0.006918 
1373625_at Serine 
hydroxymethyltransferase 1 
(soluble) 
Shmt1 GO 2.68 0.000609 
1388695_at Serine 
hydroxymethyltransferase 2 
(mitochondrial) 
Shmt2 KEGG 1.59 0.016279 
1375441_at Seryl-aminoacyl-tRNA 
synthetase 1 
Sars1 KEGG 1.28 0.041713 
1393947_at Solute carrier family 25 
(mitochondrial carrier; 
ornithine transporter) member 
15 
Slc25a1
5 
GO 2.72 0.000541 
1368391_at Solute carrier family 7 
(cationic amino acid 
transporter, y+ system), 
member 1 
Slc7a1 GO 2.83 0.000403 
1370355_at Stearoyl-Coenzyme A 
desaturase 1 
Scd1 GO 2.56 0.000842 
1370420_at Steroid 5 alpha-reductase 1 Srd5a1 KEGG -1.88 0.006582 
1390777_at 
1387926_at 
Sterol-C5-desaturase 
   
Sc5d GO 2.57 
4.13 
0.000832 
0.000033 
1388975_at 
1381671_at 
1383438_at 
Succinate-Coenzyme A 
ligase, ADP-forming, beta 
subunit  
Sucla2 KEGG 1.76 
1.40 
1.32 
0.009563 
0.029126 
0.037555 
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1372123_at Succinate dehydrogenase 
complex, subunit B, iron 
sulfur (Ip)  
Sdhb KEGG 2.70 0.000569 
1388294_at 
1371296_at 
Succinate dehydrogenase 
complex, subunit D, integral 
membrane protein 
Sdhd KEGG 3.33 
3.46 
0.000134 
0.000100 
1371311_at Succinate dehydrogenase 
complex, subunit C, integral 
membrane protein 
Sdhc KEGG 1.87 0.006773 
1372145_at Threonyl-tRNA synthetase Tars KEGG 2.27 0.001999 
1375753_at 
1373760_at 
Threonyl-tRNA synthetase 2 
  
Tars2 KEGG 3.11 
2.46 
0.000208 
0.001115 
1387357_at Trimethyllysine hydroxylase, 
epsilon 
Tmlhe GO 3.48 0.000098 
1367603_at Triosephosphate isomerase 1 Tpi1 KEGG 1.54 0.018714 
1371182_at Thyroid peroxidase Tpo KEGG -1.50 0.021233 
1369790_at Tyrosine aminotransferase Tat GO 5.14 0.000012 
1368463_at  Vascular endothelial growth 
factor C 
Vegfc GO 2.63 0.000688 
 
Table 5.6 Significantly Perturbed Transcripts of Carboxylic Acid Metabolism. 
The table shows a list of differentially expressed genes involved in Carboxylic Acid 
Metabolism (p < 0.05) from cells expressing A6ND91-FLAG. Affymetrix probe-set ID 
is shown in column Probe ID. Program ID, represents either GO, KEGG-PATHWAY 
analysis or literature identified transcripts (Section 5.2.4); Fold-change and p values 
(p < 0.05) are shown.  
# 
Program ID = MAN, shows transcripts searched for manually (i.e. not recognised by either GO or 
KEGG-PATHWAY analysis). 
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5.2.4.1 Amino Acid Metabolism 
In total, GO and KEGG PATHWAY analysis identified 76 genes involved in 
amino acid metabolism. The perturbed transcripts clustered predominantly on the 
metabolism of: Alanine and Aspartate (Section 5.2.5.2); Glutamate (Section 5.2.5.3); 
Arginine and Proline (Section 5.5.5.4); Valine, Leucine and Isoleucine (Section 
5.5.5.5); plus Glycine, Serine and Threonine (Section 5.5.5.6). 
This section also represents significantly enriched GO BP categories; Amino 
Acid and Derivative Metabolism, Urea Cycle (Section 5.5.5.4), Glycine Metabolism 
(Section 5.5.5.6). 
 
5.2.4.2 Alanine and Aspartate 
Figure 5.1 and Table 5.6 show transcripts perturbed in cells over-expressing 
A6ND91-FLAG in relation to Alanine and Aspartate metabolism. Probe-set values 
representing Aars1 and 2, which respectively encode cytosolic and mitochondrial L-
Alanine-tRNA synthetases, were increased. Dars and Nars representing, cytosolic L-
Aspartyl-tRNA synthetase and L-Asparaginyl tRNA synthetase, respectively, were 
also increased. By contrast, probes representing mitochondrial L-Aspartyl-tRNA 
returned decreased probe values.      
Probe values were increased for peroxisomal/mitochondrial L-Alanine: 
glyoxylate aminotransferase (Agtx), which utilises the amino group of L-Alanine to 
detoxify glyoxylate to glycine. In comparison, probe values for Agxt2 (mitochondrial) 
were unaltered. The -amino-group of L-Alanine can also be transferred by 
Glutamic-pyruvate transaminase (Gpt) to 2-oxoglutarate, generating higher specific 
activity than Gpt2 (Liu et al 2008, Yang et al 2009), returned decreased expression 
values. Gpt2 expression values were unaltered.   
The amino-group of L-Aspartate can be donated to 2-oxoglutarate, yielding 
oxaloacetate (OAA) plus L-Glutamate in a reaction catalysed by Glutamate 
oxaloacetate transaminase (Got). Expression values for the probes representing 
mitochondrial (Got2) and cytosolic Got (Got1) were increased and unaltered, 
respectively.  
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Figure 5.1 Schematic Representation of Alanine and Aspartate Metabolism. 
Figure is adapted from KEGG Alanine and Aspartate metabolism pathway. L-
Aspartate is a non-essential amino acid, being produced from L-Asparagine in a 
reaction hydrolysed by Asparaginase (Asrgl1). L-Aspartate is converted into 
fumarate, by Argininosuccinate synthetase (Ass) plus Argininosuccinate lyase (Asl). 
Cont’d page 158. 
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Cont’d. Figure 5.1 Schematic Representation of L-Alanine and L-Aspartate 
Metabolism. Additionally, L-Aspartate may be catabolised to oxaloacetate (OAA) 
plus L-Glutamate by Glutamate oxaloacetate transaminase (Got), with reverse 
reaction forming L-Aspartate plus 2-oxo-glutarate. L-Alanine can also be 
transaminated by Glutamic pyruvic transaminase (Gpt), forming pyruvate plus L-
Glutamate. Several substrates (e.g. OAA, fumarate and 2-oxoglutarate) overlap with 
the TCA cycle.  In mammals, L-Alanine is additionally used to detoxify glyoxylate to 
glycine utilizing pyruvate in a reaction catalysed by Alanine-glyoxylate 
aminotransferase (Agxt). Specific Aminoacyl-tRNA synthetases in the cytosol and 
mitochondria catalyze the esterification of L-Aspartate (Aspartyl-tRNA synthetase, 
(Dars)), L-Asparagine (Asparaginyl-tRNA synthetase, (Nars)) and L-Alanine (Alanyl-
tRNA synthetase (Aars)). Representation of data described in Figure 5.0. See 
Section 5.2.4.2 and Table 5.6 for gene names, expression fold-changes and p 
values.  
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Probe-sets representing Asparagine synthetase (Asns) and Argininosuccinate 
synthetase (Ass) also returned unaltered expression values. In these enzymatic 
reactions, L-Asparagine is formed from L-Aspartate using the amino group of L-
Glutamine; and L-Aspartate is joined to citrulline to form argininosuccinate in a 
reaction utilizing ATP.   
Increased expression values were observed for probe-sets representing 
cytosolic Argininosuccinate lyase (Asl), which retains the nitrogen of 
argininosuccinate in the reaction product L-Arginine, and releases the L-Aspartate 
skeleton as fumarate. Upon addition of water, fumarate is converted to L-Malate, a 
substrate that can be readily oxidized to OAA. Collectively, KEGG annotation of L-
Alanine and L-Aspartate metabolism suggests that A6ND91-FLAG expression may 
effect the expression of genes involved in OAA, L-Glutamate, glyoxylate and/or 
pyruvate metabolism.   
 
5.2.4.3. Glutamate Metabolism  
Figure 5.2 shows an adapted, KEGG-annotated pathway of L-Glutamate 
metabolism. Probe values for Eprs representing cytosolic L-Glutamyl-tRNA 
synthetase were increased, while probe values for Qars encoding cytosolic L-
Glutaminyl-tRNA were unaltered. No expression values were obtained for probes 
representing the corresponding mitochondrial t-RNA synthetases.  
Figure 5.2 provides further evidence that A6ND91-FLAG expression perturbs 
expression of genes regulating L-Glutamate metabolism, plus amino acid sugar 
metabolism.  Specifically, increased expression values were returned for probes 
representing Glutamine synthetase (i.e. Glul) plus Glutamate dehydrogenase 
(Glud1), which functions in both L-Glutamate catabolism and biosynthesis.    
Data in Figure 5.2 also suggests that A6ND91 expression has downstream 
consequences on gene-products regulating the metabolism of glutathione, L-
Glutamine, carbamyl phosphate and GMP synthesis. Thus, increased probe values 
were returned for Glutathione synthetase (Gss), which condenses -L-glutamyl-L-
cysteine with glycine to form reduced glutathione (i.e. GSH).  
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Figure 5.2 Schematic Representation of Glutamate Metabolism. Figure is 
adapted from KEGG Glutamate metabolism pathway. L-Glutamate is synthesized by 
reductive amination of 2-oxo-glutarate involving Glutamate dehydrogenase (Glud). L-
Glutamate is also synthesised by Glutamic pyruvic transaminase (Gpt) or Glutamate 
oxaloacetate transaminase (Got) with amino-nitrogen donation from L-Alanine and L-
Aspartate, respectively. L-Glutamate may undergo decarboxylation to 4-amino-
butanoate (GABA) by Glutamate decarboxylase (Gad) involving GABA plus 2-
oxoglutarate being catabolised to succinate-semialdehyde plus L-Glutamate. 
Succinate is produced through 4-aminobutyrate aminotransferase (Abat) and 
Succinate-semialdehyde dehydrogenase (Aldh5a1), respectively. Cont’d Page 161. 
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Cont’d. Figure 5.2 Schematic Representation of Glutamate Metabolism. L-
Glutamate is also used to synthesise the antioxidant glutathione. The majority of L-
Glutamate is catabolised to L-Glutamine by Glutamine synthatase (Glul) through 
incorporation of NH3
+.  Glutaminase (Gls) converts L-Glutamine to L-Glutamate and 
NH3
+, with NH3
+ being eliminated through the Urea Cycle, via the mitochondrial 
matrix enzyme Carbamyl phosphate synthetase-1 (Cps1). L-Glutamate produced 
from L-Glutamine is converted to 2-oxo-glutarate, making L-Glutamine a glucogenic 
amino acid. Liver contains both Glutamine synthetase (Glu1) and Glutaminase (Gls) 
but the enzymes are localized in different cellular compartments. This ensures that 
the liver is neither a net producer nor consumer of L-Glutamine allowing the use of 
NH3
+ that is not incorporated into the Urea Cycle. L-Glutamine is used to synthesise 
GMP and 5-phosphoribosylamine substrates important for purine synthesis. L-
Glutamine is used to produce NAD+ and is a key metabolite in amino-sugar 
metabolism. Representation of data described in Figure 5.0. See Section 5.2.4.3 and 
Table 5.6 for gene names, expression fold-changes and p values.  
 
 
 
 
 
 
 
 
 
 
 
 
 
163 
 
Likewise, expression values of probe representing NADPH-dependent glutathione 
reductase (Gsr), required for converting oxidized glutathione back to GSH, were 
increased. Regarding L-Glutamine, expression values for Gls1 which encodes a 
mammalian Glutaminase with high-affinity for L-Glutamine (Curthoys et al 1995), 
were increased. By contrast, probes representing Glutaminase 2 (i.e. Gls2), which 
requires high L-Glutamine concentrations to display optimal activity (Curthoys et al 
1995), were decreased. 
Finally, probes representing GMP synthetase (Gmps), which utilises amide 
nitrogen of L-Glutamine in the synthesis of GMP from XMP, were increased in cells 
expressing levels of A6ND91-FLAG. However, probes representing NAD synthetase 
1 (NADsyn1) and Phosphoribosyl-pyrophosphate amidotransferase (Ppat), which 
also utilise the amide nitrogen of L-Glutamine in the synthesis of NAD and IMP, were 
unaltered.   
 
5.2.4.4 Arginine and Proline Metabolism 
Figure 5.3 shows that L-Arginine and L-Proline metabolism overlaps with L-
Alanine and L-Aspartate metabolism, plus L-Glutamate metabolism. Connection‟s 
between L-Arginine metabolism and creatine-phosphate synthesis are also shown. 
Figure 5.3 shows that metabolism of citrulline is complex.  For example, it can be 
produced from L-Arginine via nitric oxide synthetase (Nos) and from asymmetric 
NGNG-dimethyl-L-arginine via Dimethylarginine dimethylaminohydrolase (Ddah).  
Probe values representing three Nitric oxide synthetases (i.e. Nos1-3) were 
unaltered by A6ND91-FLAG expression.  However, decreased expression values 
were returned for Ddah1, which converts the major endogenous nitric-oxide inhibitor, 
asymmetric NGNG-dimethyl-L-arginine (MacAllister et al 1996) to citrulline.  The 
transport of citrulline and/or ornithine from the cytosol into the mitochondria matrix is 
orchestrated by Ornithine/citrulline carrier (Slc25a15) (Morizono et al 2005, Tonazzi 
et al 2005). Probe-sets representing this gene displayed increased expression 
values. Expression values were unaltered for probes representing Ornithine 
transcarbamylase (Otc), which in the mitochondria matrix transfers a carbamyl 
moiety of carbamyl phosphate to ornithine, generating citrulline.  
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Figure 5.3 Schematic Representation of Arginine and Proline Metabolism. 
Figure is adapted from KEGG Arginine and Proline metabolism pathway. Cont’d 
Page 164. 
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Cont’d. Figure 5.3 Schematic Representation of Arginine and Proline 
Metabolism. Catabolism of L-Arginine is shown in context of the urea cycle. L-
Arginine is hydrolyzed to urea and L-Ornithine by Arginase (Arg) or via the creatine 
pathway. Ornithine transcarbamoylase (Otc) condenses L-Ornithine with carbamyl 
phosphate, producing citrulline. Carbamyl phosphate is synthesised from NH3
+, 
carbon-dioxide (CO2) and ATP by mitochondrial Carbamyl phosphate synthetase 
(Cps1). Cps1 is positively regulated by the allosteric effector N-acetyl-glutamate 
(NAG) (denoted by + sign). L-Citrulline is condensed to L-Aspartate by cytosolic 
Argininosuccinate synthetase (Asl), forming argininosuccinate. L-Arginine and 
fumarate are produced from argininosuccinate by cytosolic enzyme 
Argininosuccinate lyase (Asl). L-Arginine is converted to L-Ornithine by Arg, 
completing the cycle. L-Ornithine undergoes irreversible transamination by Ornithine 
aminotransferase (Oat) forming L-Glutamate-5-semialdehyde, which serves as a 
precursor for synthesis of the non-essential amino acid L-Proline involving Pyrroline-
5-carboxylate reductase (Pycr). Proline dehydrogenase (Prodh) dehydrogenates L-
Proline to L-1-Pyrroline-5-carboxylate, the first step in L-Proline breakdown. L-
Proline also undergoes oxidation by Prolyl-4-hydroxylase becoming trans-4-
hydroxyproline. L-Arginine and L-Proline undergo esterification by their respective 
aminoacyl-tRNA synthetases, Arginyl-tRNA (Rars) synthetase and Prolyl-tRNA 
synthetase (Eprs) forming aminoacyl-tRNAs. Additionally, N-terminal L-Proline can 
be released from peptides by prolyl aminopeptidase (Lap3). Representation of data 
described in Fig 5.0. See Section 5.2.4.4 and Table 5.6 for gene names, expression 
fold-changes and p values.  
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Probe values representing Glud1, which supplies ammonia for carbamyl phosphate 
synthesis, were increased. Expression values were also increased for N-acetyl 
glutamate synthase (Nags), which synthesises an allosteric activator of Carbamyl 
phosphate synthetase I (N-acetylglutamate) (Caldovic et al 2002, Caldovic et al 
2006), from L-Glutamate plus acetyl-CoA.  Thus, these data indicate that expression 
of a significant number of gene-products contributing to the regulation of three 
interconnecting metabolic pathways (i.e. L-Alanine and L-Aspartate; L-Glutamate; 
plus L-Arginine and L-Proline metabolism) are perturbed by A6ND91-FLAG 
expression.  In addition, A6ND91-FLAG may affect expression and/or activities of 
three major genes (i.e. Nos, Ddah1 and Cps1) regulating the flux of citrulline into the 
urea cycle for L-Arginine synthesis.  
Expression values of probes representing L-Arginine: glycine 
amidinotransferase (Gatm), which catalyses the transfer of guanido group from L-
Arginine to glycine, generating ornithine plus guanidinoacetate, were increased 
(Figure 5.3). Increased expression values were also returned for probes representing 
Guanidinoacetate methyltransferase (Gamt), which catalyses the ATP-dependent 
transfer of a methyl-group from S-adenosylmethionine (SAM) to guanidinoacetate, 
yielding creatine plus S-adenosylhomocysteine. Likewise, probes values for Creatine 
kinase (Ckm), which catalyses the reversible transfer of -phosphate group of ATP to 
the guanidine group of creatine, were increased.   
Increased expression values were also returned for probes representing 
Ornithine aminotransferase (Oat), which irreversibly catalyses L-Ornithine plus 2-
oxoglutarate to L-Glutamate--semialdehyde and L-Glutamate (Markova et al 2005). 
Conversely, probes values for delta1-pyrroline-5-caboxylate synthase (Pycs), an 
ATP- and NAD(P)H-dependent mitochondrial enzyme that couples phosphorylation 
and reductive-conversion of L-Glutamate to delta1-pyrroline-5-caboxylate, were 
decreased.     
Increased and unaltered expression values were returned for probes 
representing Pyrroline-5-reductase 1 and 2 (Pycr1 and 2), which physiologically 
irreversibly catalyse the reduction of delta1-pyrroline-5-carboxylate and delta1-
pyrroline-3-hydroxy-5-carboxylate to L-Proline and trans-4-hydroxyproline, 
respectively (Meng et al 2006, Cooper et al 2008). Decreased expression values 
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were observed for Proline dehydrogenase (Prodh), which irreversibly oxidises L-
Proline to delta1-pyrroline-5-carboxylate (Tanner et al 2008), for ultimate conversion 
to L-Glutamate. Probes representing Propyl-aminopeptidase (Lap3), which releases 
N-terminal prolines from peptides, displayed increased expression values.   
Expression values were also increased for probes representing Prolyl-4-
hydroxylase (P4ha2), which both hydroxylates peptide-bound proline and 
decarboxylates 2-oxoglutarate to yield trans-4-hydroxy-L-proline and succinate.  
However, expression values for Prodh2, which catalyses the conversion of trans-4-
hydroxyproline to delta1-pyrroline-3-hydroxy-5-carboxylate, were unaltered. No data 
was extracted for the transcript encoding the final enzyme of the pathway that 
putatively generates glyoxylate and pyruvate because the gene-product(s) has yet to 
be defined.   
Collectively, these results suggest that expression of genes operating within 
Arginine and Proline metabolism plus the Urea Cycle are altered in cells expressing 
A6ND91-FLAG. These pathways maybe responding to increased in acidosis by 
altering the flux of NH4 through the urea cycle.  
 
5.2.4.5 Valine, Leucine and Isoleucine Metabolism 
Catabolism of essential amino acids L-Valine, L-Leucine and L-Isoleucine 
commences with the vitamin B6-dependent Branched-chain aminotransferases 
(Bcat), which catalyses the transfer of the -amino group of L-Valine, L-Leucine and 
L-Isoleucine to 2-oxoglutarate to form three branched-chain -keto acids plus L-
Glutamate (Figure 5.4). Probe-sets representing Bcat1 and Bcat2 both displayed 
increased expression values.  
Oxidative decarboxylation of branch chained amino acids (BCAA) to Acyl-
CoAs is catalysed by Branched-chain -keto acid dehydrogenase complex (Bckdh) 
(Shimomura et al 2004). Expression values of probe-sets representing the E1 
subunit of Bckdh (i.e. Bckdha) were reduced. Probe values for Bckdh kinase 
(Bckdk), required for inactivating the complex through phosphorylation of E1b 
(encoded by Bckdhb) (Popov et al 1997) were increased.  
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Figure 5.4 Schematic Representation of Branched-Chain Amino Acids (BCAA) 
BCAAs, L-Leucine, L-Isoleucine and L-Valine are esterified by Leucyl-tRNA 
synthetase (Lars), Isoleucyl-tRNA (Iars) synthetase and Valyl-tRNA synthetase 
(Vars) to their cognate tRNAs forming their respective aminoacyl-tRNAs. Cont’d 
page 168. 
 
 
169 
 
Cont’d. Figure 5.4 Schematic Representation of Branched-Chain Amino Acids 
(BCAA). L-Leucine, L-Isoleucine and L-Valine are initially catabolised to their 
respective branch chain -keto acids involving Branched chain aminotransferase 
(Bcat) using 2-oxoglutarate as an amine acceptor. Subsequent conversion to their 
respective -CoA derivatives is performed by branched chain alpha-ketoacid 
dehydrogenase (Bckdh). This enzyme and Bcat share the E3 subunit encoded by 
Dihydrolipoamide dehydrogenase (Dld). Many of the subsequent divergent reactions 
have been defined through mutation analyses of rare genetic disorders of L-
Isoleucine, L-Leucine and L-Valine metabolism (Section 5.2.4.5). L-Isoleucine 
catabolism terminates with the production of acetyl-CoA and propionyl-CoA; thus L-
Isoleucine is both glucogenic and ketogenic. L-Leucine generates acetyl-CoA and 
acetoacetyl-CoA, and is thus classified as strictly ketogenic. The principal product 
from L-Valine is propionyl-CoA, the glucogenic precursor of the TCA cycle substrate, 
succinyl-CoA. In liver mitochondria, excess acetyl-CoA is converted to acetoacetate 
and -hydroxybutyrate, collectively called ketone bodies. Representation of data 
described in Figure 5.0. See Section 5.2.4.5 and Table 5.6 for gene names, 
expression fold-changes and p values. 
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Probe values for Dbt and DlD, encoding the E2 and E3 subunits of Bckdh were 
unchanged.  Collectively, these data suggest that A6ND91-FLAG expression 
induces gene expression within BCAA metabolism to their respective -hydroxyacyl-
CoA thioesters however this observation is unsupported by scientific literature.  
Expression values were also increased for probes representing the second L-
Isoleucine-specific gene-product (i.e. 3-hydroxyacyl-CoA dehydrogenase type II, 
Hadh2) plus mitochondrial Acetoacetyl-CoA thiolase (Acaa2) required for completing 
-oxidation of (S) 2-methy-but-2-enol CoA to acetyl CoA plus the release of the 
glucogenic part of this fatty acid (i.e. Propanoyl-CoA). Likewise, increased probe 
values were returned for mitochondrial Acetyl-CoA acetyltransferase (Acat2) and 
HMG-CoA synthase (Hmgcs2), which may affect the rate-limiting, irreversible 
(Harper et al 1984) step of branched-chain amino acid catabolism.  
Catabolism of L-Isoleucine-derived (S)-2-methylbutanoyl-CoA to Propionyl-
CoA plus acetyl-CoA is initiated by short/branch chain Acyl-CoA dehydrogenase 
(Acadsb). Probes representing this L-Isoleucine-specific pathway gene-product were 
unaltered.  Expression values were increased for probes representing Trans 2-enoyl-
CoA hydratase (Echs1), which is proposed by KEGG, to catabolise a variety of 
substrates including 3-methyl-crotonyl-CoA (L-Leucine catabolism) and 2-methyl- By 
contrast, probes representing cytosolic Acetoacetyl-CoA synthetase (Aacs), 
essential for initiating fatty acid and cholesterol biosynthesis from ketone bodies 
(Bergstrom et al 1984), were unaltered.   
Figure 5.4 shows that probes representing biotin-containing and Propanoyl-
CoA binding subunits of Propanoyl-CoA carboxylase (i.e. Pcca and Pccb) returned 
increased and decreased values, respectively. No alteration in expression values 
was observed for Methylmalonyl-CoA 2-eperimase (Mcee), which catalyses the 
reversible isomerization of S-methylmalonyl-CoA (i.e. product of Propanoyl-CoA 
carboxylase reaction) to R-methylmalonyl-CoA. By contrast, increased probe values 
were returned for Methylmalonyl-CoA mutase (Mut), which catalyses the reversible 
isomerization of R-methylmalonyl-CoA to Succinyl-CoA.   
Catabolism of L-Leucine-derived isovaleryl-CoA to Hmg-CoA involves three 
pathway-specific enzymes: Isovaleryl-CoA dehydrogenase (Ivd), biotin-dependent 3-
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methylcrotonyl-CoA carboxylase (Mccc) plus Auh gene-product, 3-Methylglutaconyl-
CoA hydratase.  Probes representing Ivd and 3-methylcrotonyl-CoA binding subunit 
of Mccc (i.e. Mccc2) returned unaltered expression values. Increased expression 
values were obtained for probes representing the biotin-containing subunit of Mccc 
(Mccc1) (Dantas et al 2005) and Auh gene-product, which reversibly hydrates 3-
methylglutaryl-CoA to Hmg-CoA (Ly et al 2003). Finally, unaltered probe values were 
obtained for Hmg-CoA lyase (Hmgcls).   
Increased expression values were obtained for probes representing 
Isobutyryl-CoA dehydrogenase (i.e. Acad8), which catalyses the first L-Valine-
specific catabolic reaction (Nguyen et al 2002). Probe values were also increased for 
bifunctional enzyme 3-Hydroxyisobutyryl hydrolyase (Hibch), which catabolises 3-
hydroxyisobutyryl plus 3-hydroxypropanoyl-CoA, an intermediate formed on a minor 
pathway of proponate metabolism (Loupatty et al 2007). However, decreased probe 
values were returned for 3-hydroxyisobutyrate dehydrogenase (Hibadh), which 
oxidizes S-3-hydroxyisobutyrate to S-methylmalonate semialdehyde (Lokanath et al 
2005). By contrast, increased values were obtained for probes representing -CoA-
dependent Methylmalonate semialdehyde dehydrogenase (Aldh6a1), which 
catalyses the NAD-dependent oxidation of S-methylmalonate semialdehyde and 
malonate semialdehyde respectively to Propanoyl-CoA and acetyl-CoA (Chambliss 
et al 2000) (Figure 5.4).  
 
5.2.4.6 Glycine, Serine and Threonine Metabolism 
Table 5.6 and Figure 5.5 summarise expression data for probes representing 
gene-products contributing to Glycine, Serine and Threonine Metabolism. Data that 
form part of Alanine and Aspartate metabolism (Agxt) as well as Arginine and Proline 
(Gatm) metabolism are included.  
Increased probe values were returned for both cytosolic and mitochondrial 
forms of serine hydroxymethyltransferase (Shmt1 and 2), which reversibly catalyze 
transfer of the hydroxymethyl group of L-Serine to tetrahydrofolate (THF) to generate 
Glycine plus 5,10-methyleneTHF.  
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Figure 5.5 Schematic Representation of Glycine, L-Serine and L-Threonine 
metabolism. De novo biosynthesis of non-essential amino acid L-Serine mainly 
derives from the glycolytic intermediate 3-D-phosphoglycerate. L-Serine can also be 
derived from glycine (and visa versa) by Serine hydroxymethyltransferase (Shmt). 
Cont’d page 172. 
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Cont’d. Figure 5.5 Schematic Representation of Glycine, L-Serine and L-
Threonine metabolism. Both L-Serine and glycine is generated through the 
detoxification of glyoxylate by Alanine-glyoxylate aminotransferase (Agxt). Serine 
dehydratase (Sds) deaminates L-Serine to pyruvate. Glycine synthesis occurs in 
several ways; L-Serine derived from 3-phosphoglycerate by Shmt, Glycine cleavage 
enzyme (Gcsh) reversibly converts 5, 10-Methylene-THF, contributing to “one carbon 
pool by folate” through the substrate -THF. Additional routes include choline via a 
series of enzymes (e.g. Choline kinase a (Chka) and Sarcosine dehydrogenase 
(Sardh)). Glycine is degraded via several pathways, the predominant pathway 
involves Gcsh. The second pathway, involves glycine degradation to L-Serine by 
Serine hydroxymethyl transferase (Shmt), with L-Serine then being converted to 
pyruvate by Sds. In the third pathway of glycine degradation, glycine is converted to 
glyoxylate by Agxt. Finally glycine may be utilised in the synthesis of creatine. L-
Threonine is an essential amino acid obtained through the diet. It is metabolised by 
L-Threonine dehydrogenase (Thd) to L-2-amino-acetoacetate, a precursor to 
pyruvate via methylgloxal. Glycine, L-Serine and L-Threonine undergo esterification 
by their respective aminoacyl-tRNA synthetases, Glycyl-tRNA synthetase, Seryl-
tRNA synthetase and Threonyl-tRNA synthetase to their compatible cognate tRNAs 
forming aminoacyl-tRNAs. Representation of data described in Fig 5.0. See Section 
5.2.4.6 and Table 5.6 for gene names, expression fold-changes and p values.  
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Similarly, increased expression values were obtained for probes representing 
the Aminomethyltransferase (Amt) and hydrogen carrier protein (Gcsh) subunits of 
mitochondrial Glycine-cleavage system complex, which reversibly catalyses the 
oxidation of Glycine, yielding carbon dioxide, ammonia, 5,10-methyleneTHF plus a 
reduced pyridine nucleotide. Probe values for Glycine decarboxylase (Gldc) and 
Dihydrolipoamide dehydrogenase (Dld) subunits of the cleavage system were 
unaltered.   
Increased probe values were returned for Sarcosine dehydrogenase (Sardh), 
which generates Glycine from sarcosine via donation of one-carbon unit to THF. 
However, unaltered expression values were obtained for probes representing 
Dimethylglycine dehydrogenase (Dmgdh), which also donates a 1-carbon unit from 
it‟s substrate to THF, generating sarcosine plus 5, 10-methyleneTHF. This branch of 
the Glycine biosynthetic pathway returned increased expression values for 
mitochondrial Phosphatidylethanolamine-N-methyltransferase (Pemt), which 
catalyses all three S-adenoylmethionine (SAM)-dependent methylation events 
required for conversion of phosphatidyl-N-methylethanolamine to lecithin. Likewise, 
the probes for choline kinase- (Chka) displayed increased values.  
As shown in Figure 5.5, Glycine can also be formed from detoxification of 
glyoxylate, an intermediary on the metabolic pathway that converts two acetyl-CoA 
units into C4-units (succinate). Probes representing peroxisomal/mitochondrial Agxt 
returned increased values.  Glycine can be generated through degradation of 
essential amino acid L-Threonine (Edgar et al 2002). On this pathway, decreased 
probe values were returned for L-Threonine 3-dehydrogenase (Tdh), which 
catabolises L-Threonine to 2-amino-3-ketobutyrate. By contrast, expression values 
were unaltered for probes representing 2-Amino-3-ketobutyrate CoA ligase (Gcat), 
which catalyses the subsequent reaction: production of acetyl-CoA plus Glycine from 
2-amino-3-ketobutyrate and -CoA. As indicated in Figure 5.5, 2-amino-3-ketobutyrate 
has an additional metabolic fate: spontaneous decarboxylation to aminoacetone, 
which at physiological pH can undergo fast enolization, followed by aerobic oxidation 
to yield methylglyoxal (Dutra et al 2004). No information could be derived for 
Threonine aldolase, which makes a minor contribution to the cellular Glycine pool 
(House et al 2001), as this activity (EC 5.1.2.5) has yet to be assigned to a specific 
mammalian gene-product.   
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Figure 5.5 shows Agxt can reversibly generate L-Serine (plus 
hydroxypyruvate) by transferring the amino-group of L-Alanine to pyruvate. Probes 
representing Hydroxypyruvate reductase/Glyoxylate reductase (Grhpr), which 
respectively catalyse the reduction of hydroxypyruvate and glyoxylate to D-Glycerate 
and glycolate, displayed decreased expression values.  Figure 5.5 also shows that 
de novo L-Serine biosynthesis can be initiated by the glycolytic intermediate 3-D-
phosphoglycerate. Phosphoglycerate dehydrogenase (Phgdh) converts 3-D-
phosphoglycerate to 3-phosphohydroxypyruvate; Phosphohydroxypyruvate 
aminotransferase (Psat) transaminates phosphohydroxypyruvate to phosphoserine 
utilizing 2-oxoglutarate and generating L-Glutamate; while Phosphoserine 
phosphatase (Psph) dephosphorylates phosphoserine.  Probe-sets representing all 
three enzymes returned increased expression values. In comparison, expression 
values were unaltered for probes representing L-Serine/Threonine dehydratase 
(Sds), which catabolises L-Serine to pyruvate, albeit to a lesser extent than Agxt1/2 
(Xue et al 1999 (A), Xue et al 1999 (B)).  
Figure 5.5 shows that expression values were unaltered for probes 
representing SAM-allosterically activated enzyme Cystathionine -synthase (Cbs), 
which condenses L-Serine with homocysteine to form L-Cystathionine plus water. 
However, expression values were increased for probes representing Cystathionine -
lyase (Cth), which cleaves L-Cystathionine to yield L-Cysteine plus -ketobutyrate 
and NH3 as by-products.   
Increased expression values were returned for probes representing 
mitochondrial and cytosolic t-RNA synthases for L-Serine (Sars1 and 2) and L-
Cysteine (Cars1 and Cars2). Additionally, probe values for both cytosolic and 
mitochondrial L-Threonyl-tRNA synthetase (Tars1 and Tars2, respectively) were 
increased.  By contrast, probe values for Gars (i.e. cytosolic/mitochondrial L-Glycyl-
tRNA synthetase) were unaltered.  
 
5.2.4.7 One Carbon Metabolism by Folate  
Figure 5.6 and Table 5.6 provide further evidence that A6ND91-FLAG 
perturbs expression genes active in One-Carbon Metabolism by Folate. As shown, 
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the pathway is connected to metabolism of Glycine, Serine and Threonine (Section 
5.2.5.6) via Shmt and the Glycine Cleavage System complex.  
Increased expression values were returned for probes representing the 
cytosolic, NADP-dependent trifunctional enzyme (Mthfd1), which converts via its 
formyl-THF synthetase activity, THF to 10-formyl-THF. Expression values were also 
increased for the bifunctional enzyme, Aminoimidazole-4-carboxamide 
ribonucleotide transformylase/IMP cyclohydrolase (Atic). This enzyme catalyses the 
transfer of formyl groups from 10-formyl-THF to aminoimidazole-4-carboxamide 
ribonucleotide (AICAR) generating 5-formyl-AICAR and THF, followed by intra-
cyclization of 5-formyl-AICAR to generate IMP (Cheong et al 2004). By contrast, 
probe values for 10-FormylTHF dehydrogenase (Fthfd), which catalyses NADP+ 
dependent conversion of 10-formyTHF to THF plus formate (Anguera et al 2006), 
were unaltered.   
In common with the tri-functional protein Mthfd1, increased expression values 
were also returned for probes encoding the equivalent mitochondrial enzymatic 
activities, specifically 10-Formyl-THF synthetase (Mthfd1l) (Morel et al 2005), plus 
the bifunctional enzyme Methylenyl-THF cyclohydrolase and Methylene-THF 
dehydrogenase (Mthfd2).    
Decreased expression values were returned for probes representing 
Formiminotransferase cyclodeaminase (Ftcd), which catalyses the transfer of carbon 
units from formimino-L-glutamic acid to THF, forming L-Glutamate, ammonia and 
5,10-methenyl-TFH (Mao et al 2004). Likewise, decreased values were observed for 
Thymidylate synthetase (Tyms), which uses 5, 10 methylene-THF generating dTMP 
from dUTP. Conversely, increased probe values were observed for Methenyl-THF 
synthetase (Mthfs), which regenerates 5, 10-methenyl-TFH from 5-formyl-THF 
(Huang et al 1995), and for Dihydrofolate reductase (Dhfr), which maintains 
intracellular pools of THF through catalysing hydrogen transfer from NAD+ to 7, 8-
dihydrofolate (Figure 5.6).  
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Figure 5.6 Schematic Representation of the “One-carbon pool by Folate”. 
Figure is adapted from KEGG “One carbon pool by Folate” pathway. Folate functions 
mainly as chemically reduced tetrahydrofolate (THF), conveying one-carbon units. 
THF metabolism is required for synthesis of purines, thymidylate, and methionine. 
Before folate can carry a one-carbon unit, it must be reduced to dihydrofolate (DHF) 
and tetrahydrofolate (THF) by Dihydrofolate reductase (Dhfr). Cont’d page 177. 
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Cont’d. Figure 5.6 Schematic Representation of the “One-carbon pool by 
Folate”. DHF plus thymidine monophosphate (dTMP), is produced by reductive 
methylation of deoxyuridine monophosphate (dUMP) and 5,10-methylene-THF by 
Thymidylate synthetase (Tyms). 5-Methyltetrahydrofolate-homocysteine 
methyltransferase (Mtr) metabolises 5-methyl-THF plus L-Homocysteine, 
regenerating THF plus L-Methionine, providing methyl groups to S-adenosyl 
methionine cycle.  Next, Methylene tetrahydrofolate reductase (Mthfr) irreversibly 
reduces 5,10-methylene-THF to 5-methyl-THF. The substrate 5,10-methylene-THF 
is catabolised by Aminomethyltransferase (Amt), resulting in THF regeneration. Amt 
hydrolyses 5,10-methenyl to 5-formyl-THF, converting it back to THF through 
Formimidoyltetra-hydrofolate cyclodeaminase (Ftcd). Ftcd deaminates the formimino 
group of 5-formimino-THF regenerating 5,10-methenyl-THF. The Hydroxy-methyl 
group of L-Serine is a major source of one-carbon units through activity of 
cytoplasmic Serine hydroxymethyltransferase (Shmt). Shmt transfers β-carbon of L-
Serine to THF forming 5,10-methenyl-THF plus glycine. Substrate 5,10-methenyl-
THF is reduced to 5,10-methylene-THF, followed by another reduction to 5-methyl-
THF by methylenetetrahydrofolate dehydrogenase (Mthfdl1). Mitochondrial derived 
formate functions as a one-carbon unit for folate metabolism. 
Phosphoribosylglycinamide formyltransferase (Gart) converts 10-formyl-THF plus 
glycinamide ribonucleotide (GAR) forming THF plus N-Formyl-GAR and 5-
aminoimidazole-4-carboxamide ribonucleotide formyltransferase (Atic). 
Representation of data described in Figure 5.0. See Section 5.2.4.7 and Table 5.6 
for gene names, expression fold-changes and p values.  
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5.2.4.8 Bile Acid Metabolism 
The data summarised in Figure 5.7 and Table 5.6 support evidence presented 
in Steroid and Cholesterol Metabolism (Section 5.2.2) that A6ND91-FLAG 
expression perturbs transcript values for genes regulating Bile Acid Biosynthesis. 
The first step in acidic bile acid synthesis, Sterol 27-hydroxylase (Cyp27A1), 
returned increased probe values. Cyp27A1 also catalyses the bile acid intermediates 
such as 3, 7, 12, trihydroxy-5-cholestane produced on the neutral bile-acid 
pathway (Norlin et al 2003, Mast et al 2006). Likewise, probes representing C27 3-
Hydroxysteroid dehydrogenase (Hsd3b7) which performs the third enzymatic 
reaction on the acidic pathway (Schwarz et al 2000) displayed increased expression 
values.    
Increased probe values were returned for ATP-binding cassette transporter 3 
(Abcd3), which may promote the transport of bile-acid precursors and branched-
chain fatty acids into the peroxisome for -oxidation (Hunt et al 2008).  Increased 
expression values were also returned for probes representing 2-methylacyl-CoA 
racemase (Amacr), which both initiates the peroxisomal -oxidation of Cbile acid 
intermediates in preparation for their conjugation to taurine or Glycine (Setchell et al 
2003) plus the detoxification of methyl-branched fatty acids (Poirier et al 2006). 
Additionally, probes representing the peroxisomal multifunctional protein (Hsd17b4), 
which is also active in the -oxidation step of bile acid synthesis (Huyghe et al 2006) 
displayed increased values. However, probes representing broad-range Acyl-CoA 
thioesterase gene-product, Acot2, which in vitro displays high activities towards bile 
acid precursors and Propanoyl-CoA (Hunt et al 2002, Hunt et al 2005), were 
unaltered.  
Finally, increased expression values were returned for probes representing 
Bile acid coenzyme A: amino acid transferase (Baat), which in vivo catalyses the 
attachment of a Glycine or taurine to newly synthesised C24 bile acids plus de-
conjugated bile acids returned to the liver (Styles et al 2007).   
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Figure 5.7 Schematic Representation of Bile Acid Biosynthesis. Figure is 
adapted from KEGG Bile Acid Biosynthesis pathway. The major pathway for bile salt 
synthesis in the liver begins with the conversion of cholesterol to 7a-
hydroxycholesterol. This rate limiting step is catalyzed by the enzyme 7a-
hydroxylase (Cyp7a1). Cont’d page 180. 
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Cont’d. Figure 5.7 Schematic Representation of Bile Acid Biosynthesis. Next, 
7a-hydroxycholesterol enters the Classic “Neutral” bile acid biosynthetic pathway 
through conversion to 7a-hydroxycholest-4-en-3-one. The pathway then branches; 
hydroxylation of 7a-hydroxycholest-4-en-3-one to 7a, 12a-dihydroxycholest-4-en-3-
one, leading ultimately to the formation of cholate; while its reduction to 7a, 12a-
dihydroxy-5b-cholestan-3-one leads to chenodeoxyglycocholate formation. In both 
branches, steps include modifications to ring structure (cytosol), shortening and 
oxidation of the side chain (cytosol, mitochondria), conversion to -CoA derivative 
(peroxisome) and conjugation with the amino acids glycine or taurine (peroxisome). 
In the Alternative “Acidic” pathway, cholesterol is first converted to oxysterols, 
involving Sterol 27-hydroxylase (Cyp27a1). Oxysterols are then hydroxylated by 
Cytochrome P450, family 7, subfamily b, polypeptide 1 (Cyp7b1). The alternative 
pathway produces mainly chenodeoxycholic acid. Representation of data described 
in Fig 5.0. See Section 5.2.4.8 and Table 5.6 for gene names, expression fold-
changes and p values.  
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5.2.4.9 Fatty Acid Metabolism 
Expression values were unaltered for probes representing cytosolic acetyl-
CoA carboxylase (Acaca), required for synthesis of Malonyl-CoA from acetyl-CoA 
(Figure 5.8 and Table 5.6). Expression values were also unaltered for probes 
representing two specific subunits (i.e. Prkaa2, Prkag1) of the AMP-activated protein 
kinase. By contrast, decreased expression values were returned for 2 (Prkab2), 2 
(Prkag2) and 3 (Prkag3) subunits, while increased values were obtained for the 1 
(Prkaa1) and 1 (Prkab1) subunits. Thus, these data provide little insight into the 
regulation of Acaca activity by an AMPK-dependent mechanism (Munday et al 2002) 
in cells expressing A6ND91-FLAG. 
Reduced probe values were returned for Fatty acid synthase (Fasn), which 
catalyses NADPH-dependent generation of Palmitate-CoA from acetyl-CoA and 
Malonyl-CoA.  By contrast, unaltered expression values were returned for probes 
representing three enzymes catalysing elongation of saturated fatty acids in the 
endoplasmic reticulum (Elovl1, Elovl3 and Elovl6) (McMahon et al 2007). Similarly, 
two (Elovl5 and Elovl4) of the three polyunsaturated fatty acid elongases (McMahon 
et al 2007) displayed probes with unaltered expression values. Probes for the third 
elongase (Elovl2) (McMahon et al 2007, Igarashi et al 2008) displayed decreased 
expression values. Collectively, these data indicate that A6ND91-FLAG expression 
may decrease the activity of genes in fatty acid biosynthesis.   
Increased probe values were returned for Stearoyl-CoA desaturase 1 and 2 
(Scd1 and Scd2), which de-saturates both C16:0-CoA and 18:0-CoA (Miyazaki et al 
2006). Similarly, transcript values were increased for Sterol-C5-desaturase (Sc5d), a 
GO-identified gene product linked to fatty acid metabolism however this is 
unsupported by scientific literature. Fatty acid desaturase 1 (Fads1), an enzyme 
active in polyunsaturated fatty acid synthesis (Schaeffer et al 2006), were increased. 
Transcript values were increased for probes representing cytochrome P-450 
arachidonic acid epoxygenase (Cyp2c23), which catalyses NADPH-dependent 
conversion of arachidonic acid to a mixture of epoxy-eicosatrienoic acids (Karara et 
al 1993) plus epoxygenation of 20-hydroxy-eicosatrienoic acid to hydroxyl-
epoxyeicosatrienoic acid (Muller et al 2004).  
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Figure 5.8 Schematic Representation of Fatty Acid Metabolism. Figure is adapted from KEGG Fatty Acid Biosynthesis, 
Metabolism and Elongation pathways. Fatty acid biosynthesis begins with the committed step converting Acetyl-CoA to malonyl-
CoA, by Acetyl-CoA Carboxylase (Acac). Fatty acid elongation is catalyzed by Fatty Acid Synthase (Fasn), involving: 1. 
condensation of acetyl-ACP and malonyl-ACP resulting in acetoacetyl-ACP; 2. Acetoacetyl-ACP reduction by NADPH into D-3-
Hydroxybutyryl-ACP; 3. Dehydration to crotonyl-ACP; 4. Crotonyl-ACP is reduced by NADPH into butyryl-ACP. In the second round 
of elongation, butyryl-ACP condenses with malonyl-ACP to form acyl-ACP. This continues until C16 Long-chain fatty acids (LCFA) 
(e.g. palmitate), which are actively transported into mitochondrial matrix by Carnitine transfer protein (Cpt), where -oxidation 
occurs. Elongation beyond C16 length occurs in the endoplasmic reticulum (ER), with Malonyl-CoA donating 2-carbon units forming 
C18 stearate by Fatty Acid Elongases (Elovl). Desaturation of stearate (18:0) to oleate (18:1 cis D9) also occurs in the ER as does 
the metabolism of polyunsaturated fatty acids Arachidonic acid, Sphingomyelin and ceramide. -Oxidation of very-LCFA (VLCFA) 
to LCFA or medium chain fatty acids (MCFA) occurs within peroxisomes before transfer to the mitochondria. Peroxisomes also 
contain enzymes involved in -oxidation of methyl branched fatty acids (i.e. phytanic and pristanic acid). Mitochondrial -oxidation 
of fatty acids involves four repeat reactions, progressively shortening the fatty acid by two carbons realising acetyl-CoA, NADH and 
FADH2. This is repeated until the fatty acid is entirely converted to Acetyl-CoA or to propionyl-CoA. Representation of data 
described in Figure 5.0. See Section 5.2.4.9 and Table 5.6 for gene names, expression fold-changes and p values.
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Additionally, increased probe values were observed for soluble Epoxide hydrolase 
(Ephx2), which catalyses the degradation of epoxy lipids (e.g. epoxy-eicosatrienoic 
acids) to their less active diols (e.g. dihydroeicosatrienoic acids) (Zhang et al 2007).   
The combined GO and KEGG PATHWAY analysis also revealed that probes 
representing three gene-products active in sphingolipid metabolism returned 
increased expression values (Table 5.6); Dihydroceramide desaturase (Degs1), a 
major desaturase involved in de novo biosynthesis of ceramide from Palmitoyl-CoA 
plus L-Serine (Kraveka et al 2007, Sabourdy  et al 2008); Sphingomyelin 
phosphodiesterase (Smpd1), which hydrolyses sphingomyelin yielding ceramide plus 
choline phosphate (Sabourdy et al 2008); and thirdly, N-Acylsphingosine 
amidohydrolase 1 (Asah1), an acid ceramidase that catalyses the reversible 
synthesis and degradation of ceramide into sphingosine and fatty acids (Park et al 
2006). 
Decreased expression values were returned for Carnitine palymitoyltransferse 
1(Cpt1), which converts long-chain Acyl-CoA to acylcarnitine derivatives for the 
transport of long-chain fatty acids into the mitochondria. Conversely, probes 
representing Acylcarnitine translocase (Slc25a20), required for delivering fatty acids 
moieties to the -oxidation machinery (Huizing et al 1997), displayed increased 
values. Similarly, probes representing gene-products contributing to carnitine 
biosynthesis (i.e. Tmlhe) or -oxidation of acyl-CoAs (e.g. Acadm, Gcdh) displayed 
increased expression values.   
Increased probe values were returned for mitochondrial very-long acyl-CoA 
dehydrogenase (Acadvl), Medium-chain CoA dehydrogenase (Acadm) and Acyl-CoA 
dehydrogenase 9 (Acad9), which displays activity against both saturated and 
unsaturated long-chain Acyl-CoA substrates with optimal activity towards the latter 
(Ensenauer et al 2005). Additionally, probe values were increased for the medium-
chain acyl-CoA synthetase family member 1(Bucs1), which initiates the degradation 
of medium chain fatty acids generated from -oxidation of very long- and long-chain 
fatty acids (Fujino et al 2001). Increased expression values were also returned for 
Glutaryl-CoA dehydrogenase (Gcdh), a key enzyme linking the metabolism of L-
Tryptophan, Lysine and Hydroxylysine catabolic pathways (Sauer et al 2005).  
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Expression values of probes representing long-chain acyl-CoA 
dehydrogenase (Acadl) were not increased. However, expression values of probes 
representing both subunits of mitochondrial Tri-functional protein (i.e. Hadha, Hadhb) 
that catalyses the final three steps of long-chain fatty acid -oxidation (Ibdah et al 
2001), were increased. Similarly, probes for gene-products performing the equivalent 
reactions in the -oxidation of short and short branched-chained fatty acids returned 
increased expression values (Figure 5.8 and Table 5.6).  
Figure 5.8 and Table 5.6 provide further evidence that A6ND91-FLAG alters 
the expression of genes regulating -oxidation of saturated and unsaturated fatty 
acids, plus the -oxidation of phytanic acid to pristanic acid (Jansen et al 1996). 
Specifically, probe values were increased for mitochondrial/peroxisomal delta 
3,5-delta2,4-dienoyl-CoA isomerase (Ech), required for -oxidation of unsaturated fatty 
acids (Zhang et al 2001). Likewise, increased expression values were returned for 
mitochondrial 2,4-Dienyoyl-CoA reductase (Decr1), the second of three auxiliary 
enzymes involved in-oxidation of unsaturated fatty acids (Yu et al 2005). Probes 
representing Phytanoyl-CoA 2-hydroxylase (PhyH) which catalyses the first of three 
enzymatic reactions involved in the oxidation of phytanic acid (i.e. phytanol-CoA) to 
pristanic acid (Schofield et al 2007), also displayed increased expression values. 
Conversely, decreased probe values were returned for peroxisomal Acyl-CoA 
thiesterase (Acot6) specific for phytanoyl-CoA and for Pristanoyl-CoA thioesterase 
that hydrolyse these compounds to phytanic acid, pristanic acid and -CoA (Westin et 
al 2007).   
Several transcripts involved in the transport of medium and long chain fatty 
acids displayed altered expression values. Probe-sets representing Slc27a1 
(Schaffer et al 1994), a plasma membrane localised long-chain fatty acid transporter 
displayed increased expression values. Transport of fatty acids between cellular 
compartments for -oxidation and lipid synthesis is also facilitated by fatty acid 
binding proteins (Fabp) (Sweetser et al 1987). Probe-sets for Fabp1, 3 and 7 also 
showed increased expression values. However, transcripts encoding the Fatty Acid 
translocase Cd36 involved in the uptake of long chain fatty acid (Aitman et al 1999, 
Pravenec et al 2001) displayed decreased expression values.   
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5.2.4.10 Glycolysis and Gluconeogenesis  
The information in Figure 5.9 shows that Glycolysis and Gluconeogenesis 
pathways overlap with Alanine and Aspartate metabolism through the substrate 
OAA: Glycine, Serine and Threonine metabolism via Glycerate-3-phosphate; and 
Glutamate metabolism through D-fructose-6-phosphate.  The Figure also shows that 
several probes representing gene-products mediating the physiologically irreversible 
steps of Glycolysis (depicted by grey arrows) and Gluconeogenesis (yellow arrows) 
showed altered expression values in cells expressing A6ND91-FLAG.  
Decreased probe values were returned for Glucokinase inhibitory protein 
(Gkrp), which in a fasted state (i.e. low glucose concentrations) allosterically inhibits 
Glucokinase (Agius et al 2008). Moreover, probes representing Hexokinase (Hk1) 
which like Glucokinase can phosphorylate glucose to generate -D-glucose-6-
phosphate (Sun et al 2008), displayed increased expression values.  Probe-set 
values were also increased for Pyruvate kinase (Pklr), which catalyses the third 
physiologically irreversible step of Glycolysis; namely the generation of pyruvate and 
two molecules of ATP per molecule of glucose oxidised. However, unaltered and 
decreased probe values were returned respectively for the „liver and muscle-specific‟ 
Phosphofructokinase isoenzyme (Pfkl and Pfkm), which catalyse the second, 
functionally irreversible step of Glycolysis. 
Increased expression values were returned for probes representing 
gluconeogenic-specific enzymes: Glucose 6-phosphatase (G6pc) plus cytosolic and 
mitochondrial Phosphoenolpyruvate carboxykinase (Pck1 and 2), which convert OAA 
to phosphophenolpyruvate. By contrast, probe expression values were unaltered for 
Pyruvate carboxylase (Pcx), a tetrameric-enzyme allosterically regulated by acetyl-
CoA and L-Aspartate (Jitrapakdee et al 2008). Unaltered probe values were also 
returned for Fructose-1-6-biphosphatase, which is allosterically inhibited by AMP and 
-D-fructose 1, 6-biphosphate (Liu et al 1989). Figure 5.9 also shows connections 
between the metabolism of -D-fructose-1,6 biphosphate, glyceraldehydes-3-
phosphate and glycerol. Decreased and increased probe values were returned for 
Dihydroxyacetone kinase (Dak) and Triose phosphate isomerse (Tpi1), respectively.   
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Figure 5.9 Schematic Representation of Glycolysis and Gluconeogenesis. 
Figure is adapted from the KEGG Glycolysis pathway. Blue arrows indicate flow of 
substrates through pathway (specifically, grey arrows = glycolysis; yellow arrows = 
gluconeogensis). Cont’d page 188. 
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Cont’d. Figure 5.9 Schematic Representation of Glycolysis and 
Gluconeogenesis. Glycolysis and gluconeogenesis convert either glucose into 
pyruvate or pyruvate/oxaloacetate (OAA) into glucose, respectively. In glycolysis, 
glucose is oxidized, producing two molecules of pyruvate and 2 ATP molecules. In 
eukaryotic cells the entire pathway is cytosolic, with key regulatory enzymes 
Hexokinase (Hk) / Glucokinase (Gck), Phosphofructokinase (Pfk) and Pyruvate 
kinase (Pk). Most steps in gluconeogenesis are the reverse found in glycolysis. 
Three regulated reactions are replaced with Glucose-6-phosphatase (G6pc), 
Fructose-1,6-bisphosphatase (Fbp), and PEP carboxykinase (Pck). This system of 
reciprocal control allows glycolysis and gluconeogenesis to inhibit each other 
preventing futile cycling. Gluconeogenesis begins in the mitochondria forming OAA 
by carboxylation of pyruvate by Pyruvate carboxylase (Pcx). Pcx activity is 
stimulated by high levels of acetyl-CoA and inhibited by high levels of ADP. OAA is 
converted to L-Malate using NADH for transport out of mitochondria into cytosol. 
Cytosolic, L-malate is oxidized to OAA using NAD+, where the remaining steps of 
gluconeogenesis occur. The final step of gluconeogenesis, formation of glucose, is 
carried out in endoplasmic reticulum (ER), where glucose-6-phosphate is hydrolyzed 
by glucose-6-phosphatase (G6pc). Glucose is shuttled into the cytosol by glucose 
transporters located in ER. In glycolysis, phosphoenolpyruvate (PEP) is converted to 
pyruvate by Pyruvate kinase (Pk). This reaction is strongly exergonic and 
irreversible; in gluconeogenesis, Pcx and Pck catalyze pyruvate to 
phosphoenolpyruvate. Representation of data described in Fig 5.0. See Section 
5.2.4.10 and Table 5.6 for gene names, expression fold-changes and p values.  
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These data suggest that regulation of genes active in biosynthesis of 
dihydroxyacetone phosphate which spontaneously degrades to methylglyoxal, are 
perturbed by A6ND91-FLAG expression.  
A6ND91-FLAG expression was also associated with altered expression of 
genes regulating Glyconeogenesis and galactose utilization (Figure 5.9). For 
example, increased expression values were obtained for UDP-glucose 
pyrophosphorylase, which reversibly catalyzes the transfer of a glucose moiety from 
glucose-1-phosphate to MgUTP to form active nucleotide UDP-glucose plus MgPPi. 
Decreased probe values were returned for Phosphoglucomutase (Pgm1) and 
Galactose-1-phosphate uridyl transferase (Galt), which catalyses the formation of 
glucose-1-phosphate and UDP-galactose from UDP-glucose plus phosphorylated 
galactose.  Decreased probe values were also observed for Glycogen synthase 2 
(Gys2) and Glycogen phosphorylase (Pygm), which respectively catalyse the rate-
limiting steps of Glycogenesis and Glycogenolysis.  
Probe values were unaltered for UDP-glucose dehydrogenase (Ugdh), which 
oxidizes UDP-glucose to active-glucoronate (i.e. UDP-glucoronate). However, 
altered probe values were returned for a number of UDP-glucoronosyltransferases 
(e.g. Ugt2a1, Ugt2b3 and Ugt2b5) that catalyse UDP-glucoronate conjugation 
reactions.  Additionally, increased probe values were returned for -Glucoronidase 
(Gusb), a lysosomal hydrolase involved in stepwise degradation of glucuronic acid-
containing glycosaminoglycans (Shipley et al 1993). GO analysis also implicated 
Acetate Non-utilizing 9 (Acn9) in gluconeogenesis through the metabolism of acetate 
and its regulation by glucose (Dennis et al 1999). Probes representing Acn9 were 
decreased in expression.   
 
5.2.4.11 Pyruvate Metabolism 
The metabolism of pyruvate overlaps with Leucine, Isoleucine and Valine 
Metabolism; Fatty Acid Metabolism via the production of acetyl-CoA and 
Acetoacetyl-CoA ; Alanine and Aspartate Metabolism via OAA; Glycine, Serine and 
Threonine Metabolism via the activities of Agxt and Sds; and Glycolysis and 
Gluconeogenesis via phosphophenolpyruvate.   
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Figure 5.10 Schematic Representation of Pyruvate Metabolism. Figure is 
adapted from KEGG Pyruvate Metabolism pathway. Pyruvate is a key metabolite 
intersecting several metabolic pathways. Pyruvate synthesis from 
phosphoenolpyruvate, forming ATP, is catalyzed by Pyruvate kinase (Pk). This 
reaction is essentially irreversible. Malic enzyme (Me) catalyzes reversible oxidative 
decarboxylation of malate to pyruvate using either NAD+ or NADP+ as a cofactor. 
Conversion of pyruvate to acetyl-CoA is carried out by mitochondrial Pyruvate 
dehydrogenase complex (Pdhx). Cont’d page 191. 
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Cont’d. Figure 5.10 Schematic Representation of Pyruvate Metabolism. This 
process consists of five distinct reactions. First, pyruvate is oxidatively 
decarboxylated, by the E1 component of the complex, Pyruvate dehydrogenase 
(Pdh). Lipoamide associated with E1 is reduced at the same time. Next, the acetyl 
group derived from pyruvate is transferred to -CoA in two steps catalyzed by the E2 
component of the complex dihydrolipolyl-transacetylase (Dlat). Finally, the oxidized 
form of lipoamide is regenerated and electrons are transferred to NAD+ in two steps 
catalyzed by the E3 component of the complex dihydrolipoyl dehydrogenase (Dld). 
Pyruvate is also converted to oxaloacetate (OAA) through carboxylation by pyruvate 
carboxylase (Pcx). OAA is condensed to L-Malate producing phosphoenolpyruvate 
through the action of Pyruvate carboxykinase (Pck), the first enzyme in 
gluconeogenesis. If insufficient oxygen is available, pyruvate is anaerobically 
reduced, using the enzyme lactate dehydrogenase (Ldh) and the co-enzyme NADH, 
creating lactate in animals. Representation of data described in Figure 5.0. See 
Section 5.2.4.11 and Table 5.6 for gene names, expression fold-changes and p 
values.  
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Figure 5.10 shows A6ND91-FLAG induces gene expression changes that may effect 
reversible conversion of mitochondrial and cytosolic OAA to L-Malate.  
Probe values were increased for mitochondrial Malate dehydrogenase 
(Mdh2), required for converting OAA to L-Malate for transfer into cytosol. Likewise, 
probes representing cytosolic Malate dehydrogenase (Mdh1) returned increased 
values.  Increased probe values were also returned for cytosolic Malic enzyme 
(Me1), which catalyses reversible oxidative decarboxylation of L-Malate to pyruvate 
and CO2. In comparison, probe values for two mitochondrial iso-enzymes of Malic 
enzyme (Me2 and 3) were unaltered. Thus, these data suggest that A6ND91-FLAG 
expression may primarily affect the expression of genes concerned with cytosolic 
pyruvate metabolism. 
Probes representing two subunits of multi-enzyme Pyruvate dehydrogenase 
complex subunits (i.e. Pdha1 and Dlat) displayed increased expression in cells 
expressing A6ND91-FLAG. Reduced probe values were also returned for Pyruvate 
dehydrogenase kinase isoform 3 (Pdk3), one of four kinases that inactivates the 
catalytic activity of Pyruvate dehydrogenase through phosphorylation of the 
E1subunit (i.e. Pdha1 and Pdha2) (Tso et al 2006). These data provide evidence 
that A6ND91-FLAG affects the expression of genes involved in regulating the 
conversion of pyruvate to acetyl-CoA.  
Expression values for probes representing four iso-enzymes of Lactate 
dehydrogenase (Ldha-d) provide further evidence that A6ND91-FLAG affects the 
expression of genes regulating metabolism of pyruvate and methylglyoxal.  
Increased expression values were returned for probes representing L-Lactate 
dehydrogenase isoforms M (Ldha) and C (Ldhc), which inter-converts pyruvate to L-
Lactate and NADH to NAD+ providing an important source of NAD+ for Glycolysis 
(Brooks et al 1999). By contrast, decreased expression values were observed for L-
Lactate dehydrogenase isozyme H (Ldlb). Probe values were also increased for D-
Lactate dehydrogenase (Ldhd) (Flick et al 2002), Glyoxylase I (Glo1) and II (Hagh) 
required for detoxifying methylglyoxal to D-lactate via the Glutathionine-dependent 
glyoxalase system (Ahmed et al 2003).  
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5.2.4.12 Glyoxylate and Dicarboxylate Metabolism 
Acetyl-CoA connects the Glyoxylate Cycle with the metabolism of Cholesterol 
and Steroids; Leucine, Isoleucine and Valine; Pyruvate; and Fatty Acid Metabolism. 
The Glyoxylate Cycle (Figure 5.11) processes two molecules of acetyl-CoA into 
succinate which either replenishes the TCA cycle or acts as precursors for amino 
acid and carbohydrate biosynthesis. This figure also shows that glyoxylate overlaps 
with; Alanine and Aspartate metabolism via OAA; Glycine, Serine and Threonine 
metabolism through the activities of Agxt and Grhpr; Glycolysis and 
Gluconeogenesis via 3-D-phosphoglycerate and 1-carbon pool by folate metabolism 
via formate production.    
Decreased probe values were returned for Citrate synthase (Cs), which irreversibly 
catalyses the condensation of OAA with acetyl-CoA to form citrate (Greksak et al 
1982). Additionally, decreased expression values were obtained for probes 
representing cytosolic Aconitase (Aco1), which reversibly converts citrate to iso-
citrate (Tong et al 2007). In comparison, increased expression values were returned 
for both 2-hydroxy acid oxidases (Hao1 and 2), which oxidise a broad range of 2-
hydroxy acids including glycolate to glyoxylate (Jones et al 2000). Likewise, 
increased expression values were returned for cytosolic Malate dehydrogenase 
(Mdh1), which catalyses the reversible reaction: L-malate plus NAD+ to OAA plus 
NADH.   
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Figure 5.11 Schematic Representation of Glyoxylate Metabolism. Figure is 
adapted from KEGG Glyoxylate and Dicarboxylate Metabolism pathway. The 
glyoxylate cycle enables the use of fatty acids, via acetyl-CoA for the synthesis of 
phosphoenolpyruvate, the first substrate of gluconeogenesis. The two initial steps of 
this cycle are identical to those in the TCA cycle: citrate → cis aconitate → isocitrate. 
However, the cycle by-passes the steps where carbon is lost (CO2) as in the TCA 
cycle. Isocitrate undergoes cleavage into succinate and glyoxylate by the first 
glyoxylate cycle enzyme,  isocitrate lyase (Icl). Succinate generated in the first step 
enters into the TCA cycle, eventually forming oxaloacetate. Cont’d page 195. 
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Cont’d. Figure 5.11 Schematic Representation of Glyoxylate Metabolism. 
Glyoxylate then condenses with acetyl-CoA catalyzed by Malate synthase (Mls), 
yielding L-Malate. The glyoxylate cycle replenishes intermediates of the TCA cycle 
whilst conserving the carbon that would otherwise be oxidized and lost. 
Representation of data described in Figure 5.0. See Section 5.2.4.12 and Table 5.6 
for gene names, expression fold-changes and p values.  
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5.2.4.13 Tricarboxylic Acid Cycle (TCA Cycle) 
Figure 5.12 shows the TCA Cycle links to several carboxylic acid metabolic 
pathways; Alanine and Aspartate (Section 5.2.5.2); Glutamate (Section 5.2.5.3); 
Arginine and Proline (Section 5.5.5.4) and Glyoxylate and Dicarboxylate (Section 
5.2.10) metabolism. 
In contrast to cytosolic Aco1 (Section 5.2.10, Figure 5.11), increased 
expression values were returned for mitochondrial Aco (Aco2) (Figure 5.12). 
Increased expression values were also returned for probes representing the -
subunit of the mitochondrial NAD-dependent Isocitrate dehydrogenase (Idh3g), 
which reversibly catalyses oxidative carboxylation of iso-citrate into 2-oxoglutarate. 
Additionally, probes representing mitochondrial NADP-dependent Idh (Idh2) returned 
increased expression values.  In comparison, expression values of the probes 
representing the  (Idh3a) and  (Idh3b) subunits of Idh and cytosolic NADP-
dependent form of Idh (Idh1) were not increased.  
Increased expression values were obtained for probes representing one of the 
subunits of Oxoglutarate dehydrogenase complex (i.e. Oghd), which irreversibly 
catalyses the generation of succinyl-CoA (Koike et al 1971, Tanaka et al 1972). 
Probe values representing the -subunit of succinyl-CoA synthetase (Suclg1) were 
not increased.  However, increased probe values were obtained for the -subunits of 
Succinyl-CoA synthetase (i.e Sucla2 and Suclg2), which respectively perform 
catabolic and anabolic functions (Fraser et al 2006). Similarly, probes representing 
three of the four subunits of the Succinate dehydrogenase complex (Sdhb, c and d), 
plus Fumarate hydratase (Fh1) and mitochondrial Mdh (Mdh2) also displayed 
increased expression values.   
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Figure 5.12 Schematic Representation of Tricarboxylic Acid Cycle (TCA) Cycle. 
Figure is adapted from KEGG TCA Cycle. The TCA cycle takes place in the 
mitochondria where acetyl-CoA is oxidised, releasing energy as reduced high-energy 
electron carriers, NADH and FADH2, plus carbon dioxide (CO2). Acetyl-CoA 
generated in the mitochondria enters the TCA cycle and through the action of Citrate 
synthase (Cs) and condenses with oxaloacetate forming citrate and -CoA. As the 
cycle proceeds, the TCA cycle intermediates are oxidized, transferring their energy 
to create NADH and FADH2. The TCA cycle is regulated by the irreversible synthesis 
of acetyl-CoA from pyruvate by Pyruvate dehydrogenase (Pdh), which is inhibited by 
high concentrations of ATP, which indicates the presence of abundant energy. Cs, 
oxoglutarate dehydrogenase (lipoamide) (Ogdh) and isocitrate dehydrogenase (Idh) 
are regulatory steps in the cycle and inhibited by high concentrations of ATP or 
NADH. Cont’d page 198.  
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Cont’d. Figure 5.12 Schematic Representation of Tricarboxylic Acid Cycle 
(TCA) Cycle. Succinyl-CoA synthetase containing Sucla2 gene-product generates 
succinate, -CoA and ATP from succinyl-CoA, while those comprising the Suclg2 
gene-product promote succinyl-CoA synthesis in a reaction requiring succinate, -
CoA and GTP. Representation of data described in Figure 5.0. See Section 5.2.4.13 
and Table 5.6 for gene names, expression fold-changes and p values.  
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5.2.4.14 Miscellaneous Carboxylic Acid Metabolism  
Six of the 58 genes (i.e. Egfr, Mcfd2, Pdgfc, Pcbd1, Sc5d and Vegfc) (Table 
5.6) classified by GO were unsupported by subsequent KEGG PATHWAY analyses 
and literature searches as being involved in carboxylic acid metabolism. Other GO 
identified transcripts were involved in pathways involved in carboxylic acid but 
unsupported sufficiently by KEGG-PATHWAY analysis. These include Fah and Tat, 
involved in the metabolism of tyrosine derived products (Endo et al 1997, 
Rettenmeier et al 1990); Msra and Mars1 involved in Methionine metabolism 
(Kuschel et al 1999, Lage et al 1996) ; Gne the rate limiting step of in Sialic Acid 
biosynthesis (Keppler et al 1999); Gulo involved in Ascorbate synthesis (Koshizaka 
et al 1988). 
 
5.2.5 Complement Activation 
GO classification placed 7 of the 1934 differentially expressed genes (FDR = 
0.005211) in Complement Activation category. KEGG detected a further 14 genes on 
this pathway plus another 24 transcripts associated with the overlapping Coagulation 
Cascade (Figure 5.13). Table 5.7 shows their respective fold-changes and 
associated p values.  
The complement and coagulation cascades share several protein-protein and 
enzymatic interactions (Amara et al 2008). Figure 5.13 shows the overlap between 
the two cascades. Activation of the Complement pathway can happen through three 
different pathways: the classical pathway, the lectin pathway, and the alternative 
pathway. The coagulation cascade is initiated by two different routes, the intrinsic or 
contact factor pathway and the extrinsic or tissue factor pathway. The two pathways 
are additionally linked through the Kallikrein Kinin System. This system is involved in 
inflammation, blood pressure control, coagulation and pain (Schmaier et al 2008).  
Intrinsic activation of the coagulation cascade starts with Factor XII (F12), 
then Factor IX (F9), and Factor XI (F11). Respective probe-set values for F9 were 
decreased and no probe-set values were available for F11 and F12 in cells 
expressing A6ND91-FLAG.  
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Figure 5.13 Complement and Coagulation Cascade. Schematic representation of 
the Coagulation and Complement Cascade. Figure is adapted from KEGG 
Coagulation and Complement Cascades. Vitamin K dependent proteins are high-
lighted with “K” yellow stars. Those proteins which control the expression or activity 
of other proteins are shown with “T” bars. Representation of data described in Figure 
5.0. See Section 5.2.5 and Table 5.7 for gene names, expression fold-changes and 
p values.  
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Probe ID Gene Name Gene 
Symbol 
Program 
ID 
Fold-
change 
P Value 
1370649_at 
1370650_s_at 
Bradykinin receptor, beta 2 
 
Bdkrb2 KEGG -2.04 
-1.81 
0.003977 
0.008048 
1368442_at Coagulation factor II F2 KEGG 2.20 0.002470 
1374320_at Coagulation factor V   F5 KEGG -1.39 0.030265 
1382194_at 
1380367_at 
1395015_at 
1395916_at 
Coagulation factor VIII  F8 KEGG 2.40 
1.89 
1.56 
-1.54 
0.001335 
0.006301 
0.017566 
0.018510 
1380104_at Coagulation factor IX F9 KEGG -1.36 0.033099 
1369852_at Coagulation factor X F10 KEGG 4.64 0.000019 
1369724_at Coagulation factor XIII, A1 
subunit 
F13a1 KEGG -1.37 0.032214 
1370215_at
  
Complement component 1, q 
subcomponent, beta polypeptide 
C1qb KEGG -1.31 0.037910 
1383241_at Complement component 1, r 
subcomponent 
C1r KEGG 1.96 0.005138 
1387893_at Complement component 1, s 
subcomponent 
C1s KEGG 1.43 0.026615 
1393219_at 
1383392_at 
Complement component 2 C2 KEGG 1.85 
1.35 
0.007154 
0.033530 
1368000_at 
1389188_at 
Complement component 3 C3 GO -11.36 
-2.69 
0.000001 
0.000587 
1369764_at Complement component 4 
binding protein, alpha 
C4bpa KEGG -3.21 0.000170 
1368695_at Complement component 4 
binding protein, beta 
C4bpb KEGG 4.44 0.000023 
1384580_at Complement component 6 C6 GO 3.71 0.000067 
1389470_at Complement factor B Cfb KEGG -1.28 0.042337 
1382554_at Complement component 8, alpha 
polypeptide   
C8a KEGG 3.85 0.000053 
1371109_at Complement component 8, beta 
polypeptide  
C8b KEGG 3.10 0.000214 
1393123_at Complement component 8, 
gamma polypeptide 
C8g KEGG -1.57 0.017079 
1388602_at Complement factor D (adipsin) Cfd KEGG 2.00 0.004479 
1383046_at 
1370676_at 
1387029_at 
Complement component factor H 
 
 
Cfh GO 3.46 
3.39 
-3.18 
0.000102 
0.000117 
0.000183 
1387798_a_at Complement receptor related 
protein 
Crry GO 2.57 0.000814 
1370406_a_at 
1387951_at 
Decay accelarating factor 1 Daf1 KEGG -2.23 
1.99 
0.002222 
0.004703 
1370992_a_at 
1371258_at 
Fibrinogen, alpha polypeptide Fga KEGG 2.12 
2.26 
0.003173 
0.002081 
1387323_at Kallikrein B, plasma 1 Klkb1 KEGG 5.20 0.000011 
1369226_at Kininogen 1 Kng1 KEGG 1.62 0.014811 
1389543_at Mannan-binding lectin serine 
peptidase 1 
Masp1 GO 2.77 0.000471 
1387765_at Mannose binding lectin 1, A Mbl1 KEGG -1.57 0.017136 
1387528_at Mannose binding lectin 2, C Mbl2 GO 4.20 0.000031 
1368360_at Plasminogen Plg KEGG 3.73 0.000064 
1369286_at Protein C ProC KEGG 4.13 0.000033 
1371037_at Protein S (alpha)   ProS1 KEGG 2.97 0.000290 
1367647_at Serine (or cysteine) proteinase 
inhibitor, clade A (alpha-1) 
Serpina1 KEGG 4.91 0.000015 
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Probe ID Gene Name Gene 
Symbol 
Program 
ID 
Fold-
change 
P Value 
1368617_at Serine (or cysteine) peptidase 
inhibitor, clade A, member 5 
Serpina5 KEGG -1.45 0.024830 
1398260_a_at Serine (or cysteine) peptidase 
inhibitor, clade D, member 1 
Serpind1 KEGG 4.50 0.000022 
1368519_at 
1392264_s_at 
Serine (or cysteine) peptidase 
inhibitor, clade E, member 1 
Serpine1 KEGG 2.08 
2.16 
0.003559 
0.002751 
1392090_at Serine (or cysteine) peptidase 
inhibitor, clade C (antithrombin), 
member   
Serpinc1 KEGG 2.89 0.000345 
1377033_at Serine (or cysteine) peptidase 
inhibitor, clade F, member 2  
Serpinf2 KEGG 4.02 0.000040 
1372254_at Serine (or cysteine) peptidase 
inhibitor, clade G, member 1 
Serping1 GO 7.15 0.000010 
1368900_at Thrombomodulin Thbd KEGG -1.53 0.019292 
1389234_at Von-Willebrand factor Vwf KEGG 1.76 0.009504 
 
Table 5.7 Significantly Perturbed Transcripts of the Complement and 
Coagulation Cascades. The table shows a list of differentially expressed genes 
involved in Complement and Coagulation Cascades (p < 0.05) from cells expressing 
A6ND91-FLAG. Affymetrix probe-set ID is shown in column Probe ID. Program ID, 
represents either GO, KEGG-PATHWAY analysis or literature identified transcripts 
(Section 5.2.5); Fold-change and p values (p < 0.05) are shown.   
 
 
 
 
 
 
 
 
 
 
204 
 
Extrinsic activation starts with the interaction of Tissue Factor (F3, Factor III) with 
Factor VII (F7). Increased probe-set values were returned for F3 however no probe-
set values were available for F7. 
The IXa-VIIIa (F9-F8) complex from both intrinsic and extrinsic pathways 
converts Factor X (F10) to Xa, which in the Xa-Va (F10-F5) complex activates 
Thrombin (Factor II, F2). Thrombin cleaves Fibrinogen (Fga) into Fibrin, which is 
cross-linked by XIIIa (F13) to form the Fibrin clot. The fibrin clot is broken down by 
Plasminogen (Plg). Probe-set values for F9, F5 and F13 were decreased, whereas 
probes for F10, Fga, FII and Plg were increased. Three BLAST verified probe-sets 
representing F8 displayed increased expression, whereas one probe displayed 
decreased expression.  
There are many additional regulatory factors involved in the coagulation 
cascade. For example, plasma Kallikrein (Klkb1) circulate in blood as separate 
complexes with high molecular weight Kininogen (Kng1). Similarly, Von-Willebrand 
factor (vWF) is a carrier for Factor VIII (F8). Binding of thrombin (F2) to one of its 
receptors, Thrombomodulin (Thbh) activates protein C-protein S complex, which 
degrades Factors V (F5) and VIIIa (F8) and reduces the amount of Thrombin 
generated. Activated Factors II (F2), VII (F7), IX (F9), X (F10), XI (F11) and XII (F12) 
and Protein C are inhibited by serine protease inhibitors such as Serpins A1, A5, C1, 
D1, E1, F2 and G1. Increased probe-set values were returned for Klkb1, Kng, vWF, 
protein C, protein S, Serpins A1, C1, D1, G1, E1 and F2 whereas decreased values 
were returned for probes representing Thbd, V and Serpin A5. 
Activation of the complement cascade by the classical pathway takes place 
when antibody/antigen complexes interact with C1, a multi-molecular complex 
consisting of C1qb, C1r and C1s. Both C1s and Mannan-binding lectin serine 
peptidase (Masp) cleave C2 and C5. C4-binding protein (C4bpa/b) interacts with C4 
and vitamin K dependent Protein S (ProS). Mannose binding lectin protein (Mbl) also 
activates Masp cleavage of C2 and C4 via the Lectin pathway. The alternative 
pathway starts with activation of Factor D (Cfd), Factor B (Cfb) and C3. All three 
pathways merge at C3 Convertase. The addition of C6, C7, C8 (a, b and y subunits) 
and C9 units forms the membrane attack complex (MAC), which binds to the cell 
surface and initiates membrane lysis. There are many regulatory factors involved in 
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the three pathways, such as Serine (or cysteine) proteinase inhibitor (Serpin) G1 
(Serping1), Decay accelerating factor (Daf), Complement component factor H (Cfh) 
and Complement receptor related protein (Crry). Increased probe-set values were 
returned for C1r, C1s, Masp1, C2, Mbl2, Cfd, C6, C8a, C8b, Serping1, subunit 
C4bpb, Crry and ProS, whereas decreased values were returned for probes 
representing C1q, Mbl2, C3, C8, Cfb and subunit C4bpa. No probe-set values could 
be determined for C5. Table 5.7 shows that discrepant BLAST verified probe-set 
values were returned for Daf1 and Cfh.  
Figure 5.13 also shows that several differentially expressed transcripts 
encode genes that are vitamin K-dependent (K). These include F2, F7, F9 and F10, 
plus inhibitors of coagulation factors, such as Protein C, Protein S and inflammatory 
associated Protein Z.  
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5.3 Discussion 
To identify major perturbed metabolic pathways in cells expressing A6ND91-
FLAG, microarray data were analysed using a combined Gene Ontology (GO) and 
KEGG PATHWAY approach. This analytical method has previously revealed key 
signalling pathways commonly induced by PPAR-ligands in colorectal cancer cells 
(Cekanova et al 2008) and identified altered inflammatory and energy metabolic 
pathways in ischemic brain (Feng et al 2007). In the current study, this approach 
suggests that A6ND91 may perturb key metabolites within gluconeogenesis/ 
glycolysis and pyruvate metabolism, possibly performing the same biological function 
proposed for the homologous thermophilic bacterium protein TM1643 (Yang et al 
2004): dehydrogenating L-Aspartate to form unstable iminoaspartate. Moreover, due 
to the absence of an iminoaspartate metabolising pathway in mammalian cells, an 
alternative mechanism is proposed whereby in an aqueous environment, such as in 
the cytosol, iminoaspartate is rapidly decomposed to OAA plus NH3
+, followed by 
spontaneous decarboxylation to pyruvate.  
KEGG PATHWAY comprises 73,424 pathways generated from 360 reference 
pathways (Te Pas et al 2007). Reference Pathway maps are based on 
amalgamation of many organisms, but it is possible to identify the organism‟s 
specific pathways. Biochemical pathways such as those stored in the KEGG 
database describe physiological processes. However, one should keep in mind that 
the description of the biological process may be species-specific. Furthermore, the 
microarray gene list may be incomplete for a pathway, due to inadequate annotation 
of genes. These considerations may hamper the analysis of the microarray results 
for the pathways. 
In the current study, KEGG PATHWAY placed approximately 43% of the 
microarray gene entries from the A6ND91-FLAG dataset (n =10,986, p < 0.05) onto 
one or more pathways. The reasons for not finding pathway information for an entry 
may relate to probe-set annotation: (1) gene entries indicated by a locus (LOC) 
number are rarely found on a pathway; (2) hypothetical protein entries are also rarely 
found on a pathway; (3) entries indicated by a chromosomal position are never 
placed on a pathway; (4) the annotation of the rat genome is less advanced than the 
human genome; and (5) not all genes are involved directly in metabolic pathways.  
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Those genes that were placed on significantly perturbed pathways were 
subjected to extensive manual checking, as it became apparent KEGG PATHWAY 
and GO inappropriately placed genes within certain pathways. Examples of which 
were Echs1 which KEGG placed within Leucine and Valine metabolism, Sc5d which 
GO placed within fatty acid metabolism and another GO-categorised gene Pcbd1 
placed within carboxylic acid metabolism. This extra validation step is time-
consuming and still prone to error but a necessary step to ensure data is as accurate 
as possible. This stringent checking step identified that many (i.e. ~50 %) of the GO 
annotated transcripts in Xenobiotic Metabolism over-lapped with Carboxylic Acid 
Metabolism (i.e. glycolysis/gluconeogenesis,  bile acid, fatty acid, amino acid and 
glucuronate metabolism) (Table 5.3).  
Figure 5.14 shows the hub of significantly perturbed pathways in cells 
expressing A6ND91-FLAG centres on pyruvate metabolism. Pyruvate metabolism 
intersects several metabolic pathways, including Alanine and Aspartate, Glycolysis 
and Gluconeogenesis, TCA cycle, Glyoxylate Metabolism and Fatty Acid 
Metabolism. Thus, in-depth microarray analyses of cells expressing A6ND91-FLAG 
supports the hypothesis that this protein may ultimately perturb pyruvate metabolism 
through the proposed catalytic activity of A6ND91: dehydrogenation of L-Aspartate, 
producing oxaloacetate plus NH3
+.  
Most of the metabolic information was extracted from the GO category 
Carboxylic Acid metabolism, in particular amino acid metabolism and those 
metabolic pathways involved in pyruvate metabolism. Several key enzymes involved 
in the metabolism of glucogenic amino acids displayed differentially probe-set 
values. In cells expressing A6ND91-FLAG increased expression values were 
detected for Agxt, an enzyme that links glucogenic amino acids L-Alanine, L-Serine 
and glycine with glyoxylate and pyruvate synthesis (Nishiyama et al 1991). Increased 
expression values were also returned for the transaminase Gpt, which transaminates 
L-Alanine plus 2-oxoglutarate to pyruvate plus L-Glutamate. In the livers of KLF15-/- 
mice with fasting hypoglycaemia there was reduced mRNA expression of amino 
acid-degrading enzymes plus 50% decrease in enzymatic activity of Gpt, which 
converts the critical glucogenic amino acid L-Alanine into pyruvate (Gray et al 2007). 
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Figure 5.14 Overlap of Significantly Perturbed Metabolic Pathways in A6ND91-FLAG cells. Blue ovals represent KEGG 
pathways as identified by GO and KEGG-PATHWAY analysis. RED arrows show the flow of metabolites within inter-linking 
pathways; OAA, Oxaloacetate; THF, tetrahydrofolate; LDL, Low Density Lipoprotein; 3-P-D-Glycerate, 3-Phospho-D-glycerate.2
08
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Increased expression of another amino acid transaminase, mitochondrial Got 
(Got2) indicates altered inter-conversion of the TCA substrates 2-oxoglutarate and 
oxaloacetate into the glucogenic amino acids L-Aspartate and L-Glutamate (Jenkins 
et al 1959).  However, in HepG2 cells exposed to ethanol, increased Got2 mRNA 
expression was found to be correlated with increased Got2 protein synthesis and 
expression on the plasma membrane, not the mitochondria. At the plasma 
membrane surface, the protein facilitated the uptake of long chain free fatty acids 
(Zhou et al 1998). Observations that mitochondrial Got2 catalyzes the conversion of 
L-Aspartate plus L-Glutamate to their respective TCA substrates and also 
orchestrates fatty acid uptake at plasma membranes demonstrates mitochondrial 
disturbances can have downstream physiological consequences at the cell surface.   
Altered L-Glutamate levels were observed in mice deficient for the high affinity 
peptide transporter, PEPT2. In this model increased L-Glutamate levels were 
associated with increased Glud1 mRNA plus protein expression as-well as, 
increased Gatm mRNA expression which encodes the rate-limiting enzyme linking 
the urea cycle with creatine biosynthesis pathway (Frey et al 2006, Humm et al 
1997).  Glud1 dehydrogenates L-Glutamate, creating the TCA intermediate 2-
oxoglutarate plus an NH3
+ which enters the urea cycle. Increased Glud1 RNA levels 
have been documented in acute and chronic acidosis, and associated with 
ammoniagenesis (Kaiser et al 1992). Expression of Glud1 is increased in cells 
expressing A6ND91-FLAG, raising the possibility that cells may have developed an 
acid-base imbalance. In support of this, cellular acidosis and NH3
+ depletion induces 
a 6-fold increase in Gls1 mRNA levels (Curthoys et al 1995). The same study also 
identified the mRNA levels for Gls2 were increased during starvation, diabetes, and 
feeding a high-protein diet. Gls1transcript values were increased in A6ND91-FLAG 
cells, where-as decreased expression values were returned for Gls2. These results 
suggest that A6ND91-FLAG expression may alter the cellular acid-base balance, 
inducing acidosis and additionally impacting on metabolites key to energy 
metabolism.  
The current dataset also indicates that cells expressing A6ND91-FLAG may 
have perturbations within the urea cycle. This pathway is involved in the metabolism 
of abnormal quantities of the glucogenic amino acids L-Arginine and Glycine to 
creatine and creatinine via the urea cycle. Cps1 is the rate-limiting enzyme that 
 
 
210 
 
catalyzes the first committed step of the hepatic urea cycle (Yefimenko et al 2005). 
In vertebrates, NAG is an essential allosteric cofactor for Cps1, the first enzyme of 
the urea cycle (Caldovic and Tuchman 2003). Decreased cellular pH as seen in 
acidosis diminishes the synthesis of N-Acetylglutamate (NAG) (Nissim et al 
1996).Reduced NAG synthesis decreases Cps1 activity, resulting in 
hyperammonemia (Caldovic et al 2003).  
Collectively, these results indicate that A6ND91-FLAG expression perturbs 
cellular acid-base balance, inducing acidosis. Metabolic acidosis may stem from 
lactic acidosis, ketoacidosis or chronic renal failure (Halperin et al 1977, Laing et al 
2006). Lactic acidosis can result from excess pyruvate production from glycolysis or 
deficiency in Pyruvate dehydrogenase, leading to pyruvate accumulation (Gore et al 
1996, Endo et al 1989).  Excess cellular lactate is excreted into the blood, hence 
causing lactic acidosis. Pyruvate is dehydrogenated by the enzyme Lactate 
dehydrogenase (Ldh). In the current study increased expression values were 
returned for testis-specific Ldhc and D-lactate Ldhd, decreased for heart-specific 
Ldhb and unaltered for the muscle specific Ldha. Due to varied RNA expression 
values of the different tissue specific Ldh detected in cells expressing A6ND91-FLAG 
cells, it is difficult to ascertain the flux of the reaction.  
 Ketoacidosis, commonly found in diabetes, is due to excess production of 
ketone bodies (i.e. -hydroxybutyrate and acetoacetate) (Fasanmade et al 2008). In 
humans, ketone bodies are synthesized in the liver from acetyl-CoA. Chronic renal 
failure, a complication of diabetes and/or hypertension, leads to the accumulation of 
sulfates, phosphates and uric acid (Laing et al 2006). Ketoacidosis may also result 
from perturbed metabolism of BCAA; L-Valine, L-Leucine and L-Isoleucine (Section 
5.2.4.5). The catabolism of L-Leucine ultimately results in acetyl-CoA, rendering it 
ketogenic. Isoleucine is both ketogenic and glucogenic producing acetyl-CoA and 
succinyl-CoA. L-Valine is glucogenic and is degraded to the TCA cycle substrate, 
succinyl-CoA (Banerjee et al 1997). Metabolism of ketogenic BCAA‟s to acetyl-CoA 
and ketone bodies, alters the acid-base balance in cells, resulting in acidosis (Menao 
et al 2009). Additionally, chronic metabolic acidosis, by itself, reduces plasma BCAA 
levels and increases their oxidative decarboxylation in muscle (Hara et al 1987). 
Most enzymes orchestrating BCAA degradation are increased in expression in 
A6ND91-FLAG cells. However, the rate-limiting step in BCAA catalysed by 
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Branched-chain -keto acid dehydrogenase complex (Bckdh) (Shimomura et al 
2004), showed decreased expression for the catalytic subunit (Bckdha) and 
increased expression for the inactivating kinase (Bckdk) (Popov et al 1997). 
Mutations in Bckdha result low-abundance of mRNA and cause Maple Syrup Urine 
Disease with severe keto-acidosis (Chuang et al 1994).   
Generally, acetyl-CoA is derived from -oxidation of fatty acids or glycolysis 
and feeds into the TCA cycle, increasing the net production of cellular ATP. Acetyl-
CoA is a product of mitochondrial Acetoacetyl-CoA thiolase (Acat1), Acetyl-CoA 
acyltransferase (Acaa2) and mitochondrial Trifunctional protein (Hadha and Hadhb). 
Figure 5.8 shows increased expression values are paralleled with several other -
oxidation enzymes (i.e. Acadvl, Acam, Acad9, Bucs1, Ech, Hsd17b4, Decr and 
Hadh2), suggesting increased mitochondrial fatty acid oxidation in cells expressing 
A6ND91-FLAG. Prior to mitochondrial -oxidation of VFCFA‟s, peroxisomal-
oxidation shortens the fatty acid chain by Acetyl-CoA acyltransferase (Acaa1) also 
contributing to cellular acetyl-CoA pools (Bout et al 1991). Transcription of 
Acetoacetyl-CoA thiolase‟s correlate to levels of functional enzyme activity (Fukao et 
al 2003, Ozasa et al 1984, Miyazawa et al 1980, Furuta et al 1982). Acetyl-CoA 
produced by mitochondrial -oxidation of fatty acids enters either the TCA cycle or is 
converted to the ketone bodies acetoacetate and -hydroxybutyrate.   
Acetyl-CoA synthesis from glycolysis is controlled by the rate-limiting enzyme 
Phosphofructokinase (Pfk). Transcript values for Pfk liver and muscle isoforms were 
unaltered and decreased, respectively. Pfk is highly regulated by ATP, citrate and its 
own product -D-Fructose-1; 6P2, and is inhibited by low pH (i.e. acidosis) to prevent 
the accumulation of hydrogen ions in muscle. A decrease in the muscle isoform, 
Pfkm, may indicate the cells are acidotic. The product of Pfk, -D-Fructose-1; 6P2 
can be converted into glycerone phosphate and can be removed from glycolysis by 
conversion into glycerol-3-phosphate, which can be used to form triglycerides (Nye 
et al 2008). Conversely, triglycerides can be broken down into fatty acids and 
glycerol, the latter re-entering the Glycolysis pathway. This may explain the 
biochemical data detecting increased triglyceride synthesis and secretion in cells 
expressing A6ND91-FLAG (Section 1.4, Figure 1.9 and 1.10), however very little 
data regarding the triglyceride synthesis was extracted using microarray analysis.  
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The last regulatory step in glycolysis involves phosphoenolpyruvate (PEP) 
which is irreversibly converted to pyruvate by pyruvate kinase. Increased expression 
values were observed with the liver isoform (Pklr), however decrease expression 
values were returned for the muscle isoform (Pkm2) of this enzyme. Since Pklr and 
Pkm2 expression are both up-regulated by glucose (Yamada et al 1999, Ashizawa et 
al 1991) it is difficult to extract information regarding the glycolytic flux in cells 
expressing A6ND91-FLAG.  To determine glycolytic flux in cells expressing A6ND91-
FLAG plus their cellular media, measuring glycolysis/gluconeogenesis metabolites, 
such as glucose, lactate, pyruvate, may provide insights into glycolytic flux direction. 
Pyruvate can either re-enter glycolysis through gluconeogenesis or is 
irreversibly converted to acetyl-CoA. The two of the three regulatory enzymes of 
gluconeogenesis; glucose-6-phosphatase (G6pc) and PEP carboxykinase (Pck1, 
Pck2) displayed increased expression values, whereas probe-sets representing 
fructose-1, 6-bisphosphatase (Fbp) were unaltered. Increased transcription of the 
catalytic subunit, G6pc, enhances hepatic glucose production in individuals with non-
insulin-dependent diabetes mellitus (NIDDM) (Valenti et al 2008). Expression of Pck 
mRNA is increased during acidosis, thus promoting the transformation of 
oxaloacetate to PEP (Kaiser et al 1991). The regulation of gluconeogenesis appears 
increased, possibly responding to increased levels of oxaloacetate and/or an altered 
acid-base ratio in cells expressing A6ND91-FLAG. 
Pyruvate is also decarboxylated by the pyruvate dehydrogenase complex 
producing acetyl-CoA. Pyruvate dehydrogenase (Pdha1, Pdha2 and Pdh2) catalyzes 
the irreversible conversion of pyruvate into acetyl-CoA which feeds into the TCA 
cycle. Tan et al reported glucose-mediated regulation of total Pdx activity and 
specific-Pdha1 gene expression in HepG2 cells (Tan et al 1998). The effect of high 
levels of glucose on Pdha1 gene expression is at the transcription level increasing 
Pdha1 mRNA levels two-fold. Expression values were increased for the catalytic 
subunit Pdha in cells expressing A6ND91-FLAG, indicating an increased Pdx activity 
and synthesis of acetyl-CoA.  
Mitochondrial acetyl-CoA is utilised the TCA cycle. Condensation of acetyl-
CoA plus OAA forms citrate by the rate-limiting enzyme of the TCA cycle, Citrate 
synthase (Cs). This enzyme is inhibited by high ratios of ATP: ADP, acetyl-CoA: 
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CoA, and NADH: NAD (Bayer et al 1981). High concentrations of ATP, acetyl-CoA, 
and NADH show that cellular energy supply is high thus inhibiting Cs activity, 
preventing excessive synthesis of NADH plus ATP. In support of this, a decrease in 
Cs activity occurs in islet cells cultured in high-dose glucose or LCFA (Liu et al 
1998). Additionally, depletion of glucose results in a 3-fold to 10-fold increase in TCA 
cycle mRNAs (i.e. Cs, Idh1 and 2, Ogdh, Sdh 1-4 and Fh1)) (DeRisi et al 1997). In 
cells expressing A6ND91-FLAG, transcript values for the majority of TCA cycle 
enzymes were increased, except for Cs. Decrease in Cs expression maybe 
explained by a high cellular concentration of fatty acid, glucose, ATP, acetyl-CoA 
and/or NADH. Increased de novo fatty acid synthesis (Section 1.4, Figure 1.9) and 
increased NADH levels (Section 3.3.7, Figure 3.17) were detected in A6ND91-FLAG 
expressing cells, thus providing a mechanism of decreased Cs expression. The 
remainder of TCA cycle enzymes showed evidence of increased transcription, 
contradictory to the expression value detected for Cs. This can be explained in terms 
of TCA intermediates ability to enter (i.e. anaplerosis) or leave (i.e. cataplerosis) the 
cycle, such as in amino acid catabolism or gluconeogenesis (Owen et al 2002). 
Cataplerotic and anaplerotic amino acids include L-Glutamate that is converted to 2-
oxo-glutarate and L-Aspartate which are converted to OAA. These 
substrates/products can move either in to or out of the TCA cycle, depending on the 
relative concentrations on each side of the chemical equation.   
Acetyl-CoA is also utilised by the rate limiting enzyme acetyl-CoA carboxylase 
(Acaca and Acacab) into de novo fatty acid synthesis, producing malonyl-CoA (Abu-
Elheiga et al 2001, Abu-Elheiga et al 2003). Expression values were unaltered in 
cells expressing A6ND91-FLAG. The activity of Acaca is dependent on 
polymerization and is enhanced by citrate, L-Glutamate and other dicarboxylic acids 
and inhibited by short and long-chain fatty acids (Lane et al 1974, Vagelos et al 
1963, Boone et al 2000).  Additionally, malonyl-CoA, free -CoA and fatty acyl-CoA 
esters are inhibitory to Acaca activity (Ogiwara et al 1978, Moule et al 1992). Acaca 
is also controlled phosphorylation by AMP-Kinase (AMPK) (Brownsey et al 2006). 
Expression values for AMPK catalytic Prkaa1 subunit and regulatory Prkab1 and 
Prkag1subunits were all increased, suggesting increases in phosphorylation of 
Acaca; thus inactivation of Acaca (Brownsey et al 2006). Fatty acid synthesis is also 
dependent of the multifunctional enzyme Fasn which, in the presence of NADPH 
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condenses acetyl-CoA with malonyl-CoA forming LCFA (Wakil et al 1989). 
Decreased expression values were evident in cells expressing A6ND91-FLAG, again 
suggesting decreased de novo fatty acid synthesis. Expression values of Fasn are 
decreased with exposure to PUFA (Ahnadi et al 2002, Teran-Garcia et al 2007). 
Additionally, activation of transcription of Fasn and Acaca is controlled by Usf and 
Srebf1 (Paulauskis et al 1989, Latasa et al 2003), which returned decreased and 
increased expression values, respectively, in cells expressing A6ND91-FLAG. These 
results are contradictory to biochemical data (Section 1.4, Figure 1.9), showing 
increases in de novo fatty acid synthesis. Combined, microarray and biochemical 
data indicate the regulation of de novo fatty acid synthesis in cells expressing 
A6ND91-FLAG is complex, undergoing much regulation by metabolites, 
phosphorylation and transcription. Microarray did not provide a good platform in 
understanding the regulation of de novo fatty acid synthesis in cells expressing 
A6ND91-FLAG.  
Cytosolic acetyl-CoA is converted to HMG-CoA by Hmgcs, before being 
converted to mevalonate by Hmgcr, the rate-limiting enzyme in the cholesterol 
biosynthesis pathway (Friesen et al 2004). Expression values for cytosolic Hmgcs 
were increased; however expression values of Hmgcr were unaltered in A6ND91-
FLAG cells. However it is important to remember that this enzyme is highly regulated 
post-translationally. Several non-covalent modifications that inhibit Hmgcr include -
CoA, acetyl-CoA, acetoacetyl-CoA, and 3-hydroxy-3-methylglutaric acid 
(unpublished data, Beg et al 1978), cholesterol (Ness et al 1991) and ATP plus Mg2
+ 
(Beg et al 1978). Other factors that influence Hmgcr activity include reversible 
phosphorylation (Hardie et al 1997), reversible thiol-disulfide formation and allosteric 
activation by NAD(P)H (Roitelman et al 1984), Sterols and non-sterol mevalonate 
metabolites also enhance Hmgcr degradation (Nakanishi et al 1988, Roitelman et al 
1992, Correll et al 1994). Thus, transcription of Hmgcr is not a good indicator of its 
enzymatic activity. A large majority of cholesterol genes, including those involved in 
the secretion of lipoproteins displayed increased probe-set values in cells expressing 
A6ND91-FLAG. Excess hepatic cholesterol can be directed to bile acid synthesis 
and subsequently excreted by the liver (Javitt et al 1994). The rate limiting step of 
the classic bile acid biosynthetic pathway is Cyp7a1 (Russell et al 2003), whereas 
the alternative (acidic) pathway is initiated by Cyp27a1 (Chiang et al 2009). Both 
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returned increased expression values in A6ND91-FLAG cells, suggesting excess 
cholesterol is incorporated in to bile acid synthesis. This data correlates well with the 
biochemical assays showing significant increases in cholesterol synthesis and VLDL 
secretion in A6ND91-FLAG cells (Section 1.4, Figure 1.10). 
The secretion of VLDL and associated hyperlipidemia can lead to activation of 
thrombosis via the intrinsic clotting cascade (Olufadi et al 2006). Lansbury et al 
presented data suggesting individuals with the Metabolic Syndrome (characterised 
by increased VLDL and hyperlipideamia) (Reaven et al 1988) displayed alterations 
within their coagulation cascade due to an increases in factor VII (F7), fibrinogen and 
Von Willebrand Factor (VWF). This in turn resulted in an increase in the risk of 
coronary vascular disease (Lansbury et al 2002). These findings are corroborated in 
the spontaneously hypertensive and hyperlipidemic rat where significant increases in 
hepatic mRNA expression of the coagulative and fibrinolytic (i.e. α- (Fga) and β 
(Fgb) -chains and prothrombin (F2)) factors were identified (Amagasa et al 2005). In 
cells expressing A6ND91-FLAG the Complement and Coagulation cascade (Section 
5.2.13, Figure 5.7) was identified as being perturbed by GO and KEGG PATHWAY 
analysis. Increased probe-set expression values were returned for Fga and F2 and 
VWF. These results suggest that increases in cholesterol and VLDL synthesis and 
secretion impacts on complement and coagulation cascade in cells expressing 
A5ND91-FLAG. 
Collectively, these data suggest that A6ND91-FLAG expression in two rat 
hepatoma cell lines influences several pathways involved in pyruvate metabolism 
(Figure 5.13). Pyruvate metabolism links amino acid metabolism, TCA cycle and 
Fatty acid Metabolism, Glycolysis/Gluconeogenesis and Glyoxylate Metabolism 
These pathways in turn perturb Steroid/Cholesterol metabolism, Bile Acid 
metabolism as well as Complement and Coagulation cascades. Microarray analysis 
of cells expressing A6ND91 provides evidence that key metabolites energy 
metabolism (i.e. OAA, pyruvate, glucose) and in cellular acid-base levels (i.e. NH3
+) 
are perturbed. A6ND91 may perform the same biological function proposed for the 
homologous thermophilic bacterium protein TM1643 (Yang et al 2003): 
dehydrogenating L-Aspartate to form unstable iminoaspartate. Due to no known 
iminoaspartate metabolising pathway in mammalian cells, an alternative mechanism 
is proposed whereby in an aqueous environment, such as in the cytosol, 
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iminoaspartate is rapidly decomposed to OAA plus NH3
+, followed by spontaneous 
decarboxylation to pyruvate.
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Chapter 6 Concluding Comments 
A putative L-Aspartate Dehydrogenase (ASP-DH) protein was isolated in 
elevated amounts (i.e. ~fifteen-fold increase at the 14-day time point) from liver 
microsomal fractions of rats fed Orotic Acid. This model of fatty liver is associated 
with: increased hepatic de novo lipogenesis; enhanced  triglyceride, cholesterol plus 
phospholipid synthesis; decreased hepatic glucose levels correlated to increased 
levels of plasma -hydroxybutyrate, lactate, acetate plus glucose levels; decreased 
hepatic secretion of lipoproteins; and, altered levels of several enzymes involved in 
glucose, pyruvate and amino acid metabolism (Creasey et al 1961, Windmueller et al 
1964, Sabesin et al 1977, Bogin et al 1986, Griffin et al 2004). Klain and Whitten 
additionally reported increased incorporation of glucose into de novo synthesised 
fatty acids in the adipose tissues of OA fed rats (Klain et al 1967). Combining these 
results suggest that OA may increase hepatic lipogenesis via perturbed 
gluconeogenesis/glycolysis through altered pyruvate and related substrates (i.e. 
oxaloacetate, acetyl-CoA and glucose). Moreover, increased levels of the putative 
rat ASP-DH in OA fed rats may result from reduced utilization L-Aspartate for de 
novo synthesis of OA. These possibilities will need to be examined by assessing the 
response of the putative rat ASP-DH to increased cellular L-Aspartate levels.  
Additionally, future studies will address the impact of silencing rat/human ASP-DH on 
L-Aspartate metabolism.    
Human putative ASP-DH, A6ND91, was cloned and revealed extensive 
sequence identity with an ancient family of proteins containing a Domain of Unknown 
Function (DUF 108). Highly conserved residues are predicted to form a Rossmann 
fold that binds dinucleotides. Yang et al successfully crystallised a homologous 
protein from eubacterium Thermatoga maritime (TM1643) and showed the co-
ordination of dinucleotides NAD+/NADP+ (Yang et al 2003). The group also identified 
that TM1643 possesses dehydrogenase activity toward L-Aspartate. In bacteria 
dehydrogenation of L-Aspartate produces iminoaspartate, which is a substrate for 
NAD synthesis. In mammals this pathway is no longer operative, thus an alternative 
mechanism is suggested by suggested where iminoaspartate rapidly degrades to 
oxaloacetate plus ammonia (Section 3.0, Figure 3.1).  
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Stable transfected rat hepatoma cells (McA-RH7777) expressing human 
A6ND91-FLAG showed increased synthesis of cholesterol, fatty acid, TG (Section 
1.2, Figure 1.9), increased total cellular TG level and increased secretion of TG-rich, 
ApoB-containing lipoproteins (Section 1.2, Figure 1.10). Cells also displayed an 
increased NADH/NAD ratio, suggesting that A6ND91 may increase cellular NADH 
levels by its proposed dehydrogenase activity (Section 3.3.7, Figure 3.7). 
Additionally, microarray analysis on these cells identified several perturbed metabolic 
pathways, including cholesterol metabolism, de novo fatty acid synthesis plus 
catabolism, glycolysis/gluconeogenesis, and amino acid metabolism, all interlinked 
by pyruvate metabolism (Section 5.3, Figure 5.14).  
Pyruvate metabolism inter-links with gluconeogenesis through various 
substrates, including amino acids, lactate and pyruvate. The gluconeogenesis 
pathway operates in most liver cells and in certain kidney cells, such as those in the 
proximal tubule (Stumvoll et al 1998, Cojocel et al 2003). These tissues show high 
levels of A6ND91 mRNA expression (Section 3.2.2, Figure 3.4). Additionally, both rat 
and human putative ASP-DH are predominantly localised to the cytosol (Section 
3.2.6, Figure 3.14 ad 3.15), where most glycolysis/gluconeogenesis reactions occur. 
This thesis also shows human A6ND91 is phosphorylated (Section 3.2.5, Figure 
3.11), and that this phosphorylation event potentially occurs by the kinase GSK3, 
which controls the activity of GS a key enzyme in the metabolism of glucose. 
Confirmation that this is the kinase involved would provide additional information 
regarding the regulation of A6ND91, in particular its‟ relationship with the other 
pathways regulated by GSK3. Moreover, assessing the cellular metabolites in 
A6ND91-FLAG cells is required as this could provide information on the flux of 
metabolites through the perturbed metabolic pathways. 
It is known that carbohydrate and amino acid metabolism also contribute to 
plasma lipid levels (Nagata et al 1982, Sugiyama et al 1986). Cytosolic oxaloacetate, 
for example, increases cytosolic acetyl-CoA levels impacting on lipogenesis 
(Spencer and Lowenstein 1962). Collectively, results reported here show that human 
A6ND91 impacts on hepatic lipogenesis possibly through perturbed oxaloacetate 
and pyruvate metabolism and that this protein may have retained its‟ L-Aspartate 
Dehydrogenase activity, thereby altering levels of cytosolic oxaloacetate, impacting 
on pyruvate metabolism, glycolysis/ gluconeogenesis and lipogenesis.  
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One must consider the phenotype displayed by cells expressing A6ND91: 
increased de novo fatty acids, cholesterol, phospholipid and triglyceride; increased 
secretion of triglyceride rich lipoproteins; increased cellular triglycerides; perturbed 
gene expression of gene products encoding proteins active in pyruvate and 
glycolysis/gluconeogenesis pathways. Several of these phenotypes are present in 
the metabolic syndrome. The clustering of impaired glucose tolerance, hypertension, 
hypertriglyceridaemia and hypercholesterolemia was first described by Reaven in 
1988 (Reaven et al 1988). The syndrome is increasing in prevalence on a worldwide 
level, impacting on the prevalence of cardiovascular disease and type-2 diabetes. 
The prevalence of the metabolic syndrome in Europeans is between 12% and 25% 
(Sattar et al, 2003, Rennie et al, 2003, Laaksonen et al, 2002, Villegas et al, 2003). 
The human putative ASP-DH, A6ND91 may be involved in the generation of this 
syndrome and/or the individual clusters contributing to this syndrome.   
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Appendix I; Solutions and Buffers 
10X CAPS solution 
100mM CAPs 
75mM NaOH 
pH11.0 
 
Colloidal Coomassie Blue Solution 
10% (NH4)2SO4 
0.1% Commassie G250 
3% Ortho-Phosphoric Acid 
20% Ethanol 
Make to 1litre H2O 
 
HST 
10mM NaCl 
10mM Tris-HCL, pH7.4 
0.5% Tween-20 
 
IEF Equilibration Buffer 
6M Urea  
2% SDS  
375mM Tris-Cl pH 8.8  
20% glycerol 
2% DTT 
2.5% Iodoacetamide 
 
LB 
10% Bacto-tryptone 
0.5% Bacto-yeast extract 
10mM NaCl 
 
Loading Dye (DNA Agarose Gel) 
30% Glycerol 
70% 1X TBE 
0.25% w/v bromophenol blue 
 
PBS 
137mM NaCl 
2.7mM KCL 
4.3mM NaHPO4 
1.4mM KH2PO4 
 
SDS Loading Buffer 
60mM Tris-HCL, pH6.8 
10% Glycerol 
2% SDS 
0.005% (w/v) bromophenol blue 
0.05% -mercaptoethanol 
 
SDS-Polyacrylamide Separating Gel  
12% Acrylamide 
3.75ml 3M Tris-HCL pH8.8 
300l 10% SDS 
30l TEMED 
150l 10% APS 
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TBE Buffer 
89mM Tris base 
89mM Boric acid 
2mM EDTA 
 
 
 
 
SDS-Polyacrylamide Stacking Gel (1%) 
1% Acrylamide 
1.25ml 1M Tris-HCL pH6.8 
100l 10% SDS 
15l TEMED 
75l 10% APS 
 
SDS-PAGE Running Buffer (1X) 
3.025g Tris-HCL 
14.4 Glycine 
0.1% SDS 
H2O to 1 litre 
 
SSC (2X) 
0.3M NaCl 
3mM Na3 Citrate, pH7.0 
 
TAE Buffer (1X) 
40mM Tris Acetate 
2mM EDTA 
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Appendix II; Oligonucleotides 
Oligonucleotide ID Sequence (5’ to 3’) Section 
Human OAP37A GAATTCGCCATGGCCGACAGGGG 2.2.3 
Human OAP37B2 CGCGTAGCGGCCGCTACTTGTCGTCATCATCCTTGTAAT
CCTCGAGGCAGAGATGGATCCCCGG 
2.2.3 
Prbm12 GTGTTTGTGGCCCGAGGG 2.2.1 
EDM0794-Forward ATGCAAGCTTGATATGGACGCTAGTATGGTCCC 2.3.1 
2.3.7 
EDM0794-FLAG 
Reverse 
GTACGAATTCTCACTTGTCGTCATCATCCTTGTAATCGCA
GAGGCGGATCCCAGGT 
2.3.1 
2.3.7 
FPcDNA/F2 CGCAAATGGGCGGTAGGCGTG 2.3.7 
RPcDNA/R2 TAGAAGGCACAGTCGAGG 2.3.7 
A6ND91/FRTPCR ATGTAGAGCTGAGCGGACCC 2.4.12 
A6ND91/RRTPCR ATGGATCCCCGGCCTG 2.4.12 
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Appendix III; Nucleotide Sequence A6ND91 
atggccgacaggggcccgtggagggtgggcgtggtgggctatggccgcctcggacagtcc 
 M  A  D  R  G  P  W  R  V  G  V  V  G  Y  G  R  L  G  Q  S  
ctcgtctcccgcctcttggctcagggaccagaacttggcctagaacttgtttttgtctgg 
 L  V  S  R  L  L  A  Q  G  P  E  L  G  L  E  L  V  F  V  W  
aatcgtgacccaggacgaatggcagggagcgtgcccccttccctgcagctccagaacctt 
 N  R  D  P  G  R  M  A  G  S  V  P  P  S  L  Q  L  Q  N  L  
gctgcccttggggaaaggcgccctgatctggttgtggaagtggcccatcccaaaataatc 
 A  A  L  G  E  R  R  P  D  L  V  V  E  V  A  H  P  K  I  I  
catgaatctggggcacaaatcctgcgccatgccaatctcctggtggggtccccctcagct 
 H  E  S  G  A  Q  I  L  R  H  A  N  L  L  V  G  S  P  S  A  
ctaagtgaccagaccacagagcggcagctcttggaggcctcacagcactgggaccacgcc 
 L  S  D  Q  T  T  E  R  Q  L  L  E  A  S  Q  H  W  D  H  A  
gtgtttgtggcccgaggggccctgtggggcgctgaggacatcaggagattggatgcagct 
 V  F  V  A  R  G  A  L  W  G  A  E  D  I  R  R  L  D  A  A  
gggggcctccggagccttcgtgtcaccatggccacacaccccgatggcttccggcttgag 
 G  G  L  R  S  L  R  V  T  M  A  T  H  P  D  G  F  R  L  E  
ggacccctggctgcagcccacagccctgggccttgcactgtgctctacgaaggccctgtc 
 G  P  L  A  A  A  H  S  P  G  P  C  T  V  L  Y  E  G  P  V  
cgtgggctctgcccctttgccccgcgaaattccaacaccatggcggcggctgccctggct 
 R  G  L  C  P  F  A  P  R  N  S  N  T  M  A  A  A  A  L  A  
gcccccagcctgggcttcgatggggtgattggggtgctcgtggctgataccagcctcacg 
 A  P  S  L  G  F  D  G  V  I  G  V  L  V  A  D  T  S  L  T  
gacatgcacgtggtggatgtagagctgagcggaccccggggccccacgggccgaagcttt 
 D  M  H  V  V  D  V  E  L  S  G  P  R  G  P  T  G  R  S  F  
gctgtgcacacccgcagagagaaccctgccgagccaggcgcggtcaccggctccgccacc 
 A  V  H  T  R  R  E  N  P  A  E  P  G  A  V  T  G  S  A  T  
gtcacggccttctggcagagcctcctggcctgctgccagctcccctccaggccggggatc 
 V  T  A  F  W  Q  S  L  L  A  C  C  Q  L  P  S  R  P  G  I  
catctctgctgagaagcctcctccctcccgagacaagatcatctgcctggcctctcacca 
 H  L  C  - 
 
Homo Sapiens Aspartate Dehydrogenase (A6ND91) mRNA Sequence. 
NM_001114598 nucleotide sequence is shown with its corresponding amino acids. 
Expressed Sequence Tag W88721.1 (Section 2.2.1) is shown in yellow. 
 
 
 
1 
61 
181 
241 
301 
361 
421 
481 
541 
601 
661 
721 
781 
841 
901 
 
60 
180 
240 
300 
360 
420 
480 
540 
600 
660 
720 
780 
840 
900 
960 
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Appendix IV; Wesdtern Blot of A6ND91-FLAG 
 
 
Western Blot of A6ND91-FLAG and -Actin in Cells Expressing A6ND91-FLAG. 
An example of a total Western blot image. Fluorescent orientation marker is shown 
at the top of image. Biorad Broad Range size markers (115 to 20 kDa) are shown on 
left hand side of blot image. Corners of blot are marked to aid orientation. See 
Section 2.1.10  for protocol information. 
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Appendix V; Names and Addresses of Collaborators 
Professor Carol Shoulders; Department of Endocrinology, William Harvey 
Research Institute, John Vane Science Centre, Charterhouse Square, Barts & The 
London, Queen Mary University of London, London EC1M 6BQ 
 
Professor James Scott; Imperial College London, South Kensington Campus, 
London SW7 2AZ. 
 
Professor Geoffrey Gibbons and Dr. Abdul Hebbachi; Oxford Centre for 
Diabetes, Endocrinology and Metabolism, The Churchill Hospital, Headington, 
Oxford, OX3 7LJ. 
 
Dr. Robin Waite; Senior Lecturer in Proteomics, Imperial College London, Kennedy 
Institute of Rheumatology, Mass Spectrometry and Proteomics Unit, London, W6 
8LH. 
 
Dr. Chris Mann; Genetix Ltd, Queensway, New Milton, Hampshire, BH25 5NN. 
 
CSC/IC Microarray Centre (MaC); Genomics Laboratory, MRC Clinical Sciences 
Centre, Faculty of Medicine, Imperial College London, Hammersmith Hospital 
Campus, Du Cane Road, London, W12 0NN. 
 
Miss Dinah Raman; Imperial College Proteomics Department, Faculty of Medicine, 
Imperial College London, Hammersmith Hospital Campus , Du Cane Road, London, 
W12 0NN. 
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